

# References

\*\*\*\*\*

- 1- **Aas T. and others** : Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients, *Nature Med* 1996; 2(7):811-814.
- 2- **Abbruzzese IL., and others** : Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin, *J Clin Oncol* 1995; 13:2094.
- 3- **Abdin, F.H., Towfik, H.s., and Khalil, A.M.** : Experience with the pathology of breast lesions. *Kasr-EL-Aini. J. Surg.*1973, 13:95.
- 4- **Abner AL, Recht A, Eberlein T, et al.** : prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. *J Clin Oncol* 1993; 11:44-48.
- 5- **Abrams J and others** : Dose- response trail of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741, *J Clin Oncol* 1999; 17:64.
- 6- **Achat H. and others** : A prospect study of job strain and risk of breast cancer, *Int. J. Epidemiol.* 2000; 29:622-628.
- 7- **Adalet I., and others** : 99m Tc-Tetrofosmin scintigraphy in the evaluation of palpable breast masses, *Nucl Med Commun* 1997; 18:118.
- 8- **Adami Ho., Signorello LB., Trichopoulos D.,** : Towards an understanding of breast cancer etiology. *Semin Cancer Biol* 1998; 8:255-262.
- 9- **Adler LP., Crowe JP., AL-Kaisi NK., Sunshine HL.,** : Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. *Radiology* 1993; 187:743-750.
- 10- **Aebi S, Gelber S, Castiglione- Gertsch M, et al.:** is chemotherapy alone adequate or young women with estrogen receptors positive breast cancer? *Lancet* 2000;355:1864-1874
- 11- **Ahearne. P.M., Leach, S.D and Feig B.W:** Invasive breast cancer, In: M.D. ANDERSON SURGICAL ONCOLOGY, HAND BOOK, 2<sup>nd</sup> edn., ed. By Feig B.W., David H.B., &George M., Lippincott Williams & Wilkins. Philadelphia, New York, London. 1999:PP.13-38.
- 12- **AKhtar S, Zablow A, Michaelson RA, Hutter RVP, Leitner SP,:** Predictors of axillary lymph node metastases in small (one centimeter or less) T1a, b primary breast cancer. *Prac Am Soc Clin Oncol* 1998; 17:120a (abst).
- 13- **Albonico, G., Querzoli, P., Ferretti, S., Rinoldi, R., Nenci, I** : Biological profile of in-situ breast cancer investigated by immuno- histochemical technique. *Cancer Detect Prev* 1998;22:213.
- 14- **Alexander FE, Anderson TJ, Brown H, et al.:** the Edinburgh randomized trial of breast cancer screening: results after 10 years of followup. *Br J Cancer* 1994;70:542-548.
- 15- **Alexander FE, Anderson TJ, Brown HK, et al. :** 14 years of follow-up from the Edinburgh randomized trial of breast-cancer screening. *Lancet* 1999; 353:1903-1908.
- 16- **AL-Hakeem Ms, Fix RJ, De Cordier BC, Vasconez LO** : Breast reconstruction, *Curr Pobl Surg* 2000; 37 (9): 585-632.

- 17- **Allain D, Gilligan MA, Redlich PN** : Genetics and genetic counseling for breast cancer. In: Donegan, W. and Spratt, J.N., *Cancer of the breast*, 5<sup>th</sup> ed. by Saunders, Philadelphia, London, New York, St.Louis, Sydney, Toronto. 2002; 19:377-416.
- 18- **Alpers CE, Wellings SR**: The prevalence of carcinoma in situ in normal and cancer-associated breasts. *Hum Pathol* 1985; 16:796-807.
- 19- **AL-Sobhi SS, Helvie MA, Pass HA, Chang AE**, : Extent of lumpectomy for breast cancer after diagnosis by stereotactic core versus wire localization biopsy, *Am Surg Oncol* 1999; 6(4): 330-335.
- 20- **Ambrosone C.B., and others** : Cigarette smoking, N-acetyltransferase 2 genetic polymorphism, and breast cancer risk, *JAMA* 1996; 276:1494-1501.
- 21- **Ambrosone CB., and others** : Cigarette smoking, N-acetyl transferase 2 genetic polymorphisms, and breast cancer risk, *JAMA* 1996; 276(18): 1491-1501.
- 22- **American Cancer Society (ACS)** : Cancer facts & figures 2001, Atlanta 2001, American Cancer Society, Surveillance Research, pp 1-41.
- 23- **American College of Obstetricians and Gynecology (ACOG)**, Committee Opinion Number 185. Washington DC, ACOG. September 1997.
- 24- **American College of Radiology (ACR)** : Illustrated breast imaging reporting and data systems (BI-RADS), ed.3, Reston, Va, 1998, American College of Radiology.
- 25- **American College of Radiology (ACR)** : Standards for the performance of screening mammography [Adopted by the ACR Council 1990, Revised 1994]. In : *ACR Digest of Official Actions*. Reston, VA: ACR, 1994
- 26- **American College of Radiology (ACR)**: Standard for the performance of screening mammography, Reston, Va, 1999, American College of Radiology.
- 27- **American Joint Committee on Cancer (AJCC)** : AJCC cancer staging manual, ed 5, Philadelphia, New York, 1997, Lippincott-Raven, PP 174-175.
- 28- **American Joint Committee on Cancer** : AJCC cancer staging manual, ed. 6, New York, 2002, Springer.
- 29- **Ames FC, Balch CM** : Management of local and regional recurrence after mastectomy or breast-conserving treatment, *Surg Clin North Am* 1990; 70:1115-1124.
- 30- **Amichetti M and others** : Quality of life in patients with ductal carcinoma in situ of the breast treated with conservative surgery and postoperative irradiation, *Breast Cancer Res Treat* 1999; 54: 109-115.
- 31- **Amichetti M and others** : Ten-year results of treatment of ductal carcinoma in situ (DCIS) of the breast with conservative surgery and radiotherapy, *Eur J Cancer* 1997; 33:1559-1565.
- 32- **Amparo, R.S., Angel, C.D., Ana, L.H.** : Inflammatory breast carcinoma: Pathological or clinical entity? *Breast cancer Res Treat* 2000; 64:127.
- 33- **Ampil FL, Burton GV, Li BD, Mills GM**, : Radiotherapy with and without chemotherapy after breast conservation surgery for early stage breast cancer: a review of timing, *Eur J Gynaecol Oncol* 1999; 20(4): 254-257.
- 34- **Anderson DE, Badzioch MD** : Risk of female breast cancer, *Cancer* 1985; 56(2): 383-387.

- 35- **Anderson E, Clark RB., Howell A.,** : Estrogen responsiveness and control of normal human breast proliferation, *J. Mammary Gland Biol., Metaplasia* 1998; 3:23-35.
- 36- **Anderson I.:** Mammography in clinical practice, *Med Radiogr Photogr* 1986;62(2) :2-40.
- 37- **Anderson TJ, Lamb J, Alexander F, et al.:** Comparative pathology of prevalent and incident cancers detected by breast cancer screening: Edinburgh Breast Screening Project. *Lancet* 1986; 1:519-523.
- 38- **Andersson I, Janzon L:** reduced breast cancer mortality in women under age 50: updated results from the Malmö mammographic screening program, *Monogr Natl Cancer Inst* 1997; 22:63-68.
- 39- **Andersson M, Kamby C, Jensen MB, et al.:** Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy: report from the Danish Breast Cancer Cooperative Group DBCG 82B Trial. *Eur J Cancer* 1999; 35:1659-1666.
- 40- **Apter, D., Vihko, R;** : Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles, *J. Clin. Endocrinol. Metab* ; 1983,57:82-86.
- 41- **Arbutina DR and others** : Multifocality in the earliest detectable breast carcinoma, *Arch Surg* 1992; 127:421-423.
- 42- **Archer S., and Winchester D.J.** : Invasive breast cancer, In: Anderson M.D *Surgical Oncology Handbook*, Brown and company Boston- New York, Toronto, London 1997; 99 1-5.
- 43- **Argy O., Hughes K.S., and Roche C.A.,** : Managing the patient with a Breast Mass, In: *Manual OF Breast Diseases*, Ed. By ISMAIL JATOI, Lippincott Williams & Wilkins. New York, London, Tokyo, Sydney; 2002;6:135-148.
- 44- **Armstrong B., Doll, R.:** Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practice, *Int. J. Cancer* 1975, 15; 617-631.
- 45- **Armstrong B., Stevens N., Foll, R.:** Retrospective study of the association between use of rawolfia derivatives and breast cancer in English woman. *Lancet*, 1974;2 :672.
- 46- **Armstrong K, Eisen A, Weber B,** : Assessing the risk of breast cancer, *N Engl J Med* 2000; 342:564-570.
- 47- **Armstrong K, Eisen A, Weber B:** Assessing the risk of breast cancer, *N Engl J Med* 2000; 342(8): 564-571.
- 48- **Arriagada R and others** : Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with 15 years of follow-up data, *J Clin Oncol* 1996; 14:1558-1564.
- 49- **Arriagada R, Le MG, Contesso G, Guinebretiere JM, Rochard F, Spi-elmann M** : Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. *Ann Oncol* 2002; 13:1404-1413.
- 50- **ASCO Annual meeting** : tamoxifen remains the standard for preventing breast cancer; *Cancer Lett* 2002;28(21):3
- 51- **ASCO** statement on genetic testing for cancer susceptibility, *J Clin Oncol* 1996; 14:1730-1736.
- 52- **Ashikari R., and others** : Breast cancer presenting as an axillary mass, *Ann Surg* 1976; 183:415.
- 53- **Aspegren K, Holmberg L, Adami HG,:** Standardization of the surgical technique in breast-conserving treatment of mammary cancer. *Br J Surg* 1988,75:80-810.

- 54- **Astor MB, Hilaris BS, Gruerio A, Varricchione T, Smith D.** : Preclinical studies with the photon radiosurgery system (PRS). *Int J Radiat Oncol Biol Phys* 2000; 47:809-813.
- 55- **Athas WF, Adams-Cameron M, Hunt WC, Amir-Fazli A, Key CR.,** : Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. *J Natl Cancer Inst* 2000; 42: 269-271.
- 56- **Athma P. Rappaport R, Swift M** : Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer, *Cancer Genet Cytogenet* 1996; 92:130-134.
- 57- **Atkins H, Hayward JL, Klugman DJ, Wayte AB,** : Treatment of early breast cancer: a report after 10 years of a clinical trial, *Br Merd J* 1972; May 20.
- 58- **Auclerc G and others** : Tamoxifen as sole treatment in patients (PTS) aged 65 years and over with primary breast cancer: a multicenter study with 78 PTS (meeting abstract), *Proc Am Soc Clin Oncol* 1990;4:A173.
- 59- **Avril A, Faucher A, Bussieres E, et al.** : Results of 10 years of a randomized trial of neoadjuvant chemotherapy in breast cancer larger than 3 cm. *Chirurgie* 1998; 123:247.
- 60- **Axelsson C, Mouridsen H, Zedeler K, et al:** axillary dissection of level I and II lymph nodes is important in breast cancer classification. *Eur J cancer* 1992;28A :1415.
- 61- **Azzopardi, J. G., Eusebi, V.,** : Melanocyte colonization and pigmentation of breast carcinoma. *Histopathology* 1977;1:21.
- 62- **Azzopardi, J.G., Ahmed, A., Millis, R.R.,:** Problems in breast pathology, London, 1979, WB Saunders.
- 63- **Baines C:** Breast self-examination, *Cancer* 1992; 69:1942-1946.
- 64- **Baker LH:** Breast cancer detection demonstration project 5 year summary report. *CAJ Cancer J Clin* 1982; 42:1-35.
- 65- **Baker LH:** Breast cancer detection demonstration project: 5 year summary report, *CA Cancer J Cln* 1982;32:194-225.
- 66- **Balch C., Singletary E., Bland K** : clinical decision-making in early breast cancer, *Ann Surg* 1993; 217:207-222.
- 67- **Balch CM and others** : Efficacy of an elective regional lymph node dissection of 1 to 4mm thick melanomas for patients 60 years of age and younger. *Ann Surg* 1996; 224:255-263.
- 68- **Ball ABS, Waters R, Meirion TJ,** : Formal axillary dissection, *Br J Hosp Med* 1990; 44:396-399.
- 69- **Ballard-Barbach R., and others:** Body fat distribution and breast cancer in the Framingham study, *J. Natl Cancer Inst.* ; 82:286-290.
- 70- **Ballo MT, Strom EA, Singletary SE, et al.** : Predicting outcome in patients with loco-regionally recurrent breast carcinoma after mastectomy. *Int J Radiat Oncol Biol Phys* 1999; 45: 310 (abst).
- 71- **Banadonna G, Valagussa P, Brambilla C, et al.:** primary chemotherapy in operable breast cancer: eight -years experience at the Milan cancer Institute. *J Clin Oncol* 1998;16:43
- 72- **Barbareschi M., Pelosio P., Caffo O., Buttita F., Barbazza R.:** Cyclin-D1-gene amplification and

- expression in breast carcinoma: relation with clinico-pathologic characteristics and with retinoblastoma gene product. P53 and P21 WAF1 immunohistochemical-expression. *Int. J. Cancer*. 1997; 74:171-174.
- 73- **Barnwell JM and others** : Sentinel node biopsy in breast cancer, *Ann Surg Oncol* 1998; 5:126-130.
- 74- **Bartelink H and others** : Impact of a boost dose of 16 Gy on the local control and cosmesis in patients with early breast cancer: The EORTC boost versus no boost trial. Proceedings of the 42<sup>nd</sup> Annual Astro Meeting, *Int J Radiat Oncol Biol Phys* 2000; 48:111.
- 75- **Bartelink H, Horiot JC, Poortmans P et al.** : Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. *N Engl J Med* 2001; 345: 1378-1387.
- 76- **Bartelink H.,** : Intensity modulated radiation therapy (IMRT) in breast cancer. *Eur J of cancer*, 2003; vol 37, suppl. 6, October 2001, page 134.
- 77- **Bartelink H.,** : The role of radiotherapy, *Eur J of cancer, Supplements vol. 1 No. 5, September 2003, P. S 105.*
- 78- **Barth A, Craig PH, Silverstein MJ,** : Predictors of axillary lymph node metastases in patients with T1 breast carcinoma, *Cancer* 1997; 79: 1918-1922.
- 79- **Barton MB, Harris R, Fletcher SW:** Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? *JAMA* 1999; 282:1270-1280.
- 80- **Bass SS and others** : The role of sentinel lymph node biopsy in breast cancer, *J Am Coll Surg* 1999; 189: 184-194.
- 81- **Bassa P., and others** : Evaluation of preoperative chemotherapy using PET with fluorine-18fluorodeoxyglucose in breast cancer, *J Nucl Med* 1996; 37:931-938.
- 82- **Bassett L. W., and Hoyt A.C.,** : Breast Imaging, In : *MANUAL OF BREAST DISEASES*. Ed. by. Ismail Jatoi, Lippincott Williams & Wilkins. New York, London, Tokyo, Sydney, 2002;9:201-230.
- 83- **Bassett L., Winchester DP., Caplan RB., et al.** : Stereotactic core-needle biopsy of the breast: a report of the joint task force of the American College of Radiology, American College of Surgeons, and College of American Pathologists. *CA Cancer J Clin* 1997; 47:171.
- 84- **Bassett LW.,** : Mammographic analysis of calcifications, *Radiol Clin North Am* 1992; 30(1) 93-105.
- 85- **Bassett LW., Hendrick RE., Bassford TL, et al.** : Quality determinates of mammography: clinical practice guideline. No 13. AHCPR publication 95-0632. Rockville, MD: Agency for Health care Policy and Research, Public Health service, U.S. Department of Health and Human Services, October 1994.
- 86- **Bassett LW., Winchester DP., Caplan RB., et al.** : Stereotactic core-needle biopsy of the breast. *CA Cancer J Clin* 1997; 47:171-190.
- 87- **Bates T and others** : Breast cancer in elderly women: a cancer research campaign Trail comparing treatment with tamoxifen and optimal surgery with tamoxifen a lone the Elderly breast cancer working party . *Br J Surg* 1991;78:591.
- 88- **Bauer TW and others** : Subareolar injection simplifies sentinel lymph node mapping for breast cancer (abstract), presented at the meeting of the Society of Surgical Oncology, Washington, DC, March 15-18,2001.

- 89- **Baum M, Colletta A** :Breast cancer: a revolutionary concept. *Breast Cancer* 1995;2:9-18.
- 90- **Baum M, Houghton J, Odling-Smee W et al.** : Adjuvant "Zoladex" in premenopausal patients with early breast cancer: results from the zipp trial [abstract]. *Breast* 2001; 10 (Suppl. 1): S32 - S33.
- 91- **Baum M, Sainsbury R**: Recent developments in the endocrine therapy of early breast cancer. In: Taylor I, Johnson C, Recent Advances in surgery, 26, the Royal society of Medicine press limited, 2003;14:183-200.
- 92- **Baum, M., saunders, C.. M** :Breast cancer. In: Bailey and Loves Short practice of surgery 23<sup>rd</sup> edn. Chapman and Hall Medical, London, Glasgow, New York, 2000;749-772.
- 93- **Baxter N, McCready DR, Chapman JA, et al.** : Clinical behavior of untreated axillary nodes after local Treatment of primary breast cancer. *Ann Surg Oncol* 1996; 3:235-240.
- 94- **Beadle GF, and others** : Cosmetic results following primary radiation therapy for early breast cancer, *Cancer* 1984; 54: 2911-2918.
- 95- **Beck RM., Gotz L., Heywang-Kobrunner SH.,** : Stereotaxis vacuum core breast biopsy-experience of 560 patients, *Swiss Surg* 2000; 6(3) : 108 – 110.
- 96- **Beck TM and others** : Local or regionally recurrent carcinoma of the breast : results of therapy in 121 patients, *J Clin oncol* 1983; 1:400.
- 97- **Bedrosian I and others** : Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. *Cancer* 2000; 88: 2540-2545.
- 98- **Bedwinek J, Lee J, Fineberg B, Ocwieza M.,** : Prognostic indicators in patients with isolated local-regional recurrence of breast cancer. *Cancer* 1981; 47:2232.
- 99- **Bedwinek J.,** : Breast conserving surgery and irradiation: The importance of demarcating the excision cavity with surgical clips, *Int J Radiat Oncol Biol Phys* 1993;26:675-679.
- 100- **Beemsterboer PM, Warmerdam PG, Boer R, et al.:** Radiation risk of mammography related to benefit in screening programmes: a favourable balance? *J Med Screen* 1998;5:81-87.
- 101- **Bellon JR, Lindsley KI, Ellis GK, et al.** : Feasibility of concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in the management of locally advanced breast cancer. *Int J Radiat Oncol Biol Phys* 1999; 45:309 (abst).
- 102- **Bender K., and others** : Value of 18 Fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma, *Anticancer Res* 1997;17:1687-1692.
- 103- **Ben-Jonathan N. and others** : Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects, *Endocr Rev* 1996;17(6):639-669.
- 104- **Bennett IC, Gattas M, the BT** : The genetic basis of breast cancer and its clinical implications. *Aust NZJ Surg* 1999; 69:95-105.
- 105- **Berg, J.W., Hutter, R.V.,** : Breast cancer. *Cancer* 1995; 75:257-269.
- 106- **Berger, D.H., feig, B.W., and Fuhrman, G.** : The spread of mammary carcinoma. In: ANDERSON M.D. SURGICAL ONCOLOGY HAND BOOK, Brown and company Boston New York, Toronto, London 1997; 6-13.

- 107- **Bergh J, Wiklund T, Erikstein B et al.:** Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high risk breast cancer: a randomized trial. Scandinavian Breast Group 9401 study. *Lancet* 2000; 1384-1341.
- 108- **Bergh J:** who should not receive chemotherapy? International database. NIH Consensus Development Conference on adjuvant therapy for breast cancer, Bethesda, MD, 2000, National Institutes of Health.
- 109- **Berkel H., Birdsell D.C., Jenkins H., :** Breast augmentation: a risk factor for breast cancer? *N. Engl. J. Med.* (1992); 326:1649-1653.
- 110- **Berkman BJ, Sampson SE.:** Psychological effects of cancer economics on patients and their families. *Cancer* 1993;72:2846-2849.
- 111- **Berns EM, Foekens JA, Staveren IL:** Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. *Gene* 1995;159:11.
- 112- **Bernstein JL and others :** The genetic epidemiology of second primary breast cancer, *Am. J. Epidemiol* 1992;136:937-948.
- 113- **Bernstein L and others :** Physical exercise and reduced risk of breast cancer in young women, *J. Natl. cancer Inst.* 1994; 86:1403-1408.
- 114- **Bernstein L., :** Ross R. K., : Endogenous hormones and breast cancer risk, *Epidemiol. Rev.* ; 1993;15:48-65.
- 115- **Bernstein L., Ross RK., Henderson BE., :** Prospects for primary prevention of breast cancer, *Am J Epidemiol* 1992; 135(2): 142-152.
- 116- **Berry DA and others :** Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history, *J. Natl Cancer Inst* 1997; 89:227-238
- 117- **Bezwoda WR, Seymourl, Dansey RD:** high dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial . *J Clin Oncol* 1995;13:2483-2484
- 118- **Bignell GR and others :** Low frequency of somatic mutation in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer, *Cancer Res* 1998; 58(7):1384-1386.
- 119- **Bijker N, Peterse JL, Duchateau L et al. :** Risk factors for recurrence and metastasis after breast conserving therapy for ductal carcinoma in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. *J Clin Oncol* 2001; 19:2263-2271.
- 120- **Bischoff J. R. and others :** An adenovirus mutant that replicates selectively in P53-deficient human tumor cells, *Science* 1996; 274(5286): 373-376.
- 121- **Bishop J and others:** Taxol (paclitaxel) alone is equivalent to CMFP combination chemotherapy in frontline treatment in metastatic disease. *Proc Am Soc Clin Oncol* 1997;16:153
- 122- **Bjurstam N and others:** The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization, *Cancer* 1997;80:2091-2099.
- 123- **Black Mlt., Magklara A., Obiezu C., et al. :** Expression of a prostate-associated protein, human glandular kallikrein (hk2), in breast tumors and in normal breast sections. *Br J cancer* 2000; 82: 361-367.
- 124- **Bland K.I., Copeland E.M., :** Breast, In: PRINCIPLES OF SURGERY, 6<sup>th</sup> Ed., Ed. by Schwartz S.I.,

Mc GRAW-MILL INC. New York, Paris, London, 1994; 14:531-592.

- 125- **Blichert-Toft M and others** : Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis, *J Natl Cancer Inst Monogr* 1992; 11:19-25.
- 126- **Boardman LA and others** : Increased risk for cancer in patients with the peutz-Jeghers syndrome, *Ann Intern Med* 1998; 128(11):896-899.
- 127- **Bobo JK, Lee NC, Thames SF**: Findings from 75,2081 clinical breast examinations reported to a national screening program from 1995 through 1998, *J Natl Cancer Inst* 2000; 92:971-976.
- 128- **Bobrow, :L. G., and others** : The classification of ductal carcinoma in-situ and its association with biological markers, *Semin Diagn Pathol* 1994; 11:1990.
- 129- **Boccardo F, Rubagotti A, Amoroso D et al.** : Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant study Group OZ randomized trial. *J Clin Oncol* 2000; 18:2718-2727.
- 130- **Bodian CA** : Benign breast disease, carcinoma in situ, and breast cancer risk, *Epidemiol Rev.* 1993; 15:177-187.
- 131- **Bohuslavizki KH., and others** : FDG PET detection of unknown primary tumors, *J Nucl Med* 2000; 41 (5) : 816.
- 132- **Boice JD and others** : Cancer in the contralateral breast radiotherapy for breast cancer, *N Engl Med* 1992; 326:781-785.
- 133- **Bold RJ and others** : Local rotational flaps for breast conservation therapy as an alternative to mastectomy, *Ann Surg Oncol* 1999; 4(7): 540-544.
- 134- **Bold RJ, Mansfield PF, Berger DH, et al.** : Prospective randomized double-blind study of prophylactic antibiotics in axillary lymph node dissection. *Am J Surg* 1998; 176:239-243.
- 135- **Bone B., Pentak Z., Perbeck L., Veress B.,** : Diagnostic accuracy of mammography and contrast-enhanced MR imaging in 238 histologically verified breast lesions, *Acta Radiol* 1997; 4:489.
- 136- **Bontick L, Come S, Rose C, et al.** : Primary breast irradiation and concomitant adjuvant chemotherapy. In: Harris J. Hellman S, Silen W. eds. *Conservative management of breast Cancer*. Philadelphia: *JB Lippincott*, 1983:321.
- 137- **Boregestein PJ, Pijpers R, Comans EF' et al.** : Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection *J Am coll surg* 1998; 186: 275-283
- 138- **Borgen PI., and others** : Patient regrets after bilateral prophylactic mastectomy, *Ann Surg. Oncol* 1998; 5(7): 603-606.
- 139- **Borger J, Kemperman H, Hart A, et al.** : risk factors in breast-conservation therapy. *J Clin Oncol* 1994; 12:653-660.
- 140- **Borgstein PJ and others** : Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection, *J Am Coll Surg* 1998; 186:275-283.
- 141- **Boring, C.C., Squires, T.S., and Tong T**: Cancer statistic CA; 1992,24(1):19.

- 142- **Boss SM., Huster WJ., Neild JA., et al.** : Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. *Am J Obstet Gynecol* 1997; 127:1458-1464.
- 143- **Bouvet M and others** : Role of conservation therapy for invasive lobular carcinoma of the breast, *Ann Surg Oncol* 1997; 4(8): 650-654.
- 144- **Bowcock AM:** Breast cancer genes. *Breast J* 1997; 3(suppl3): 1-6.
- 145- **Brekelmans CTM, Seynaeve C, Battels CCM et al.:** Effectiveness of breast cancer surveillance in BRCA 1/2 genes and women with high familial risk, *J Clin Oncol*, 2001;19:924-930
- 146- **Brenner A.J, Aldaz, C.N.** : Chromosome allelic loss in breast cancer. *Res. 1998;55:2892.*
- 147- **Brenner DJ, Leu CS, Beatty JF, Shefer RE.** : Clinical relative biological effectiveness of low-energy X-rays emitted by miniature X-ray devices. *Phys Med Biol* 1999; 44:323-333.
- 148- **Brezden CB, Phillips KA, Abdoell M et al.** : Cognitive function in breast cancer patients receiving adjuvant chemotherapy. *J Clin Oncol* 2000; 18:2695-2701.
- 149- **Brinton L.A., and others** : Breast cancer following augmentation mammoplasty (United States), *Cancer Causes Control* 2000, 11:819-827.
- 150- **Brinton L.A., J. Lacey JR, and Devesa, S.S.,** : Epidemiology of breast cancer, In: *Cancer of the breast*. 5<sup>th</sup> edn., ed. By Donegan W., Spratt, J., Saunders, Philadelphia, London, New York, St. Louis, Sydney, Tokyo. ; 2002,7:111-132.
- 151- **Brinton L.A.,: Daling J.R., Liff. J., Schoenber J.B,** : oral contraceptives and breast cancer risk among younger women. *J. Natl. Cancer Inst.*, ; 1983,87:827-835.
- 152- **Broët, P., de la Rochefordiere, A., Scholl, S.M., Fourquet, A., Massen, V., Durand, J.C., Pouillart, P., Asselian, B.** : Contralateral breast cancer. Annual incidence and risk parameters. *J Clin Oncol*, 1995; 13:1578-1583.
- 153- **Bronstein AD., Kilcoyne RF., Moe RE:** Complications of needle localization of foreign bodies and non palpable breast lesions, *Arch Surg* 1988; 123: 775-779.
- 154- **Brownstein M, Wolf M, Bikowski J.** : Cowden disease: a cutaneous marker of breast cancer. *Cancer* 1978; 41:2393.
- 155- **Browse N.,** : Examination of the breast, In: *AN INTRODUCTION TO SYMPTOMS AND SIGNS OF SURGICAL DISEASES*. ED. by Neoman L., Browse N., English language book society 1986; 12:262-281.
- 156- **Brunet JS and others** : Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes, *J, Natl. Cancer Inst.* ; 90:761-766.
- 157- **Bruzzi P and others:** estimating the population attributable risk for multiple risk factors using case-control data, *Am., J., Epidemiol.*, 1985; 122:904-914.
- 158- **Brzezinski A & Debi A.,** : Phytoestrogens: the "natural" selective estrogen receptor modulators? *Eur. J. obstet. Gynecol. Repod Biol* 1999; 85:47-51.
- 159- **Brzozowski AM., Pike AC., Dauter Z., et al.** : Molecular basis of agonism and antagonism in the estrogen receptor. *Nature* 1997; 389:753-758.

- 160- **Buchholz TA, Hunt KK, Amosson CM, et al.** : Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. *Cancer J Sci Am* 1999; 5:159.
- 161- **Buis D.S., and others** : Bone mineral density and endogenous hormones and risk of breast cancer in postmenopausal women (United States), *Cancer Causes Control* 2001, 12:213-222.
- 162- **Bulbrook R.D., Hayward, J.L. Spicer C.C.,:** Relation between urinary androgen and corticoid excretion and subsequent breast cancer. *Lancet*, 1976;1: 395-398.
- 163- **Bulens P. Vanyutsel L, Pigndeus A, et al.** : Breast Conserving treatment of Paget's disease. *Radiother Oncol* 1990; 17:305-304.
- 164- **Burbank F.,** : Stereotactic breast biopsy: Comparison of 14-and 11-gauge Mammotome probe performance and complication rates, *Am Surg* 1997; 63(11): 988-995.
- 165- **Burke W, Daly M, Garber J, et al.:** for the Cancer Genetics Studies Consortium. Recommendations for follow-up care of individuals with an inherited predisposition to cancer, II: BRCA1 and BRCA2, *JAMA* 1997, 277:997-1003.
- 166- **Burns RB, Freund KM, Ash AS, et al.:** As mammography use increases, are some providers omitting clinical breast examination? *Arch Intern Med* 1996;156:741-744.
- 167- **Burns RB.,** :Image-guided breast biopsy.*Am J Surg.* 1997;173:9-11.
- 168- **Burrell HC, Sibbering DM, Evans AJ.,** : Do mammography features of locally recurrent breast cancer mimic those of the original tumor? *Breast* 1996; 5:233-236.
- 169- **Buzdar A, Nabholz J, Robertson J, et al.:** Anastrozole (Arimidex) versus tamoxifen as first line the rophy for advanced breast cancer in postmenopausal women. combined analysis from two identical designed multicenter trials. *Proc Am Soc Clin Oncol* 2000 ; 14:604A
- 170- **Buzdar AU., Hortobagyi G.,** : Update on endocrine therapy for breast cancer. *Clin Cancer Res* 1998; 4:527-534.
- 171- **Byrne C., and others** : Mammographic featvres and breast cancer risk: effects with time, age, and menopause status, *J, Natl, Cancer Inst.* 1995; 87:1622-1629.
- 172- **Cabanes PA and others** : value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. *Lancet* 1992;339: 1245-1248.
- 173- **Campana F., and others** : Presentation of axillary lymphadenopathy without detectable breast primary (T0 N1b breast cancer): experience at Institut Cune, *Radiother Oncol* 1989; 15:321.
- 174- **Campbell HS and others:** Improving physicians and nurses clinical breast examination, *Am J Prev Med* 1991;7:1-8
- 175- **Campos, S.M., and Hayes, D.F.,** : Atlas of DIAGNOSTIC ONCOLOGY, 3<sup>rd</sup> ed. Ed. By skarin A.T. and associate editors, Mosby, 2003;8:243-281.
- 176- **Canavese G and others** : sentinel lymph node mapping opens new perspective in the surgical management of early stage breast cancer: a combined approach with vital blue die lymphatic mapping and radio-guided surgery, *Semin Surge Oncol* 1998; Is: 272-277.
- 177- **Canizares F., and others** : Prognostic value of ornithine decarboxylase and polyomines in human breast cancer: Correlation with clinicopathologic parameters, *Clin Cancer Res.* 1999; 5(8): 2035 -2041.

- 178- **Cantor KP., and others** : Occupational exposures and female breast cancer mortality in the United States, *J. Occup. Environ. Med.* 1995; 37:336-348.
- 179- **Capella, C., and others** : Endocrine differentiation in mucoid carcinoma of the breast. *Histopathology* 1980;4:613.**Eusebi V, & Damiani S.** : Gross and microscopic pathology. In: *Cancer Of The Breast*, 5<sup>th</sup> edn. Ed. By Donegan & Spratt, Saunders, 2002;12:347-375.
- 180- **Caporaso N., Goldstein A.,** : Cancer genes: single and susceptibility : exposing the difference, *Pharmacogenetics* 1995, 5:59-63.
- 181- **Cardenosa G.,** : Positioning and problem solving In: Cardenosa G, editor: *Breast imaging companion*, Philadelphia, 1997, Lippincott-Raven, PP 46-91.
- 182- **Cardenosa G:** Breast cancer and mammography: an overview. In Cardenosa G, editor: *Breast imaging companion*, Philadelphia, 1997, Lippincott-Raven, pp2-22.
- 183- **Carlomagno C, Perrone F, Gallo C, et al.:** C-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. *J Clin Oncol* 1996; 14:2702-2708.
- 184- **Carlson GW.,** : Risk of recurrence after treatment of early breast cancer with skin-sparing mastectomy, *Ann Surg Oncol* 1998; 5(2): 101-104.
- 185- **Carlson RW** : Update: NCCN practice guidelines for the treatment of breast cancer, *Oncology* 1999; 131(11A): 161-212.
- 186- **Carter Cl, Allen C, Henson DE** : Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. *Cancer* 1984;63:181-187
- 187- **Carter CL., Allen C., Henson OE.,** : Relation of tumor size, lymph node status, and survival in 24,730 breast cancer cases, *Cancer* 1989;63:181-187.
- 188- **Carter D., Pipkin R.D., and Shepard R.H.** : Relationship of necrosis and tumor border to lymph node metastases and ten years survival in carcinoma of the breast. *Am. J. Surg. Pathol.*, 1978; 2: 39-43.
- 189- **Cataliotti L., Distanto V., Pacini P.,** : Florence experience. In : Silverstein MJ., ed. *Ductal carcinoma in situ of the breast*. Baltimore: Williams & Wilkins, 1997 ;449.
- 190- **Cataliotti L:** What is new in breast cancer surgery: a tailored approach (Abst). *Eur J cancer suppl*, 2003 P:53.
- 191- **Cauley JA and others** : Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer-Study of Osteoporotic Fractures Research Group, *Ann Intern Med.* 1999; 130:270-277.
- 192- **Cauley JA., and others** : : Bone mineral density and risk of breast cancer in older women: The study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group, *JAMA* 1996; 276:1404-1408.
- 193- **Cavalieri E., and others** : Estrogens as endogenous genotoxic agents-DNA adducts and mutations, *J Natl cancer Inst. Monogr* 2000; 27:75-94.
- 194- **Cerhan JR., and others** : Twinship and risk of postmenopausal breast cancer, *J. Natl. Cancer Inst.*, 2000; 92:261-265.

- 195- **Cerhan JR., and others** : Twinship and risk of postmenopausal breast cancer, *J Nat/ Cancer Inst* 2000; 92(3): 261-265.
- 196- **Chabner E, Nixon A, Gelman R** : Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer, *J Clin Oncol* 1998; 16:2045-2051.
- 197- **Chalabian J Dunnington G**: Do our current assessments assure competency in clinical breast evaluation skills? *Am J Surg* 1998;175:497-502.
- 198- **Chantler ML** : Breast cancer, In: Pillot G, Chantler M, Magiera H, et al. The Washington Manual™ Subspecialty Consult Series Hematology and Oncology Subspecialty Consult. Lippincott Williams & Wilkins. Philadelphia. Baltimore. New York. London. Buenos Aires Hong Kong. Sydney. Tokyo. 2004; 19:130-142.
- 199- **Chaudary MA and others** : Loco-regional recurrence following mastectomy for early breast carcinoma: efficacy of radiotherapy at the time of recurrence, *Eur J Surg Oncol* 1997; 23(4): 348-353.
- 200- **Chaudary MA, and others** : Nipple discharge : The diagnostic value of testing for occult blood, *Ann Surg* 1982; 196:651.
- 201- **Chaudary MA, Nagadowska M, Smith P, Gregory W, Fentiman IS.,** : Local recurrence after breast conservation treatment outcome following salvage mastectomy. *Breast* 1998; 7:33-38.
- 202- **Chearskul S and others** : Serum c-erbB-2 protein in breast cancer patients, *J Med Assoc thai-* 2000;83(8):886-893.
- 203- **Chelbowski RT., Collyar DE., Somerfield MR., et al.** : American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene. *J Clin Oncol* 1999; 17:1939-1955.
- 204- **Chen J.** : Ataxia-Telangiectasia related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage, *Cancer Res* 2000; 15:5037-5039.
- 205- **Chen J. and others** : The role of ataxia-telangiectasia heterozygotes in familial breast cancer, *Cancer Res* 1998; 58:1376-1379.
- 206- **Cheng JC, Cheng SH, Lin K-J, et al.** : Diagnostic thoracic-computed tomography in radiotherapy for loco-regional recurrent breast carcinoma. *Int J Radiat Oncol Biol Phys* 1998; 41:607-613.
- 207- **Chie W.C., and others** : Age at any fullterm pregnancy and breast cancer risk, *Am. J. Epidemiol.* 2000; 151:715-722.
- 208- **Christensen S, Jansson C** : Axillary biopsy compared with dissection in the staging of lymph nodes in operable breast cancer, *Eur J Surg Oncol* 1993; 159:159-162.
- 209- **Christian MC, Mc Cobe ms, Korn EL, et al.:** The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-O6. *NEJM.* 1995., 333: 1469-1474
- 210- **Chu FCH, and others** : Radiation therapy for cancer in posthetically augmented or reconstructed breasts, *Radiology* 1992; 185:429-433.
- 211- **Chung MA and others** : Optimal surgical treatment of invasive lobular carcinoma of the breast, *Ann Surg Oncol* 1997; 4(7): 545-550.

- 212- **Ciocca DR., Parente A., Russo J.,** : Endocrinologic milieu and susceptibility of the rat mammary gland to carcinogenesis, *Am J Pathol* 1982; 109:47-56.
- 213- **Clair T, Miller WR, Cho-chung YS** : Prognostic significance of the expression of a ras protein with molecular weight of 21,000 by human breast cancer, *Cancer Res* 1987;47:5290-5293.
- 214- **Clare SE, Sener SF, Wilkens W, et al.** : Prognostic significance of occult lymph node metastases in node negative breast cancer, *Ann Surg Oncol* 1997;4:447-451.
- 215- **Clark G. M., and McGuire W.L.,** : Steroid receptors and other prognostic factors in primary breast cancer. *Semin. Oncol*, 1988; 15:10.
- 216- **Clark RM and others** : Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update, *J Natl Cancer Inst* 1996;88:1659-1664.
- 217- **Clarke D and others** : Breast edema following staging axillary node dissection in patients with breast carcinoma treated by radiotherapy, *Cancer* 1982; 49:2295.
- 218- **Clarke D, Martinez A** : Identification of patients who are at high risk for locoregional breast cancer recurrence after conservative surgery and radiotherapy: a review article for surgeons pathologists, and radiation and medical oncologists. *J Clin Oncol* 1992; 10:474.
- 219- **Clarke DH and others** : Analysis of local-regional relapses in patients with early breast cancers treated by excision and radiotherapy experience of the institute Gustave-Roussy, *Int Radiat Oncol Biol Phys* 1985; 11:137-145.
- 220- **Claus EB, Risch N, TThompson WD** : Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction, *cancer* 1994; 74:643-651.
- 221- **Claus EB, Schildkraut JM, Thompson WF, Risch NJ.** : The genetic attributable risk of breast and ovarian cancer. *Cancer* 1996; 77: 2318.
- 222- **Claus EB., and others** : Relationship between breast histopath-ology and family history of breast cancer, *Cancer* 1993; 71:147-153.
- 223- **Clemons M., Goss P.,** : Estrogen and the risk of breast cancer, *N Engl J Med* 2001; 344(4): 276-285.
- 224- **Cline M.J., Buttitora H., Yokota J.,** : Proto-oncogene abnormalities in human breast cancer. Correlations with anatomic features and clinical course of disease. *J. Clin. Oncol*, 1987;5: 999-1006.
- 225- **Clough KB and others** : Cosmetic sequelae after conservative treatment of breast cancer: classification and results of surgical correction, *Ann Plastic Surg* 1998; 41:471-481.
- 226- **Clough KB and others** : Prospective evaluation of late cosmetic results following breast reconstruction: 1. Implant reconstruction, *Plast Reconstr Surg* 2001; 107: 1072-1079.
- 227- **Cobleigh MA and others** : Fenretinide (FEN) vs. placebo in postmenopausal breast cancer patients receiving adjuvant Tamoxifen (TAM), an Eastern cooperative Oncology Group (EODG) phase III Intergroup trial (EB 193, INT-O151) (abstract 328), *Proc Am Soc Clin Oncol* 2000;19:864.
- 228- **Cobleigh MA, Vogel CL, Tripathy D, et al.** : Efficacy and safety of Ilerceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HFR2 overexpression who relapsed following chemotherapy for metastatic breast cancer [Abstract 376]. *Proceedings of the*

*American Society of Clinical Oncology 1998; 17:97a.*

- 229- **Cody HS III, Egeli RA , Urban JA.** : Rotter's node metastases: Therapeutic and prognostic consideration in early breast carcinoma, *Ann Surg 1984; 199:266-270.*
- 230- **Cody HS III:** Sentinel lymph node mapping in breast cancers, *Oncology 1999; 13(1):25-43.*
- 231- **Cohen PR, Kohn SR, Kuzrock R.:** Association of sebaceous gland tumors and internal malignancy : The Muir-torre syndrome, *Am J. Med 1991; 90:603-606.*
- 232- **Colditz GA., and others :** Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women, *JAMA 1990; 264(20)2648-2653.*
- 233- **Colditz GA., Rosner B., :** Cumulative risk of breast cancer to age 70 years according to risk factor status : data from the Nurses' Health Study, *Am J Epidemiol 2000; 152(10): 950-964.*
- 234- **Cole P, Morrison AS:** Basic issues in populations screening for cancer. *J Natl Cancer 1980; 64:1263-1272.*
- 235- **Collaborative Group on Hormonal Factors in Breast Cancer :** Breast cancer and hormonal contraceptives: collaborative analysis of individual data on 55, 297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies, *Lancet 1996; 347:1713-1727.*
- 236- **Collaborative Group on Hormonal Factors in Breast Cancer :** Breast cancer and hormonal replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer, *Lancet 1997; 350:1047-1059.*
- 237- **Collichio FA, Agnello R, staltzer J:** Pregnancy after breast cancer: from psychosocial issues through conception. *Oncology 1998; 12:759-765, 773-775.*
- 238- **Colton T., and others :** breast cancer in mothers prescribed diethylstilbestrol in pregnancy: Further follow up, *JAMA 1993; 269:2096-2100.*
- 239- **Committee on the Biological Effects of Ionizing Radiation :** Health effects of exposure to low levels of ionizing radiation : *Bier V, Washington, DC, 1990, National Academy Press*
- 240- **Conley B and others :** pilot trial of the safety, tolerability, and retinoid levels of N- (4 hdroxyphenyl) retinamide in combination with Tamoxifen in patients at high risk for developing invasive breast cancer, *J Clin Oncol 2000;18:275.*
- 241- **Connolly JL, Fitzgibbons PL, Page DL.** :Updated protocol for the examination of specimens from patients with carcinomas of the breast. *Arch Paihol Lab Med 2000;124:1026-1033.*
- 242- **Consensus Conference Committee :** Consensus on the classifica-tion of Ductal carcinoma In-Situ, April 25-28, 1997. *Cancer 1997; 80:1798 – 1802.*
- 243- **Constantin JP and Others :** Validation studies for models projecting the risk of invasive and total breast cancer incidence, *J Natl Cancer Inst 1999; 91:1541-1548.*
- 244- **Conte CC and others :** Therapeutic oophorectomy in metastatic breast cancer, *Cancer 1989;64:150.*
- 245- **Contesso G ,Omar SH., Khaled H. :** Prognostic factors, in *Breast Cancer,4<sup>th</sup> ed.* Edt. By Omar SH., Contesso G, Khaled H.,2001;14:191-213
- 246- **Contesso G ,Omar SH., Khaled H.:** Breast cancer mass screening, In: *Breast Cancer,4th ed.* Edt. By

- Omar SH., Contesso G, Khaled H.,2001; 2:13-19
- 247- **Contesso G, Omar, Sh., and Khaled H.**, : Epidemiology of breast cancer, In: Contesso G., Omar, Sh., and Khaled H., : *Breast cancer, 4<sup>th</sup> edn. 2001; 1:1-8.*
- 248- **Contesso, G., Petit, J.Y., and Gazet J.C.** : The intraductal adenocarcinoma non-infiltrative type. Bulletin du cancer 66.1. Du pronostic de cancer du sein Bulletin du cancer, 1997; 64:525-29.
- 249- **Cook I.S., and others** : Hair product use and the risk of breast cancer in young women, *Cancer Causes Control* 1999; 10:551-559.
- 250- **Cooper C., and others** : Childhood growth and age at menarche, *Br J Obstet Gynaecol* 1996; 103(8): 814-817.
- 251- **Cooper C.L, Cooper, R., Faragher E.B.,:** Incidence and perception of psycho social stress: The relationship with breast cancer, *Psychol, Med.* 1989; 415-422.
- 252- **Cooper EH., Forbes Ma., Hancock AK., :** An elevation of mucin-like carcinoma associated antigen (MCA). In breast cancer. *Br. J. Cancer*, 1989; 59:697-800.
- 253- **Copeland E.M., McBride CM., :** Axillary metastases from unknown primary sites, *Ann Surg* 1973; 178:25.
- 254- **Coradini O and others** : Time-dependent relevance of steroid receptors in breast cancer, *J Clin Oncol* 2000; 18:2708-2709.
- 255- **Corrnetta K, Moore A, Johannessohn M, Sledge GW:** Clonal dominance detected in metastasis but not primary tumours of retrovirally marked human breast carcinoma injected into nude mice. *Clin Exp Metastasis* 1994;12:3.
- 256- **Costantine M., Amoroso D., Gianni W., et al.** : A retrospective comparison of detection and treatment of breast cancer. *Breast Cancer Res. Treat* 1997, 43:91-98.
- 257- **Costantino JP and others** : Validation studies for models projecting the risk of invasive and total breast cancer incidence, *J Natl cancer Inst* 1999; 91(18): 1541-1548.
- 258- **Costanza M and others:** safety and efficacy of using a single agent or a phase II agent be for instituting standard combination chemotherapy in previously un Treated metastatic breast cancer patients: report of a randomized study: cancer and leukaemia Group B 8642, *J Clin Oncol* 1999;17:1347-1406
- 259- **Cotran, R.S., Kumar, V., and Robbins, S.L., :** The female breast, In: Robbins pathological basis of disease, 5<sup>th</sup> ed., W.B. Saunders Company 1994; 29:1089-1111.
- 260- **Couch FJ and others** : BRCA2 germline mutations in male breast cancer cases and breast cancer families, *Nat Genet* 1996; 13:123-125.
- 261- **Coughlin S.S., Piper, M., :** Genetic polymorphisms and risk of breast cancer, *Cancer Epidemiol Biomarkers Prev.* 1999; 8:1023-1032.
- 262- **Covey D.F., Hood W.F.,:** A new hypothesis based on Suicide substrate inhibitor studies for the mechanism of action of aromatase. *Cancer Res.* 1982; 42: (Supl.): 3327-33
- 263- **Cowen, P.N., Bates, C., :** The significance of intraduct appearances in breast cancer. *Clin Oncol* 1984;10:67.
- 264- **Cowie A.T.,:** Hormonal factors in mammary development and lactation. In: Stoll, B.A. ed. Mammary

- Cancer and Neuroendocrine Therapy. London: Butterworth, 1974;P: 3-24.
- 265- **Cowie, A.T., Backward, Glances, In Yokoyama, A., Mizuno, H. Nagasawa, H. (eds.):** Physiology of mammary glands. Baltimore, university park. Press, 1978;P:43.
- 266- **Criiveller: D and others:** Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and Tamoxifen for elderly patients with breast cancer: the International Breast cancer study group (IBCSG) Trial VII, *J Clin Oncol* 2000;18:1412
- 267- **Crile G Jr, :** Results of conservative treatment of breast cancer at ten and 15 years, *Ann Surg* 1975; 181:26.
- 268- **Crile G.C. :** The incidence of local recurrences of carcinoma of the breast *Surg. Gynecol. Obstet*, 1983; 156: 497-8.
- 269- **Crossin JA and others :** Gamma probe- guided resection of the sentinel lymph node in breast cancer, *Am Surg* 1998; 64:666-664.
- 270- **Crowe JP Jr and others :** Local-regional breast cancer recurrence following mastectomy, *Arch Surg* 1991; 126:429-432.
- 271- **Crowe, D.R., and Lampejo, O.T:** Malignant tumors of the breast. In: Diagnosis and management of breast disease, ed. By Blackwell, R.E., and Grotting, J.C.b. Blackwell, science 1996:5: 103-134.
- 272- **Cubilla, A.L., Woodruff, J.M. :** Primary carcinoid tumor of the breast. A report of eight patients. *Am J Surg Pathol*. 1977;1:283-292.
- 273- **Cumming SR., Eckert S., Krueger K., et al. :** the effect of raloxifen on risk of breast cancer in postmenopausal women : results form the MORE randomized trial. *JAMA* 1999;281: 2189-2197.
- 274- **Curcio LD and others :** Local recurrence in breast cancer: implications for systemic disease, *Ann Surg Oncol* 1997; 4(1): 24-27.
- 275- **Curiel MD., Calero JA., Guerrero R, et al. :** Effects of LY-117018 HCl on bone remodeling and mineral density in the oophorectomized rat. *Am J Obstet Gynecol* 1998;178:320-325.
- 276- **Cuzick J :** Update on new studies in Europe (abstract), *Eur J cancer* 2002;38(suppl3):544.
- 277- **Cuzick J and others :** Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer, *Cancer Treat Rep* 1987; 71:15-29.
- 278- **Daidone MC and others :** Clinical studies of Bcl-2 and treatment benefit in breast cancer patients, *Endocr Relat Cancer* 1999; 6:61-68.
- 279- **Dalberg K, Johansson, Rutquistl, for the Stockholm Breast cancer study Group:** A randomized trial for long-term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy for patients with early stage breast carcinoma treated with breast-conserving surgery.*Cancer* 1998; 82:2204.
- 280- **Daly M., :** NCCN practice guidelines : genetics/familial high-risk cancer screening. *Oncology* 1999; 13:161-171.
- 281- **Damiani, S., and others :** Myoepithelial cells and basal lamina in poorly differentiated in-situ duct carcinoma of the breast: an immuno-cytochemical study, *Virchows Arch* 1999;434:227.
- 282- **Damiani, S., Dina, R., Eusebi, V., :** Eosinophilic and granular cell tumors of the breast, *semin Diagn*

Pathol 1999; 16:117.

- 283- **Dao T.L., Libby P.R.:** Steroid sulfate formation in human breast tumors and hormone dependency in estrogen target tissues and neoplasia. In T.L. Dao, estrogen target tissue in neoplasia 1972; PP: 181-200. Chicago University Press, Chicago.
- 284- **Dargent M., Berger M., Lahneche B.:** Thyroid function in breast cancer patients. Acta Unio. Unt. Contra. Conc. 1962; 18, 915.
- 285- **Davidoff AM and others :** Relation between P53 overexpression and established prognostic factors in breast cancer, Surgery 1991;110:259-264.
- 286- **Davidson N, O'Neil A, Vukow A, et al.:** effect of chemohormonal Therapy in premenopausal, node (+) receptor (+) breast cancer: an Eastern Cooperative Oncology Group phase III Intergroup trial (ES188,Int-0101). *Proc Am Soc Clin Oncol* 1999;18:244A
- 287- **Davies GC, Milli RR, Hayward JL, :** Assessment of axillary lymph node status, *Ann Surg* 1980; 192:148-151.
- 288- **Dawson, P.J., :** What is new in our understanding of multifocal breast disease. *Pathol. Res. Pract*, 1993; 189: 111-116.
- 289- **Dawson, P.J., Baekey, P.A., Clark, R.A., :** Mechanisms of multifocal breast cancer. An immunocytochemical study. *Hum. Pathol*, 1995;26:965-969.
- 290- **Day R., Ganz PA., Costantion JP., et al. :** Health related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J clin Oncol* 1999; 17:2659-2669.
- 291- **Dayhoff JE, Deleo JM :** Artificial neural networks: opening the black box, *Cancer* 2001 91 (suppl):1615-1635.
- 292- **De Coster R., Van Ginckerl RF., Callens MJ., et al. :** Anti-tumoral and endocrine effects of (+) vorozole in rats bearing dimethyl-benzanthracene-induced mammary tumors. *Cancer Res* 1992; 52:1240-1244.
- 293- **De La Rochefordiere A and others :** Are cosmetic results following conservative surgery and radiation therapy for breast cancer dependent on technique? *Int J Radiat Oncol Biol Phys* 1992; 925-931.
- 294- **De la Rochefordiere A, Mouret- Fourme e, de Ricke Y, et a.,I:** local and distant relapses,in relation premenopausal patients with breast cancer. *Int J Radiat Oncol Boil Phys* 1998, 42:180(abst).
- 295- **De Waard, F., Cornelis, J.P., and yoshida, M., :** Breast cancer incidence according to weight and height of two cities of the Neither lands and in Aishiprn fecture Japan., *Cancer* 1997; 40:1269.
- 296- **Dean PB:** Final comment. The articles by **Gotzsche and Olsen** are not official Cochrane reviews and lack scientific merit. *Lakartidningen* 2000; 97:3106.
- 297- **Deapan DM., Bernstein L., Brody GS., :** Are breast implants anticarinogenic? A 14-year follow up of the Los Angeles study, *plast. Reconstr. Surg.* 1997; 99: 1346-1353.
- 298- **Deckers P, :** Axillary dissection in breast cancer: When, why, how much, and for how long? Another operation soon to be extinct? *J Surg Oncol* 1991; 48:217-219.

- 299- **Dees EC, Davidson NE** : Ovarian ablation as adjuvant therapy for breast cancer. *Semin Oncol* 2001;28:322.
- 300- **Dees EC, Shulman LN, Souba WW, Smith B** : Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? *Ann Surg* 1997; 226(3):279-287.
- 301- **Delberg K, Mattsson A, Sandelin K, Rutqvist LE** : Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer. *Breast Cancer Res Treat* 1998; 49:69.
- 302- **Delmas PD., Bjamasan NG., Mitlak BH., et al.** : Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. *N Engl J Med* 1997; 337:1641-1647.
- 303- **Demers PA., and others** : Occupational exposure to electromagnetic fields and breast cancer in men, *Am. J. Epidemiol.* 1991; 134:340-347.
- 304- **Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS** : Loss of heterozygosity in normal tissue adjacent to breast carcinoma. *Science* 1996; 274:2057-2059.
- 305- **Dershaw DD.,** : Mammography in patients with breast cancer treated by breast conservation (lumpectomy with or without radiation). *AJR Am J Roentgenol* 1995; 164:309.
- 306- **Deuschch M.,** : Repeat high dose partial breast irradiation after lumpectomy for in-breast tumor recurrence following initial lumpectomy and radiotherapy. *Int J Radiat Oncol Biol Phys* 1997; 42:255 (abst).
- 307- **Devitt JE,** : Management of nipple discharge by clinical findings, *Am J Surg* 1985; 149:789.
- 308- **Dickson R.B., Lippman M.E.,** : Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. *Endocr. Rev.* 1987; 8: 29- 43.
- 309- **Dickson RB, Lippman ME** : Molecular biology of breast cancer. In : De Vita Vt Jr, Hellman S., and Rosenberg SA., *Cancer principles and practice of oncology*, 6<sup>th</sup> eds., Lippincott-Williams & Wilkins, Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo, 2001; 37(1): 1633-1651.
- 310- **Dickson RB, Lippman ME** : Molecular biology of breast cancer. In Donegan WL, Spratt Js, *Cancer principles and practice of oncology* 5<sup>th</sup> Ed Lippincott-Raven. Philadelphia. New York. 1997, p 1541-1557.
- 311- **Dickson RB, Lippman ME:** Molecular determinants of growth, angiogenesis, and metastases in breast cancer. *Semin Oncol* 1992;19:286.
- 312- **Diehl LF and others** : Skin metastases confined to a field of previous irradiation : report of two cases and review of the literature, *Cancer* 1984; 53: 1864.
- 313- **Diel I, Cote R** : Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer, *Cancer Treat Rev* 2000;26:53-65
- 314- **Diel IJ and others** : Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis, *J Clin Oncol* 1992; 10:1534-1539.
- 315- **Diel IJ, Solomayer EF, Costa SD et al.** : Reduction in new metastases in breast cancer with adjuvant clodronate treatment. *N Engl J Med* 1998; 339:357.

- 316- **Dipaola RS, Orel SG, Fowble BL.,** : Ipsilateral breast tumor recurrence following conservative surgery and radiation therapy, *Oncology* 1994; 8(12): 59-76.
- 317- **Dirx MJ, and other** : Diet in adolescence and the risk of breast cancer; results of the Netherlands Cohort Study, *Cancer Causes Control* 1999; 10:189-199.
- 318- **Disaia PJ, Creasman WT.,** : Breast Diseases. In : Disaia Creasman clinical Gynecologic oncology, 6<sup>th</sup> edition, Ed. by Mosby, Inc, St. louis, London, Philadelphia, Sydney, Toronto 2002 (14) : 385 – 422 .
- 319- **Dixon AR and others** : Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival. *Br J Cancer* 1990;62:868.
- 320- **Dixon J M** : Adjuvant Treatment in breast cancer. In: Johnson C, Taylor I, Recent advances in Surgery 25. The Royal Society of Medicine Press Limited, 2004; 15:191-204.
- 321- **Dixon J.M, Sainsbury J.R.,** : Breast cancer, In: HAND BOOK of DISEASES OF THE BREAST. 2<sup>nd</sup> ed. Churchill Living stone co., London, Tokyo, Toronto. 1998; PP. 87-102.
- 322- **Dixon JM,** : Adjuvant treatment in breast cancer, In : Recent Advances in Surgery 25, Ed. By Johnson C, Taylor I., *The Royal Society of Medicine Press limited* 2002; 15:191-204.
- 323- **Dixon JM, Leonard RCF:** Hormones and chemotherapy. In: Farndon (ed) A Companion To specialist Surgical Practice Breast and Endocrine Surgery, 2<sup>nd</sup> edn. London: Saunders, 2001; 107-146.
- 324- **Dixon JM, Rodger A, Johnson S, Gregory K.,** : Breast cancer: non-metastatic. *Clin Evidence* 2001; 5:1218-1245.
- 325- **Dixon, J.M., Sainsbury, J.R.** : Breast cancer, In: Handbook of Diseases of the breast, 2<sup>nd</sup> ed. Churchill Livingstone Co. London Tokyo, Toronto 1998;PP.87-102.
- 326- **Dombernowsky P., Smith I., Falkson G., et al.** : Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. *J clin Oncol* 1998; 16:453-461.
- 327- **Donegan W.L,** : Diagnosis of breast cancer, In : Cancer of the Breast, 5<sup>th</sup> ed. Ed. By Donegan W., Spratt JS, Saunders 2002; 17:311-345.
- 328- **Donegan W.L., Padrta, B.,** : Combined therapy for inflammatory breast cancer, *Arch Surg* 1990;125:578-582.
- 329- **Donegan WL** : Mastectomy in the primary management of invasive mammary carcinoma. In Hardy JD, editor: Advances in surgery, vol 6, Chicago, 1972, Year Book Mmedical, P1.
- 330- **Donegan WL** : Prognostic factors: stage and receptor status in breast cancer, *Cancer* 1992; 70:1755-1764.
- 331- **Donegan WL,** : Management of early invasive carcinoma (TNM stages I and II ). In: *Donegan WL. Spratt JS. Cancer of the Breast. 5<sup>th</sup> ed. Saunders. Philadelphia, London. New York. ST Louis. 2002,24:535-565.*
- 332- **Donegan WL, Stine SB, Samter TG.,** : Implications of extracapsular nodal metastases for treatment and prognosis of breast cancer, *Cancer* 1993; 72(3): 778-782.
- 333- **Donegan WL.,** : Local and regional recurrence. In: *Donegan WL. Spratt JS. Cancer of the Breast. 5<sup>th</sup> ed. Saunders. Philadelphia, London. New York. ST Louis. Sydney. Toronto 2002,37:825-839.*

- 334- **Donegan WL.,** : The influence of untreated internal mammary metastases upon the course of mammary cancer, *Cancer* 1977; 39:533.
- 335- **Donegan, W., & Spratt, J.S.,** : CANCER of the BREAST 5<sup>th</sup> ed. By Saunders, Philadelphia, London, New York, Stlouis, Sydney, Toronto 2002; 7:111-132.
- 336- **Dooley WC., Veronesi U., Elledge R., et al.** : Detection of premalignant and malignant breast cells by ductal lavage. *Breast Cancer Res Treat* 2000; 64:17.
- 337- **Dooley WC., Veronesi U., Elledge R., et al.** : Detection of premalignant and malignant breast cells by ductal lavage. *Obstet Gynecol* 2001; 97:52.
- 338- **Dorgan JF and others** : Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5- androstene -3beta, 17 beta- diol to risk of breast cancer in postmenopausal women, *cancer Epidemiol. Biomarkers Prev.* 1997; 6:177-181.
- 339- **Dorgan JF., and others** : Relationship of serum dehydroepian-drosterone (DHEA), DHEA sulfate, and 5-androstene -3 beta 17 betadiol to risk of breast cancer in postmenopausal women, *Cancer Epidemiol Biomarkers Perv.* 1997; 6(3): 177-181.
- 340- **Dorum A., Heimdal K., Lovslett K., et al.** : Prospectively detected cancer in familial breast/ovarian cancer screening. *Acta obstet Gynecol Scand* 1999; 78:906-94.
- 341- **Dotzlaw H and others** : Epidermal growth factor gene expression in human breast cancer biopsy samples: relationship to estrogen and progesterone receptor gene expression, *Cancer Res* 1990;50:4204.
- 342- **Douglas- Jones, A. G., and others** : A critical appraisal of six modern classifications of ductal carcinoma in-situ of the breast (DCIS): Correlation with grade of associated invasive carcinoma, *Histopathology* 1996; 29:397.
- 343- **Dowsett M and others** : A dose-comparative endocrine- clinical study of leuprolide in premenopausal breast cancer patients. *Br J Cancer* 1990;62:854.
- 344- **Doyle TH, Schultz DJ, Peters CA, Solin LJ.,** : Long term results of local recurrence after breast conservation therapy for invasive breast cancer, *Int J Radiat Oncol Biol Phys* 1999; 45:309 (abst).
- 345- **Draper MW., Flowers DE., Huster WJ., et al.** : a controlled trial raloxifene (Ly 139481) Hcl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. *J Bone Miner Res* 1996; 11:835-842.
- 346- **Dreicer R, Wilding G:** steroid hormone agonists and antagonists in the treatment of cancer. *Cancer Invest* 1992;10:27.
- 347- **Drew PJ., and others** : Prospective comparison of standard triple assessment and dynamic magnetic resonance imaging of the breast for the evaluation of symptomatic breast lesions, *Ann Surg.* 1999; 230:680-685.
- 348- **D'souza B, Taylor-Papadimitriou J:** Overexpression of erbB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. *Proc Natl Acad Sci USA*, 1994;91:7202.
- 349- **Dubey AK, Recht A, come SE, et al.** : concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. *Int J Radiat Oncol Biol Phys* 1999; 45:877.

- 350- **Duffy MJ and others** : CA 15-3: a prognostic marker in breast cancer, *Int J Biol Markers* 2000; 15:330-333.
- 351- **Duffy SW, Tabar L.**: Screening mammography re-evaluated. *Lancet* 2000; 355:747-748.
- 352- **Dunning AM., and others** : A systemic review of genetic polymorphisms and breast cancer risk, *Cancer Epidemiol. Biomarker Prev.* 1999; 8:843-854.
- 353- **Dupont WD., & Page D.L.,** : Estrogen replacement therapy in women with a history of proliferate breast disease. *Cancer* 1999; 85:1277-1280.
- 354- **Dupont WD., & Page DL.,** : Risk factors for breast cancer in women with proliferative breast disease, *N. Engl. J. Med.* 1985; 312:146-151.
- 355- **Durand JC, Pilleron JP,** : Cancer of the breast, limited excision followed by radiation therapy and results in 150 cases treated at the Curie Foundation, 1960 to 1970, *Bull Cancer (Paris)* 1977; 64:611.
- 356- **Early Breast Cancer Trialists' Collaborative Group (EBCTCG)** : Tamoxifen for early Breast cancer: an overview of the randomized trials, *Lancet* 1998;351:1451-1467
- 357- **Early Breast Cancer Trialists' Collaborative Group (EBCTCC)** : Polychemotherapy for early breast cancer: an overview of the randomized trials. *Lancet* 1998; 352:930-942.
- 358- **Early Breast cancer Trialists' Collaborative Group (EBCTCG)** : Ovarian ablation in early breast cancer. Overview of the randomized trials. *Lances* 1996; 348: 1189-1196.
- 359- **Early Breast Cancer Trialists' Collaborative Group (EBCTCG)**: Systemic treatment early breast cancer by hormonal, ctotoxic, or immune therapy. *Lancet* 1992; 339:1-15,71-85.
- 360- **Early Breast Cancer Trialists' Collaborative Group(EBCTCG)** : Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. *N Engl J Med* 1995; 333:1444-1455.
- 361- **Easton D.,** : Breast cancer : not just whether but when? *Nat Genet* 2000, 26(4): 390-391.
- 362- **Easton DF.** : Cancer risk in A-heterozygotes. *Int. J. Radiat. Biol* 1994; 66 (Suppl6): 5177-82.
- 363- **Eck RW, Falkson CI.,** : Extended survival in 80 patients with operable, loco-regionally recurrent breast cancer treated with chemotherapy, *Am J Clin Oncol* 1998; 21(5): 501-504.
- 364- **Eddy DM, Hasselblad V, McGivney W, et al.:** The value of mammography screening in women under age 50 years. *JAMA* 1988;259: 1512-1519.
- 365- **Eeles RA., Powles TJ.,** :Chemoprevention options for BRCA1 and BRCA2 mutation carriers. *J Clin Oncol* 2000;18 (21 suppl 5) : 935-995.
- 366- **Egan KM., and others** : The relation of breast size to breast cancer risk in postmenopausal women (United States), *Cancer Causes Control* 1999; 10:115-118.
- 367- **Eisen A., Weber BL.,** : Prophylactic mastectomy- the price of fear, *N Engl J Med* 1999; 340(2): 137-138.
- 368- **Ekbom A., and others** : Intrauterine environment and breast cancer risk in women; apopulatio based study, *J Natl Cancer Inst* 1997; 89:71-76.
- 369- **Eklund GW., Cardenosa G., Parsons W.,** : Assessing adequacy of mammographic image quality, *Radiology* 1994;190:297-307.
- 370- **EL-Bolkainy N,** : Breast cancer. In Topographic pathology of cancer Cairo Nat cancer Instit, 1998.

- 371- **Elledge kM, Lee w.:** Life and death of p53. *Bioessays* 1995; 17:923
- 372- **Elledge RM and others :** Estrogen receptor (ER) and progesterone receptor (PR), by ligand-binding assay compared response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study, *Int J Cancer* 2000 ;89:111-117.
- 373- **Elledge RM and others :** William L. McGuire Memorial Symposium: the role and prognostic significance of P53 gene alterations in breast cancer, *Br Cancer Res Treat* 1993;27:95-102.
- 374- **Elledge RM, Green S, Ciocca D, et al. :** HER-2 expression and response to tamoxifen in estrogen receptor positive breast cancer: a South west oncology Group study. *Clin Cancer Res* 1998;4:7-12
- 375- **Elledge S. :** Cell cycle check points: Preventing an identity crisis. *Science* 1996; 27:1664-1671.
- 376- **Elmore JG and others:** Ten-year risk of false positive screening mammograms and clinical breast examinations, *N Engl J Med* 1998;338: 1089-1096.
- 377- **Elston C.W. and Ellis I.O. :** Pathological prognostic factors in breast cancer, The value of histologic grade in breast cancer: Experience from a large study with long term follow-up *Histopathology*,1991,19:403.
- 378- **Eltahir A, Heys SD, Hutcheon AW :** Treatment of large and locally advanced breast cancer using neoadjuvant chemotherapy, *Am J Surg* 1998; 175: 127-132.
- 379- **Enger SM. And others:** body size, physical activity, and breast cancer hormone receptor status : results from two case-Control studies, *Cancer Epidemiol Biomarkers Prev* 2000; 9:681-687.
- 380- **Epstein RJ :** Routine or delayed axillary dissection for primary breast cancer? *Eur J Cancer* 1995; 31A: 1570-1523.
- 381- **Ernester V., and others :** Mortality among women with ductal carcinoma in situ of the breast in population-based Surveillance, Epidemiology and End Results Program, *Arch Intern Med* 2000; 100:953-958.
- 382- **Ernester VL, Barclay J, Kerlikowske K, et al.:** Incidence of and treatment for ductal carcinoma in situ of the breast *JAMA*. 1996;275:913-918.
- 383- **Ettinger B., Black DM., Mitlak BH., et al. :** Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial : Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. *JAMA* 1999; 282:637-645.
- 384- **European Commission Working Group Breast Screening Pathology(ECWGBSP) :** Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. *Hum Pathol* 1998; 9:1056.
- 385- **Eusebi V, Damiani S. :** Gross and microscopic pathology In: *Cancer of the Breast*, 5<sup>th</sup> ed. Ed. By Donegan and Spratt, Saunders, 2002; 13:347-375.
- 386- **Eusebi, V., :** Il carcinoma lobular della mammella, *Pathologica* 1975;67:19.
- 387- **Eusebi, V., and others :** Apocrine differentiation in breast epithelium, *Adv Anat Pathol*. 1997;4:139.
- 388- **Eusebi, V., and others :** Carcinoma in-situ in sclerosing adenosis of the breast: an immunocytochemical study, *Semin Diag Pathol* 1989;6:146.

- 389- **Evan EP** : Breast. masses: Appropriate evaluation, *Radiol Clin North Am* 1995;33( 6):1085-1108.
- 390- **Evans P., and Oberman H.,** : sterotactic needle biopsy: Core and FNA in syllabus of 26<sup>th</sup> national conference of breast cancer, American Colleague of Radiology, San Diego, 1994;26:9.
- 391- **Ewers SB and others** : Flow cytometry, DNA analysis and prediction of loco-regional recurrence after mastectomy in breast cancer, *Acta Oncol* 1992; 31:733-740.
- 392- **Faber K.A., Hammond C.B.,** : Endocrine aspects of breast disease and breast function: Textbook of breast disease. Mosby Year Book. 1992;P. 87.
- 393- **Falk RT., and others** : Reproducibility and validity of radioim-munoassay for urinary hormones and metabolites in pre-and postm-enopausal women, *Cancer Epidemiol Biomarkers Prev* 1999; 8:567-577.
- 394- **Falkenberry SS., Cady B., and Chung MA.,** : Management of Ductal Carcinoma In Situ, In : Manual of Breast Diseases ed. By : Ismail Jatoi. Lippincott Williams & Wilkins. Philadelphia, Baltimore, New York. London. Buenos Aires. Hong Kong. Sydney. Tokyo,2002 ; 12: 271-288
- 395- **Fan S, Smith ML, Rivet DJ II ;et al.** : Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifyllin. *Cancer Res* 1995;55:1649.
- 396- **Fan S., and others:** BRCA1 inhibition of estrogen receptor signaling in transfected cells, *Science* 1999; 284:1354-1356.60
- 397- **Farria DM., Debruhl Na., Gorczia DP., Bassett LW.,** : Magnetic resonance imaging of breast tumors, *Semin Breast Dis* 1999; 2(1) : 74.
- 398- **Faverly D., and others:** three dimensional imaging of mammary ductal carcinoma in situ: clinical implications,*semin Diag pathol* 1994;11:193-198.
- 399- **Fechner, R.E.,** : Infiltrating lobular carcinoma without lobular carcinoma in-situ. *Cancer* 1972;24:1539.
- 400- **Feig S.A.,** : Role and evaluation of mammography and other imaging methods for breast cancer detection diagnosis, and staging, *Semin Nucl Med* 1999;29(1) :3-15.
- 401- **Feig SA and others:** American College of Radiology guidelines for breast cancer screening, *AJR Am J Roentgenol* 1998; 171:29-33.
- 402- **Feig SA,** : Ductal carcinoma in situ : implications for screening mammography, *Radiol clin North An* 2000; 38(4): 653-668.
- 403- **Feigelson HS., and others** : A polymorphism in the CYP 17 gene increases the risk of breast cancer, *Cancer Res* 1997; 57: 1063-1065.
- 404- **Fenlon HM., and others** : Benign versus malignant breast disease : Comparison of contrast-enhanced MR imaging and Tc-99m Tetrofosmin scintimammography, *Radiology* 1997; 205:214.
- 405- **Fentiman IS,** : Long-term follow-up of the first breast conservation trial: Guy's wide excision study, *the Breast* 2000; 9(1):5-8.
- 406- **Ferguson AT, Davidson NE:** Regulation of estrogen receptor and function in breast cancer *CMT. Rev. Oncol* 1997;8:29.
- 407- **Ferguson AT, Lapidus RG, Baylin SB et al.:** Demthylation of the estrogen

receptors gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. *Cancer Res.* 1995; 55:2279.

- 408- **Fischer U, Kopka L, Grabbe E:** Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach, *Radiology* 1999; 213:881-888.
- 409- **Fisher B and others :** A randomized clinical trial evaluating Tamoxifen in the treatment of patients with node negative breast cancer who have estrogen- receptor- positive tumors, *N Engl J Med* 1989;320:479.
- 410- **Fisher B and others :** Adjuvant chemotherapy with and without Tamoxifen in the treatment of primary breast cancer: 5 year results from the national surgical Adjuvant Breast and Bowel project trial, *J Clin Oncol* 1986;4:459.
- 411- **Fisher B and others :** Chemotherapy with or without Tamoxifen for patients with ER negative breast cancer and negative nodes: results from NSABP B23 (abstract 277), *Proc Am Soc Clin Oncol* 2000; 19:724
- 412- **Fisher B and others :** Comparison of radical mastectomy with alternative treatments for primary breast cancer, *Cancer* 1977; 39:2827-2839.
- 413- **Fisher B and others :** Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. *N Engl J Med* 1989; 320:822-828.
- 414- **Fisher B and others :** Five versus more than five year of Tamoxifen For lymph nod- negative breast cancer: up dated findings from the national surgical Adjuvant Breast and Bowel project B-14 Randomized Trial, *J Natl Cancer Inst* 2001;93:684.
- 415- **Fisher B and others :** Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer, *J Clin Oncol* 1983;1:227.
- 416- **Fisher B and others :** Postoperative chemotherapy and Tamoxifen compared with Tamoxifen alone in the treatment of positive- node breast cancer patients aged 50 years and older with tumors responsive Tomoxifen: results from the national surgical Adjuvant Breast and Bowel project B-16, *J Clin Oncol* 1990;8:1005.
- 417- **Fisher B and others :** Prolonging Tomoxifen therapy for primary breast cancer: findings from the national surgical Adjuvant Breast and Bowel project Clinical Trial, *Ann Intern Med* 1987; 106:649.
- 418- **Fisher B and others :** Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update, *Cancer* 1983;52:1551.
- 419- **Fisher B and others :** Significance of ipsilateral breast tumor recurrence after lumpectomy. *Lancet* 1991; 338:327-331.
- 420- **Fisher B and others :** Systemic Therapy in patients National Surgical Adjuvant Breast Bouel Project (NSABP) clininer trials, *Ann Intern Med* 1989; 111:703.
- 421- **Fisher B and others :** Tamoxifen and chemotherapy for axillary node- negative, estrogen receptor- negative breast cancer: findings from National surgical Adjuvant Breast and Bowel project B-23, *J Clin Oncol* 2001;19:931.

- 422- **Fisher B, Anderson S, Redmond CK, Wolmar KN, Wickerham DL, Cronin WM**, : Reanalysis and results after 12 years of follow-up in randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer, *N Engl J Med* 1995; 333:1456-1461.
- 423- **Fisher B, Anderson S, Wickerham DL et al.** : Increased intensification and total dose of cyclophosphamide in doxorubicin Cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. *J Clin Oncol* 1997; 15:1858-1869.
- 424- **Fisher B, Brown A, Mamounas E, et al.** : Effect of preoperative chemotherapy on local regional disease in women with operable breast cancer : findings from national surgical Adjuvant Breast and Bowel project B-18. *J Clin Oncol* 1997;15:2483.
- 425- **Fisher B, Costantino JP, Wickerham DL,et al.**: Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and Bowel Project P-I study. *J Natl. Cancer Inst.* 1998;90:1371-1388.
- 426- **Fisher B, Dignam J, Brvant J, et al.** : Five versus more than five year of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor- positive tumors. *J Natl Cancer Inst* 1996;88:1524-1542
- 427- **Fisher B, Dignam J, Wolmark N et al.** : Lumpectomy and radiation for the treatment of intraductal breast cancer; findings of the National Surgical Adjuvant Breast and Bowel Project B-17. *J Clin Oncol* 1998; 16:441-452.
- 428- **Fisher B, Dignam J, Wolmark N, et al.** : Tamoxifen and chemotherapy for lymph node negative , estrogen receptor-positive breast cancer. *J Natel Cancer Inst* 1997;89:1673-1682
- 429- **Fisher B, Redmond C.,** : Lumpectomy for breast cancer: an update of the NSABP experience, *Monogr J Natl Cancer Inst* 1992; 11:7-13.
- 430- **Fisher B, Redmond C., Fisher ER, et al.** : Ten year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation, *N Engl J Med* 1985; 312:674-681.
- 431- **Fisher B, Wickerham DL, Redmond C** : Recent developments in the use of systemic adjuvant therapy for the treatment of breast cancer, *Semin Oncol* 1992;14:263.
- 432- **Fisher B.,** : Laboratory and clinical research in breast cancer-a personal adventure: The David A. Karnofsky memorial lecture. *Cancer Res* 1980; 40: 3863-3874.
- 433- **Fisher B., and others** : Findings from National Surgical and Adjuvant Breast & Bowel Project B-17. *J clin Oncol* 1998 ; 16:441-452.
- 434- **Fisher B., Dignam J., Wolmark N., et al.** : Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial, *Lancet* 1999; 353:1993-2000.
- 435- **Fisher B., Redmond C., Fisher G.R. and participating NSABP investigators** : The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology. An overview of finding cancer. 1980; 46:1009-1025.

- 436- **Fisher B., Wolmark N., Fisher E. and Deitsch M.** : Lumpectomy and axillary dissection for breast cancer: surgical, pathological and radiation consideration. *World. J. Surg.* 1985; 9: 692-698.
- 437- **Fisher E., Digman J., Tan-Cheim E., et al.** : Pathologic finding from the National Surgical Adjuvant Breast Project (NSABP) Eight-year Update of Protocol B-17. *Cancer* 1999 ;86 : 429-438.
- 438- **Fisher ER and others** : Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4), *Am J Clin Patbol* 1976;65:439-444.
- 439- **Fisher ER,** : Lumpectomy margins and much more, *Cancer* 1997; 79(8): 1453-1458.
- 440- **Fisher ER, and others** : The pathology of invasive breast cancer : a syllabus derived from findings of the National Surgical Adjuvant Breast Project (Protocol No. 4), *Cancer* 1975;36:1.
- 441- **Fisher ER, Anderson S, Redmond C, Fisher B.,** : Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-66. *Semin Surg Oncol* 1992; 8: 161-166.
- 442- **Fisher ER, Costantino J, Fisher PHB, Paleker AS, Redmond C, Mamounas E for the National Surgical Adjuvant Breast and Bowel Project Collaborating In vestigators** : Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. *Cancer* 1995; 75:1310-1319.
- 443- **Fisher ER, Dignam J, Tan-Chiu E et al. for the National Surgical Adjuvant Breast and Bowel Project (NSABA) Collaborating In vestigators** : Pathologic findings from the national surgical adjuvant breast and Bowel Project (NSABP) eight-year update of protocol B-17. *Cancer* 1999; 86:429-438.
- 444- **Fisher, E.R., Costantino, J., fisher, B.,** : Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17 Five year observations concerning lobular carcinoma in-situ, *Cancer* 1996;78:1403.
- 445- **Fisher, E.R., Gregorio, R., Redmond, C., Vellios, F., Sommer, S.C., Fisher, B.,** : Pathological findings from the National surgical Adjuvant Breast Project (protocol no. 4). I. Observations concerning the multicentricity of mammary cancer. *Cancer*, 1975;35:247-254.
- 446- **Fishman EK and others** : Multiplanar CT evaluation of brachial plexopathy in breast cancer, *If Comput Assist Tomogr* 1991; 15(5): 790-795.
- 447- **Fitzgibbons PL, Page DL, Weaver DL, et al.** :Prognostic factors in breast cancer; College of American Pathologists consensus statement 1999. *Arch Pathol Lab Med* 2001;1 24:966-978.
- 448- **Fitzgibbons RE and others** : Prognostic factors in breast cancer: College of American Pathologists Consensus 1999, *Arch Pathol Lab Med* 2000;124:966-978.
- 449- **Fleming ID., and others, editors** : AJCC cancer staging Manual, ed 5, Philadelphia, New York 1997, Lippincott-Raven, P 173.
- 450- **Fletcher SW, Black W, Harris R, et al.:** Report of the international workshop on screening for breast cancer *J Natl Cancer Inst* 1993; 85:1644-1656.
- 451- **Fodor J and others** : Incidence and time of occurrence of regional recurrence in stage I-II breast cancer: Value of adjuvant irradiation, *Int J Radiet Oncol Biol Phy* 1999; 44(2): 281-287.
- 452- **Foekens J.A, Van Putten W.L. Portengen H.,:** Prognostic value of p53 and cathepsin Din 710 patients with primary breast tumors: multivariate analysis, *J. Clin. Oncol.*, 11(5):809.

- 453- **Foekens JA and others** : The urokinase system of plasminogen activator and prognosis in 2780 breast cancer patients, *Cancer Res* 2000; 60:636-643.
- 454- **Folkman J** : Angiogenesis in breast cancer, In : Bland KI, Copland EM, eds. *The breast*, 2<sup>nd</sup> ed. Philadelphia; WB Saunders. 1998; 586.
- 455- **Forbes JF**: chemoprevention: inside and outside trials (abstract), *Eur J Cancer* 2002;38(suppl 3):543.
- 456- **Ford D. and others** : Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast cancer Linkage Consortium, *Am J Hum Genet* 1998; 62:676-689.
- 457- **Fornander T and others** : Adjuvant Tamoxifen in early stage breast cancer: effects on intercurrent morbidity and mortality. *J Clin Oncol* 1991;4:1740.
- 458- **Forrest AP and others** : Randomized controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial, *Lancet* 1996; 348:708-713.
- 459- **Fortin A and others** : Local failure is responsible for the decrease in survival of patients with breast cancer treated with conservative surgery and postoperative radiotherapy, *J Clin Oncol* 1999; 17:101-109.
- 460- **Foschini, M.P., and others** : Microcalcification in ductal carcinoma in situ of the breast. *Hum Pathol* 1996;27:178.
- 461- **Fourquet A., dela Rochefordiere, Campana F.,** : Occult primary cancer with axillary metastases, In : Harris JR., Lippman ME., Morrow M., Osborne CK., editors: *Diseases of the breast*, ed 2 Philadelphia., 2000, Lippincott Williams & Wilkins.
- 462- **Fowble B and others** : Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment, *Int J Radiat Oncol Biol Phys* 1990; 19:833-842.
- 463- **Fowble B, Hanlon AL, Fein DA** : Results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ (DCIS), *Int Radiat Oncol Biol Phys* 1997; 38:949-957.
- 464- **Fowble B.,**: Ipsilateral breast tumor recurrence following breast-conserving surgery for early-stage invasive breast cancer. *Acta Oncol* 1999; (suppl): 9-17.
- 465- **Fowble BL and others** : Ten year results conservative surgery and irradiation for stage I and II breast cancer, *Int J Radiat Oncol Biol Phys* 1991; 21:269-277.
- 466- **Francis M and others** : Prognosis after breast recurrence following conservative surgery and radiotherapy in patients with node-negative breast cancer, *Br J Surg* 1999; 86 (12): 1556-1562.
- 467- **Frazier TG, and others** : Prognosis and treatment in minimal breast cancer, *Am J surg* 1977: 131(5): 794-803.
- 468- **Fridman V, Humblet C, Bonjean K, Boniver J** : Assessment of tumor angiogenesis and pathological factors, *Virchows Arch* 2000; 437:611-617.
- 469- **Friedenreich CM and others** : Epidemiologic issues related to the association between physical activity and breast cancer, *Cancer* 1998; 83:600-610.

- 470- **Friedrichs K and others** : Overexpression of P53 and prognosis in breast cancer, *Cancer* 1993; 72:3641-3647.
- 471- **Froud PJ and others** : Effect of time interval between breast-conserving surgery and radiation therapy on ipsilateral breast recurrence, *Int J Radiat Oncol Biol Phys* 2000; 46:363-372.
- 472- **Fryberg, E.R., and Bland, K.I.,** : Overview of the biology and management of ductal carcinoma in situ of the breast. *Cancer* 1994;74:350.
- 473- **Fuh G, Wells JA:** Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. *J Biol Chem* 1995; 270:13133.
- 474- **Fung YK, Ang A:** The role of retinoblastoma gene in breast cancer development. *Cancer Treat Res* 1992;61 :59.
- 475- **Furth, J., Clifton K.H.,:** Experimental observations on mammatropes and the mammary gland. In: *Endocrine Aspects of Breast Cancer*. P:276 eds. A.R. Currie and C.F.W. Illingsworth, Edinburgh E. and S. Livingstone. 1956.
- 476- **Futreal PA., Liu D., and Shatiuck-Eidens D.,** : BRCA1 mutations in primary breast and ovarian carcinomas, *Science* 1994; 226:120-122.
- 477- **Gaffney DK, Brohet RM, Lewis CM, et al.** : Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. *Radiother Oncol* 1998; 47:129.
- 478- **Gage I and others** : Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy, *Cancer* 1996; 78:1921-1928.
- 479- **Gage I, Recht A, Gelman R, et al.** : Long-term outcome following breast conserving surgery and radiation therapy. *Int J Radiat Oncol Biol Phys* 1995; 33:245.
- 480- **Gage I, Schnitt S, Recht A, et al.** : Skin recurrences after conserving therapy for early stage breast cancer. *J Clin Oncol* 1998; 16:480.
- 481- **Gagliardi G and others** : Radiation pneumonitis after breast cancer irradiation: analysis of the complication probability using the relative seriality model, *Int Radiat Oncol Biol Phys* 2000; 46:373-381.
- 482- **Gamal MS., Bassam M., and ELwan MS.,** : Breast conservation surgery in early breast carcinoma in Egypt. Proc. of the first annual meeting of the Syrian Association of General Surgeons and the fifth congress of pan Arab Association of Surgeons 1994.
- 483- **Gandhi A., Hollan P., Know W., et al.** : Effects of a pure antiestrogen on apoptosis and proliferation human breast ductal carcinoma in situ. *Cancer Res* 2000; 60:4285-4288.
- 484- **Ganong W.F.,:** Review of Medical physiology 18<sup>th</sup> edn. by Appleton and Lange. 1997;23 : 404 – 422.
- 485- **Ganz PA., Dooley W., Haffty B., et al.** : Identification of premalignant and malignant breast cell in mammogram and physical exam-negative women by ductal lavage : results from a multicenter trial. *Proc Am Soc clin. Oncol* 2000; 19:76.
- 486- **Gapstur SM., and others** : Increased risk of breast cancer with alcohol consumption in postmenopausal women. *Am J Epidemiol*, 1992; 136:1221-1225.
- 487- **Gapstur SM., and others** : Synergistic effect between alcohol and estrogen replacement therapy on

- risk of breast cancer differs by estrogen progesterone receptor status in the Iowa Women; Health study  
*Cancer Epidemiol Biomarkers Prev.* 1995; 4:313-318.
- 488- **Gapstur SM., Morrow M., Sellers TA.,** : Hormone replacement therapy and risk of breast cancer with a favorable histology; results of the IOW Women's Health Study, *JAMA* 1999; 281:2091-2097.
- 489- **Garcia M, Derocq D, Freiss G, et al.** : Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. *Proc Natl Acad Sci USA* 1992; 9:1 1538.
- 490- **Garica-Closas M., Rothman N., Lubin J.H:** Power and Sample size calculations in case-control studies of gene-environment interaction: Comments on different approaches [Comment], *Am J. Epidemiol* 1999; 149:689-692.
- 491- **Garica-Closas M., Rothman N., Lubin J.H:** Misclassification in case control studies of gene environment interactions: assessment of bias and sample size, *Cancer Epidemiol Biomarkers Prev.* 1999; 19:614-622.
- 492- **Garland FC., and others** : Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation, *Prev. Med* 1990; 19:614-622.
- 493- **Gasparin G., and others** : Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node positive breast cancer, *Clin Cancer Res* 1995; 1:189-198.
- 494- **Gasparin G., Pozza F., Harris AL.,** : Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients, *J Natl Cancer Inst* 1993; 85: 1206-1219.
- 495- **Gasparini G and others** : Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness, *Anticancer Res* 1991;11:2015-2021.
- 496- **Gasparini G, Gullick WJ, Maluta S, Dalla Palma P, Caffo O, Leonardi E, Boracehi P, Pozza F, Lemoine NR, and Bevilacqua P:** C-erbB -3 and c-erbB -2 protein expression in node negative breast carcinoma a non seeable immunocytochemical study. *Eur J Cancer* 1995;30:16.
- 497- **Gasparini G, Pazza F, Bevilacqua E, and Sainsburn RC** : Growth fraction (Ki-67 antibody determination in early stage breast carcinoma: histologic clinical and prognostic correlations. *The Breast* 1993;1:92.
- 498- **Gastrin G and others:** Incidence and mortality from breast cancer in the MAMA program for breast screening in Finland, 1973-86, *Cancer* 1994; 73:2168-2174.
- 499- **Gatti RA, Boder E, Vinters HV, Sparkes RS, Norman A, Lange K.:** Ataxia-Telangiectasia :an interdisciplinary approach to pathogenesis, *Medicine* 1991; 70:99-117.
- 500- **Gelber RD,Goldhirsch A, coats As** : Adjuvant therapy for breast cancer : under standing the overview *J Clin Oncol.* 1993;580-585.
- 501- **Gerdes J and others** : Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67, *J Immunol* 1984; 135:1710-1715.
- 502- **Gervais – Fagnou DD., Girouard C, Laperriere N., Pintillie M, Goss PE.,** : Breast cancer in women following supra-diaphragmatic irradiation for Hodgkin's disease. *Oncology* 1999; 57:224.

- 503- **Ghossein NA and others** : Breast cancer: importance of adequate surgical excision prior to radiotherapy in the local control of breast cancer in patients treated conservatively, *Arch Surg* 1992; 127:411-415.
- 504- **Gial MH., Benichou J.** : Validation studies on a model for breast cancer risk. *J Natl cancer Inst* 1994; 86:573-575.
- 505- **Gial MH., Brinton LA., Byar DP., et al.** : Projecting individual-ized probabilities of developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst* 1989; 81:1879-1886.
- 506- **Gibson G and others** : A comparison of ink directed and whole cavity re-excision for breast lumpectomy specimens with positive margins (abstract), presented at the meeting of the Society of Surgical Oncology, Washington, DC, March 15-18, 2001.
- 507- **Gilliland FD, Joste N, Stauber PM, et al.**: Biologic characteristics of interval and screen-detected breast cancer, *J Natl Cancer Inst* 2000; 92: 743-749.
- 508- **Gilliland MD, Barton RM., Copeland EM.** : The implications of local recurrence of breast cancer as the first site of therapeutic failure, *Ann Surg* 1983; 197:284.
- 509- **Giuliano AE and others** : Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer, *J Clin Oncol* 2000;18(13): 2553-2559.
- 510- **Giuliano AE, Jones RC, Brennan M, statman R.**: Sentinel lymphadenectomy in breast cancer .*J Clin Oncol* 1997;15:2345-2350.
- 511- **Giuliano AE., Kirgan D., & Morton D.** : Lymphatic mapping and sentinel lymphadenctomy for breast cancer. *Ann Surg*, 1994; 220:391-401.
- 512- **Glusman J., Lu y., Huster W., et al.** : Raloxifene effects on climacterial symptoms compared with hormone or estrogen replacement therapy (HRT or ERT) Proceedings of the North American Menopause society, 8<sup>th</sup> annual Meeting Program, 1997; 65(abst).
- 513- **Goffin V, Kelly PA** : Prolactin and growth hormone receptors, *Clin Endocrinol* 1996; 45(3):247-255.
- 514- **Gold K.H., Main G., Zippin C. and Annes G.P.** : Infiltration of mammary carcinomas as an indicator of axillary metastasis, cancer. 1982;33 :35-40.
- 515- **Gold RH., Montgomery CK., Rambo On.** : Significance of margination of benign and malignant infiltrative mammary lesions: roentagenographic-pathological correlation, *AJR Am J Roentgenol* 1993; 118:881-894.
- 516- **Goldhirsch A, Glick JH, Gelber RD, etal** : Meeting high lights international consensus panel on the treatment of primary breast cancer. *J Natl Cancer Inst* 1998;90:1601-1608.
- 517- **Goldhirsch A, Colleoni M, Coats AS, et al.** : Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFS a like? The International Breast Cancer Study Group (IBCSG). *Ann oncol* 1998;9:489-443

- 518- **Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J** : Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. *J Clin Oncol* 2001; 19:3817-3827.
- 519- **Golditz GA., Frazier AL.,** : Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus, *Cancer Epidemiol Biomarkers Prev* 1995; 4:567-571.
- 520- **Goldstein NS, Vincini FA, Kestin LL, et al.** : Differences in pathologic features of ductal carcinoma in-situ of the breast based on patient age. *Cancer* 2000; 88:2553-2560.
- 521- **Gollamudi SV and others** : Breast-conserving therapy for stage I-II synchronous bilateral breast carcinoma, *Cancer* 1997; 79:1362-1369.
- 522- **Goodson W.H. III** : The incidence and significance of local recurrence. In BREAST CANCER DIAGNOSIS AND TREATMENT, ed by: Ariel I.M, Clearly J.B.; Mc Graw Hill publications; New York, London 1 987;p.p.300.
- 523- **Gordon PB., Goldenberg SL.,** : Malignant breast masses detected only by ultrasound, *Cancer* 1995; 76: 628-630.
- 524- **Gorman C.A., Decker D.V., Greenspan F.S.,** : Breast cancer and thyroid therapy: Statement by the American Thyroid Association. *J. Am. Med. Assoc.* 1977; 237:1459.
- 525- **Gorsh S., Memoli V., Stukel T., Gold L. and Arrick B.,** : Immunohistochemical staining for transforming growth factor beta-1 associated with disease progression in breast cancer, Proc. Annu. Meet Assoc. Cancer Res.1993;34A:1133.
- 526- **Goss PE., Oza A., Goel R., et al.** : Liarazole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer. *Breast Cancer Res Treat* 2000; 59:55-68.
- 527- **Goss PE., Sierra S.,** : Current perspectives on radiation induced breast cancer. *J Clin Oncol* 1998 ;16:338-347.
- 528- **Goss PE., Strasser K.,** : Chemoprevention of breast. In : Manual of Breast Diseases. Ed. by Ismail Jatoi. Lippincott Williams & Wilkins. Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo, 2002; 22:481-503.
- 529- **Goss PE., Strasser K., Marques R., et al.** : Liarazole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer. *Breast Cancer Res. Treat* 2001;64:177-188.
- 530- **Goss PE., Winer EP., Tannock IF., et al.** : On behalf of the north American Vorozole Study Group. A randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. *J Clin Oncol* 1999; 17:52-63.
- 531- **Gotzsche PC, Olsen O:** Is screening for breast cancer with mammography justifiable? *Lancet* 2000; 355:129-134.
- 532- **Grabrick DM., and others** : Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer; *JAMA* 2000; 284: 1791-1798.
- 533- **Gradishar WJ** : Adjuvant systemic therapy for primary breast cancer. In: jatoi I. Manual of breast Diseases. Lippincott Williams & Wilkins. Philadelphia. Baltimore. New York. London. Buenos Aires.

Hong Kong. Sydney. Tokyo, 2002;14:304-328

- 534- **Graham S., and others** : Nutritional epidemiology of postmeno-pausal breast cancer in western New York, *Am J. Epidemiol* 1991; 134:552-566.
- 535- **Grattarolla R.,:** The premenstrual endometrial pattern of women with breast cancer. *Cancer* 1964;17:1119.
- 536- **Graverson HP, Blichert- Toft M, Andersen J, et al. for the Danish Breast Cancer Cooperative Group** : Breast cancer : risk of axillary recurrence in node-negative patients following partial dissection of the axilla. *Eur J Surg Oncol* 1988; 14:407-412
- 537- **Green A., and others** : use of permanent hair dyes and risk of breast cancer, *J Natl Cancer Inst* 1987; 79:253-257.
- 538- **Green MH.:** Genetics of breast cancer. *Myo Clin Proc* 1997; 72:54-65.
- 539- **Greenlee RT and others:** Cancer statistics, 2001, *CA Cancer J Clin* 2001; 51:15-36.
- 540- **Greenlee RT., Murray T., Bolden S., Wingo PA., :** Cancer statistics, 2000 *CA Cancer J Clin* 2000; 50:7.
- 541- **Grice O.D., Faircloth S., Thomas C.G.,:** The effect of hypothyroidism on Induced cancer of the breast. *Proc. Amer Assoc. Cancer Res.* 1966;7: 26.
- 542- **Groenendijk RP and others** : Screen-detected breast cancer have a low mitotic activity index, *Br J Cancer* 2000; 82:381-384.
- 543- **Guadagnoli E and others** : Use of breast-conserving surgery for treatment stage I and stage II breast cancer, *J Clin Oncol* 1998; 16:101-106.
- 544- **Guenther JM, Kirgan DM, Giuliano AE, :** Feasibility of breast-conserving therapy for younger women with breast cancer, *Arch Surg* 1996; 131:632-636.
- 545- **Guenther JM, Krisnamoorthy M,Tan LR:** Sentinel lymphadenec-tomy for breast cancer in a community managed care setting, *Cancer J Sci Am* 1997;3:336-340.
- 546- **Guidi A. J., and others** : Association of angiogenesis in lymph node metastases with outcome of breast cancer, *J Natl Cancer Inst* 2000; 42:486.
- 547- **Guix B., Hanriquez I., Finestres F., Martinez A., Tella J. I., Lejarcegui J.A., :** Conservative treatment of breast cancer: 20-year results boosting the tumor bed by brachytherapy, *Eur J of cancer*, 2001; Vol. 37, suppl. 6, October 2001, P. 186.
- 548- **Guix B., Henriquez I., Tello J.I., Lejarcegui J. A., Zanon G., Palombo P., Rubio D., Del Campo JM., :** Second conservative Treatment for early breast cancer :12-years results from a pilot study, *Eur J. of Cancer Supplements*, 2003; Vol. 1, No.5, Septemper 2003, P., S131.
- 549- **Gump FE, Jicha DL, Dzello L:** Ductal carcinoma in situ (DCIS): a revised concept. *Surgery* 1987; 102:790-795.
- 550- **Gurpide F.,:** Hormone and Gynecologic cancer. *Cancer* 1976;38: 503.
- 551- **Gusterson BA, Gelber RD, Goldhirsch A et al. :** Prognostic importance of c-erbB-2 expression in breast cancer. *Clin Oncol* 10:1049.

- 552- **Haagensen, C.D.:** Diseases of the breast. 3<sup>rd</sup> ed. Philadelphia, W.B. Saunders. 1986
- 553- **Haarstad H., Lanning PE., Gundersen S., et al. :** Influence of doxorifene on metastatic breast cancer as first-line endocrine treatment. *Acta Oncol* 1998;37 :365-368.
- 554- **Haas JA, Schultz DJ, Peterson ME, Solin LJ :** An analysis of age and family history on outcome after breast-conservation treatment: The University of Pennsylvania experience, *Cancer J Sci Am* 1998; 4(5): 308-315.
- 555- **Haber D., :** Roads leading to breast cancer, *N Engl J Med* 2000; 343(21): 1566-1568.
- 556- **Haffty BG and others :** Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse, *J Clin Oncol* 1996; 14:52-57.
- 557- **Haffty BG and others :** Outcome of conservatively managed early-onset breast cancer by BRCA 1/2 status *Lancet* 2002;354:1471-1477.
- 558- **Haffty BG and others :** Prognostic factors for local recurrence in the conservatively treated breast cancer patient: a cautious interpretation of the data, *J Clin Oncol* 1991; 9:997-1003.
- 559- **Hall IJ and others :** Body size and breast cancer risk in black women and white women: The Carolina breast cancer study, *Am J Epidemiol* 2000; 151:754-764.
- 560- **Hall JM, Lee MK, Newman B, et al. :** Linkage of early-onset familial breast cancer to chromosome 17q21. *Science*, 1990; 250:1684-1689.
- 561- **Hall NR and others :** Muir-Torre syndrome: a variant of the cancer family syndrome, *J Med Genet* 1994; 31:627-631.
- 562- **Halverson KJ and others :** Survival following loco-regional recurrence of breast cancer: univariate and multivariate analysis. *Int J Radiat Oncol Biol Phys* 1992, 23:285-291.
- 563- **Halverson KJ, Perez CA, Kuske RR, et al. :** Loco-regional recurrence of breast cancer; a retrospective comparison of irradiation alone versus irradiation and systemic therapy. *Am J Clin Oncol* 1992; 15:93-101.
- 564- **Hammond ME, Fitzgibbons PL, Compton CC, et al.** College of American Pathologists Conference xxxv: solid tumor prognostic factors: which, how, and so what. *Arch pathol Lab Med* 2000; 124; 958-965.
- 565- **Hancock MC, Langton BC, Chan T ;et al. :** A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis- diamine-dichloro-platinum against human breast and ovarian tumor cell lines. *Cancer Res* 1991; 51:4575.
- 566- **Hancock SL, Toker MA, Hoppe RT:** Breast cancer after treatment of Hodgkin's disease, *J Natl Cancer Inst* 1993; 85:25-31.
- 567- **Handel N and others :** Conservation therapy for breast cancer following augmentation mammoplasty, *plast Reconstr Surg* 1991; 87:873-878.
- 568- **Hankey By Bruiton 1 , Kassler 1 Sn, Miller B,Riesl, Handey B, et al. eds,** SEER cancer statistics Review 1973-1990 National Institute of Health Publication 93- 2789, Bethesda: National Institute of Health 1993 (loaded).
- 569- **Hankinson S, Willet W, Manson J et al.:** Alcohol, height and adiposity in relation to estrogen and

- prolactin levels in post menopausal women. *J Natl Cancer Inst* 1994; 87:1297.
- 570- **Hankinson S., Willet W., Manson J., et al.** : Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women, *J Natl Cancer Inst* 1999; 91:629-634.
- 571- **Hankinson S., Willet W., Manson J., et al.** : Circulating concentrations of insulin-like growth factor-I and risk of breast cancer, *Lancet* 1998; 351:1393-1396.
- 572- **Hankinson S., Willet W., Manson J., et al.** : Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women, *J Natl Cancer Inst* 1998; 90: 1292-1299.
- 573- **Hansen N, Giuliano A** : Axillary dissection for ductal carcinoma in situ. In Silverstein M, editor: Ductal carcinoma in situ of the breast, Baltimore, 1997, Williams & Wilkins, PP 577-584.
- 574- **Hanssen AMN, Fryns JP** : Cowden syndrome; *J. Med Genet* 1995; 32:117-19.
- 575- **Harbek N. Ross, J. Dettmar P.** : HER-2/neu gene amplification determined by fluorescence in-situ hybridization in breast cancer [Abstract 307]. 21<sup>st</sup> Annal San Antonio Breast Cancer Symposium, San Antonio TX, 1998.
- 576- **Hardesty L., Harris KM.,** : Positron emission tomography (PET) and sestamibi in breast imaging, *Mammo Matters* 1999; 6:24-33.
- 577- **Harms SE., and others** : MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation, *Radiology* 1993; 187:493-501.
- 578- **Harris, R.P.,** : Mammography and age : are we targeting the wrong women? A community survey of women and physicians. *Cancer*, 1991;67:2010.
- 579- **Harrold EV, Turner BC, Matloff ET et al.** : Local recurrence in conservatively treated breast cancer patients: a correlation with age and family history (see comments) *Cancer J Sci Am* 1998; 4:302-307.
- 580- **Hartmann LC., and others** : Bilateral prophylactic mastectomy (PM) in BRCA1 /2 mutation carriers, *Proc Annu Meet Am Assoc Cancer Res.* 2000; 41: 222 (abstract 1417)
- 581- **Hartmann LC., Schaid DJ., Woods JE., et al.** : Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *N Engl J Med* 1999; 340: 77-84.
- 582- **Harvey EB., and others** : Alcohol consumption and breast cancer, *J Natl Cancer Inst* 1987; 657-661.
- 583- **Harvey JA., Moran RE.,** : US-guided core needle biopsy of the breast : Technique and pitfalls, *Radiographics* 1998; 18:867-877.
- 584- **Hasbin, A., Le Pechoux, C., Roche, B:** Alternating chemotherapy and hyperfractionated accelerated radiotherapy in non-metastatic inflammatory breast cancer. *Cancer Radiother* 2000;4:265.
- 585- **Hatch EE., and others** : Cancer risk in women exposed to diethylstilbestrol in utero, *JAMA* 1998; 280:630-634.
- 586- **Hathaway PB, Mankoff DA, Maravilla KR, et al.** : Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer. Preliminary experience. *Radiology* 1999; 210:807.
- 587- **Hatteland K., and Kluge T.,** : Mondor's disease: a subcutaneous form of periarteritis nodosa? *Acta Chir Scand* 1965; 129:67.
- 588- **Hauptt Y. and others** : P53 mediated apoptosis in HELA cells: Transcription dependent and

- independent mechanisms, *Leukemia* 1997; 11(3):337-339.
- 589- **Haybittle J.L., Blamey R.W. and Elston C.W.:** A prognostic index in primary breast cancer, *Br J Cancer*, 1982;45: 361.
- 590- **Hayward J.:** Recent results in cancer research: Hormones and Human Breast Cancer, *London* 1970;15-35.
- 591- **Heaton KM and others :** Feasibility of breast cancer therapy in metachronous or synchronous bilateral breast cancer, *Ann Surg Oncol* 1999; 6:102-108.
- 592- **Heimann R, :** The role of Radiation therapy in Breast Cancer Management. In: Jatoi I. Manual of Breast Diseases. Lippincott Williams & Wilkins. Philadelphia. Baltimore. New York. London. Buenos Aires. Hong Kong. Sydney. Tokyo 2002; 15:329-352.
- 593- **Heimann R, Hellman S, :** Clinical progression of breast cancer malignant behavior: What expect and when to expect it? *J Clin Oncol* 2000; 18:591-599.
- 594- **Hellman S., :** The key and the lamppost. *J Clin oncol* 1999; 17:3007-3008.
- 595- **Helzlsouer KJ., and others :** A prospective study of endogenous hormones and breast cancer, *Cancer Detect Prev* 1994; 18:79-85.
- 596- **Hemminki A. and others :** A serine/Threonine Kinase gene defective in Peutz-Jeghers syndrome, *Nature* 1998; 391 (6663): 187-187.
- 597- **Henderson I, Berry D, Demetri G, et al. :** Improved disease- free survival and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node positive primary breast cancer. *Proc Am Soc Clin Oncol* 1998; 17:340A
- 598- **Hendrick RE, Smith RA, Rudledge JH, Smart CR :** Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials, *Monogr Natl Cancer Inst* 1997;22:87-92.
- 599- **Henry-Tillman RS., and others :** Role of breast magnetic resonance imaging in breast as a source of unknown metastatic lymphadenopathy, *Am J Surg* 1999; 178(6): 496.
- 600- **Herold AH, Roetzheim RG:** Cancer survivors. *Prim Care* 1992; 19:779-791.
- 601- **Herris JR, Hellman S :** Primary radiation therapy for early breast cancer, *Cancer* 1983; 52:2547-2552.
- 602- **Hertz R.:** The estrogen cancer hypothesis. *Cancer* 1976;38 :534.
- 603- **Hess KR., and others :** Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma, *Clin Can Res* 1995; 11: 3403-3410.
- 604- **Hetelekidis S and others :** The significance of extracapsular extension of axillary lymph nodes metastases in early stage breast cancer, *Int J Radiat Oncol Biol Phys* 2000; 46(1): 31-34.
- 605- **Hilakivi-Clark L., and others :** Psychological factors in the development and progression of breast cancer, *Breast Cancer Res Treat* 1994; 29:141-160.
- 606- **Hilakivi-Clarke L., :** Estrogens, BRCA1, and breast cancer, *Cancer Res* 2000; 60(18) : 4993-5001

- 607- **His RA, Antell A, Schultz DJ, Solin LJ** : Radiation therapy for chest wall recurrence of breast cancer after mastectomy in a favorable subgroup of patients. *Int J Radiat Oncol Biol Phys* 1998; 42:495.
- 608- **Hlobilkova, A. and others** : Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity, *EXP cell Res* 2000; 256:571-577.
- 609- **Hodsman AB., Drost D., Fraher LJ., et al.** : The addition of a raloxifene analog (Ly117018) allows for reduced PTH(1-34) dosing during reversal of osteopenia in ovariectomized rats. *J Bone Miner Res* 1999; 14:675-679.
- 610- **Hoffman-Goetz L., and others** : Possible mechanisms mediating an association between physical activity and breast cancer, *Cancer* 1998; 83:621-628.
- 611- **Holcombe C., pugh n., and Lyons K.,** : Blood flow in breast cancer and fibroadenoma estimated by colour Doppler Ultrasonography. *Br. J. Surgary* 1999; 82: 1120-1224.
- 612- **Holland R Connolly J, Gelman R, et al.** : Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ, *Lancet* 1990; 335:519-522.
- 613- **Holland R, Connolly J, Gelman R, et al.** :Histologic multifocality of Tis, T 1-2 breast conserving treatment , *J Clin Oncol* 1990;8:113
- 614- **Holland, R., and others** : Ductal carcinoma in-situ: a proposal for a new classification, *Semin Diagn Pathol* 1994; 11:167.
- 615- **Holli K, valavaara R, Blanco G, et al.** : Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node positive breast cancer. *J Clin Oncol* 2000; 18:3487-3444
- 616- **Holli K.,** : Adjuvant trials of toremifene Vs. Tamoxiène : The European experience. *Oncology* 1998;12(35 suppl): 23 – 27.
- 617- **Holmes M., Hunter D., Colditz G., et al.** : Association of diet intake of fat and fatty acids with risk of breast cancer. *JAMA* 1999; 281:914-918.
- 618- **Hopp TA., Fuqua SA.,** : Estrogen receptor variants, *J Mammary Gland Biol Neoplasia* 1998; 3:73-83.
- 619- **Horboni J., Mc Furlane** : Potential use of tumor marker CA 15-3 in staging and prognosis of patients with breast cancer, *J. R. Coll. Surg. Edinb*, 1999; 35:219.
- 620- **Hortobagyi GN** : treatment of breast cancer. *N Engl J Med* 1998;334:974.
- 621- **Hortobagyi GN, Buzdar AU, Theriault RL, et al.** : Randomized trial of high- dose chemotherapy and blood cell autografts for high risk primary breast carcinoma. *J Natl Cancer Inst* 2000; 42:225-233
- 622- **Host H, Brennhovd IO, Loeb M.,** : Postoperative radiotherapy in breast cancer: long-term results from the Oslo study, *Int Radiat Oncol Biol Phys* 1986; 12:727-732.
- 623- **Howe GR and others 1990:** Dietary factors and risk of breast cancer : Combined analysis of 12 case-control studies, *J Natl cancer Inst* 1990; 82:561-569.
- 624- **Howell A and others** : ICI 182,780 (Faslodex): development of novel, ((Pure)) antiestrogen, *Cancer* 2000; 84:817.
- 625- **Huang CS., and others** : Association between N-acetyl transferase 2 (NAT2) genetic polymorphism

- and development of breast cancer in postmenopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence, *Int J cancer* 1999; 82:175-179.
- 626- **Huang WY., and others** : Hormone related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status, *Am J Epidemiol* 2000; 151:703-714.
- 627- **Huang Z., Hankinson SE., Colditz GA., et al.** : Dual effects of weight and weight gain on breast cancer risk, *JAMA* 1997; 278:1407-1410.
- 628- **Huing J, Mackillop WJ** : Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma, *Cancer* 2001; 92:172-180.
- 629- **Humphrey L.J., Swerdlow N.,**: The relationship of breast disease to thyroid disease. *Cancer* 1964;17: 1170.
- 630- **Hunt KK and others** : Feasibility of post-mastectomy radiation therapy after TRAM flap breast reconstruction, *Ann Surg Oncol* 1997; 4(5): 377-384.
- 631- **Hunter D., Spiegelman D., Adami H., et al.** : Cohort studies of fat intake and the risk of breast cancer- a pooled analysis. *N Engl J Med* 1996; 334:356-360.
- 632- **Hunter D., Willet W.,**: Diet, body size and breast cancer, *Epidemiol-Rev* 1993; 15:110-115.
- 633- **Hunter DJ and others** : A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer, *Carcinogenesis* 1997; 18:2127-2132.
- 634- **Hunter DJ., Willett WC.,** : Diet, body size, and breast cancer, *Epidemiol Rev.* 1993; 15(1): 110-132.
- 635- **Hurd TC and others** : Impact of extensive intraductal component on recurrence and survival in patients with stage I or II breast cancer treated with breast conservation therapy, *Ann Surg Oncol* 1997; 4(2): 119-124.
- 636- **Hurly SF, Kaldor JM:** The benefits and risks of mammographic screening for breast cancer. *Epidemiol Rev* 1992; 14:101-130.
- 637- **Hussein M., and Mokhtar N.,** : Epidemiology, In : Breast cancer edited by Omar S., Contesso G., KORBA. London :1984;1-7.
- 638- **Hutchins L and others** : CMF vs. CAF with or without tamoxifen in high- risk node negative breast cancer patients and a natural history follow up study in low - risk node negative patients: update of Tamoxifen results (abstract 1), *Breast Cancer Res Treat* 1999;57:25.
- 639- **Hutchins L, Green s, Ravdin P, et al.** : CMF versus CAF with and without tamoxifen in high-risk, node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of intergroup trial INT 0162. *Proc Am Soc Clin Oncol* 1998; 17:1A.
- 640- **Ibrahem AS., and Aref N.,** : The registry of Nat. cancer Inst. Cairo Twelve years experience. *J. Egypt Nat. cancer Inst.* 1984.
- 641- **Iglehart, J.D.,**: Breast. In: Textbook of Surgery, Sabiston, D.C. (ed):W.B. Saunders Co. Philadelphia 14<sup>th</sup> ed., 1991;1:510.
- 642- **Ingvarsson S.** : Molecular genetics of breast cancer progression, *Semin cancer Biol* 1999; 9: 277-288.

- 643- **Innes KE., Byers TE** : Preeclampsia and breast cancer risk, *Epidemiol* 1999; 10:722-732.
- 644- **International (Ludwing) Breast Cancer Study Group(IBCSCG)** : Prognostic importance of occult axillary lymph node micrometastases from breast cancers, *Lancet* 1990; 335:1565-1568.
- 645- **International Breast Cancer Study Group (IBCSCG)**: Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. *J Clin Oncol* 1997; 15:1385-1394.
- 646- **Israel PZ.,** : The revolution in breast biopsy :where is the surgeon? *Am Surg* 1996; 62:93-95.
- 647- **Jackman RJ., Nowels W., Rodriguex-Soto J., et al.** : Stereotactic, automated, large-core needle biopsy of nonpalpable breast lesions : false-negative rates and histologic underestimation rates after long-term follow-up. *Radiology*, 1999;210:799-805.
- 648- **Jackson VP.,** : Galactography. In: Bassett LW., Jackson VP., Jahan R., Fu ys., Gold RH (eds) "Diagnosis of diseases of the breast." Philadelphia: WB Saunders Company; 1997; P:283-289.
- 649- **Jacobs EL., and Haskell cM.,** : Clinical use of tumor markers in oncology and radiotherapy for early breast cancer. *Cancer*, 1991; 66:1427-1438.
- 650- **Jager JJ and others** : Loco-regional recurrences after mastectomy in breast cancer: prognostic factors and implications for postoperative irradiation, *Radiother Oncol* 1999; 50:267-275.
- 651- **Jakesz R, Hausmaninger H, Samonigg H et al.** : Complete endocrine blockade with tamoxifen and goserelin is superior to CMF in the adjuvant treatment of premenopausal, lymph node-positive and-negative patients with hormone-responsive breast cancer [abstract]. *Breast* 2001; 10 (Suppl. 1): S10.
- 652- **James V.H., McNeill J.N., Lai L.C., et al.**: Aromatase activity in normal breast and tumor tissues. In vivo and in vitro studies. *Steroids*,1987;50: 269-279.
- 653- **Janjan NA and others** : Management of loco-regional recurrent breast cancer, *Cancer* 1986; 58:1552-1556.
- 654- **Janssens JP and others** : Effect of radiotherapy on steroid receptors in breast cancer, *Lancet* 1981; 2:1108.
- 655- **Jatoi I** : Management of the axilla in primary breast cancer. *Surg Clin North Am* 1999; 79:1061-1073.
- 656- **Jatoi I** : Surgery for primary invasive breast cancer. In: Jatoi I. Manual of Breast Diseases. Lippincott Williams & Wilkins, Philadelphia. Baltimore. New York. London. Buenos Aires. Hong Kong. Sydney. Tokyo. 2002; (13): 289-307.
- 657- **Jatoi I, Baum M** : Mammographically detected ductal carcinoma in situ : are we overdiagnosing breast cancer? *Surgery* 1995;118:118-120.
- 658- **Jatoi I, hilsenbeck SG, clark GM, et al.** : the significance of axillary lymph node metastasis in primary breast cancer. *J Clin Oncol* 1999;17:2334-2340.
- 659- **Jatoi I.**: Breast cancer screening. *Am J Surg* 1999; 177:518-524.
- 660- **Jatoi I.**: Principles of Breast Cancer Screening, In: Manual of Breast Diseases Edt. By Jatoi I. Lippincott Williams and Wilkins, Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo 2002;8:177-199.

- 661- **Jatoi I**: Breast cancer: a systemic or local disease? *Am J Clin Oncol* 1997; 20:536-539.
- 662- **Jensen J., and others** : Glandular replacement Therapy (GRT) for intraductal breast carcinoma (DCIS), *Proc Am Soc clin oncol* 1995 ;14:138.
- 663- **Joensuu H, Toikkanen S, Klemi PJ** : DNA index and S-phase fraction and their combinations as prognostic factors in operable ductal breast Carcinoma, *Cancer* 1990; 66:331-340.
- 664- **Johnson KC., Hu J., Mao Y.,** : Passive and active smoking and breast cancer risk in Canada 1994-1997. The Canadian Cancer Registries Epidemiology Research Group, *Cancer Causes Control* 2000; 11:211-221.
- 665- **Johnson TL, Kim SR** : Cytologic and clinicopathologic features of abnormal nipple secretions :225 cases, *Diagn. Cytopathol* 1991;7:17-22
- 666- **Johnston J.O., Wright C.L., Metcalf,:** Time-dependent inhibition of aromatase in trophoblastic tumor cells in tissue culture. *J. Steroid Biochem.* 1984
- 667- **Jordan VC** : Growth factor regulation by tamoxifen is demonstrated in patients with breast cancer. *Cancer* 1993;72:1.
- 668- **Jordan VC, Allen KE, Dix Cj** : Pharmacology of tamoxifen in laboratory animals, *Cancer Treat Rep* 1980;64:745.
- 669- **Jordan VC, Fritz NF, Langan- Fahey S, et al.** : Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. *J Natl Cancer Inst* 1991;83:1488-1441
- 670- **Jordan VC., Glusman JE., Eckert S., et al.** : Raloxifene reduces incident primary breast cancer : Integrated data from multicenter, double-blind, placebo-controlled, randomized trials in postmenopausal women. San Antonio Breast cancer Symposium Proceedings. *Breast cancer Res Treat* 1998; 21:227(abst).
- 671- **Jordan VC**: Estrogen receptor- mediated direct and indirect anti-tumor effects of Tamoxifen (editorial). *J Natl Cancer Inst* 1990;82:1662.
- 672- **Juan O, Lluch A, de Paz L, et al.** : Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED). *Breast Cancer Res Treat* 1999; 53:105.
- 673- **Julien JP, Bijker N, Fentiman IS et al.** : Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of EORIC and demised phase III trial 10853. *Lancet* 2000; 355:528-533.
- 674- **Julien JP., Mijken N., Fentimen IS., et al.** : Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomized phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. *Lancet* 2000; 12:528-533.
- 675- **Kaijser M., and others** : In utero exposures and breast cancer : a study of opposite-sexed twins, *J Nat/Cancer Inst* 2001; 93(1): 60-62.
- 676- **Kaijser M., and others** : Maternal pregnancy estriol levels in relation to anamnestic and fetal anthropometric data, *Epidemiology* 2000; 11(3): 315-319.
- 677- **Kainu T., and others** : Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus, *Proc Natl Acad Sci USA* 2000; 97:9603-9608.

- 678- **KaKuda JT, stunt 2 ME, Vargas Hi, kholkhadi I**: Status of scintimammography and it's relation to other detection methods for breast cancer. *Cancer Bioth Radiol* 1999;14(6):435-442.
- 679- **Kamby G, Sengelov L** : Pattern of dissemination and survival following isolated loco-regional recurrence of breast cancer. A prospective study with more than 10 years of follow-up. *Breast Cancer Res Treat* 1997; 45:181.
- 680- **Kapdi C.C, Wolfe J.M.,**: Breast cancer, relationship of thyroid. supplements for hypothyroidism, *J. Am. Med. Assoc.* 1976;236: 1134.
- 681- **Kardinal CG** : Hormonal and endocrine therapy of breast cancer, In: Donegan WL, Spratt JS, *Cancer of the Breast* 5<sup>th</sup> ed: Saunders, Philadelphia, London. New York. St Louis. Sydney. Toronto. 2002; 31:693-737.
- 682- **KARG D, Wearer D, Ashikaga T, et al.** : the sentinel lymph node in breast cancer: A multicenter validation study. *N Engl J med* 1998;337: 441-446.
- 683- **Karlsson P, Holmberg E, Johansson KA.,** : Soft tissue sarcoma after treatment for breast cancer, *Radiother Oncol* 1996; 38:25-31.
- 684- **Kattlove H, Liberati A, Keeler E, et al.**: Benefits and costs of screening and treatment for early breast cancer: development of a basic benefit package, *JAMA* 1995; 273:142-148.
- 685- **Katz A and others** : Loco-regional recurrence patterns after mastectomy and doxorubicin-based chemotherapy :implications for postoperative irradiation, *J Clin Oncol* 2000; 18(15): 2817-2827.
- 686- **Kaufman M , Bajetta E, Dirix ly, et al.** : exemstane is superior to megestrol acetate after tamoxifen failure in post-menopausal woman with advanced breast cancer : results of a phase III randomized double- blind trial the exemstane study Group. *J Clin Oncol* 2000; 18:1344-1411
- 687- **Kaufmann M**: "Zoladex" (goserelin) Vs CMF as adjuvant therapy in pre/perimenopausal, node-positive, early breast cancer preliminary efficacy results from the ZEBRA study [abstract]. *Breast* 2001; 10 (suppl.1): S30.
- 688- **Ke HZ., Paralkar VM., Grasser WA., et al.** : Effects of CP-336156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. *Endocrinology* 1998; 139:2068-2067.
- 689- **Kearney T, Morrow M** : Effect of reexcision on the success of breast-conserving surgery, *Ann Surg Oncol* 1995; 2(4): 303-307.
- 690- **Keidan R, Haffman J, Weese J, et al.** : Delayed breast abscesses after lumpectomy and radiation therapy. *Am Surg* 1990; 56:440.
- 691- **Kelsey JL., Bernstein L.,** : Epidemiology and prevention of breast cancer. *Annu Rev public Health* 1996; 17:47-67.
- 692- **Kelsey JL., Gammon MD., John EM.,** : Reproductive factors and breast cancer, *Epidemiol Rev.* 1993; 15(1) : 36-47.
- 693- **Kennedy MJ, Abeloff MD** : Management of locally recurrent breast cancer, *Cancer* 1993; 71: 2395-2409.

- 694- **Kenny FS and others** : Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer, *Breast* 1998; 7:335-339.
- 695- **Kerangueven F., Essioux L., Dib A., Noguchi T., All ione F., Geneix J., et al.** : Loss of heterogeneity and linkage analysis in breast carcinoma : indication for a putative third susceptibility gene on the short arm of chromosome 8. *Oncogene* 1995; 10:1023-1026.
- 696- **Kerlikowske K and others** : Variability and accuracy in mammographic interpretation using the American College of Radiology Breast Imaging Reporting and Data System, *J Natl Cancer Inst* 1998; 90:1801.
- 697- **Kerlikowske K., and others** : Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer, *J Natl cancer Inst* 1997; 89:76-82.
- 698- **Kern KA** :sentinel lymph node mapping in breast cancer using subareolar blue dye ,*J Am Coll Surg* 1999; 189:534-545.
- 699- **Kestin L and others** : Mammographically detected ductal carcinoma in situ treated with conservative surgery with or without radiation therapy: patterns of failure and 10-years results, *Ann Surg* 2000; 231:235-245.
- 700- **Kestin LL and others** : Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-Conserving therapy, *Cancer* 2000; 88:596-607.
- 701- **Key Tj., and others** : Soya food and breast cancer risk : a prospective study in Hiroshima and Nagasaki, Japan, *Br J cancer* 1999; 81:1248-1256.
- 702- **Key TJA., Pike MC., :** The role of estrogens and progestogens in the epidemiology and prevention of breast cancer, *Eur J Cancer Clin Oncol* 1988; 24:29-43.
- 703- **Khovidhunkit W., Shoback DM., :** Clinical effects of raloxifene hydrochloride in women, *Ann Intern Med* 1999; 130(5): 431-439.
- 704- **King TA., Cederbom GJ., Champaign JL., Smetherman DH., Bolton JS., Farr GH., Mc Kinnon WM., KusKe RR., Fuhrman GM., :** A core Breast Biopsy Diagnosis of Invasive Carcinoma Allows for Definitive Surgical Treatment Planning, 1998; 176:497-501.
- 705- **King, R.E., Terz, J.J., Lawrence, W Jr., :** Experience with opposite breast biopsy in patients with operable breast cancer. *Cancer* 1976; 37:43-45.
- 706- **Kini VR and others** : Long-term results with breast-conserving therapy or patients with early stage breast carcinoma in a community hospital setting, *Cancer* 1998; 82:127-133.
- 707- **Kinkel K., Vlastos G., :** MR Imaging: breast cancer Staging and Screening *Semin Surg Oncol* 2001; 20:187-196.
- 708- **Kinzler KW, Vogelstein B:** Gatekeepers and caretakers. *Nature* 1997; 386:761-63.
- 709- **Kirby, I., and Edward, M.C., :** The Breast, In: PRINCIPLES OF SURGERY, 6<sup>th</sup> edn. Ed. by Schwartz, S.I., Shires, T., and Spencer, F.C., Mc Graw Hill Inc. New York, Milan, Pans. 1994; 14:531-591.
- 710- **Kiricuta CI, Tausch J :** A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma, *Cancer-1992*; 69:2496-2501.

- 711- **Kiricuta IC and others** : The prognostic significance of the supraclavicular lymph node metastases in breast cancer patients, *Int J Radiat Oncol Biol Phys* 1994; 28:387-393
- 712- **Kirschner M.A., Schneider G., Worton E.,**: Obesity, androgens, estrogen and cancer risk. *Cancer Res.* 1982;42: Suppl. 3291-5
- 713- **Kisner WH** : Multiple spontaneous rib fractures secondary to osteoradionecrosis, *Contemp Surg* 1992; 40:22-24.
- 714- **Klauber-DeMor N, Tan LK, Liberman L, et al.** : Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma in situ and ductal carcinoma in situ with microinvasion? *Am Surg Oncol* 2000; 7:636-642.
- 715- **Klijn J G and others** : Combined tamoxifen and luteinizing hormone- releasing hormone (LHRH) against versus LHRH agonist alone in premenopausal advanced breast cancer: a meta analysis of four randomized trials, *J Clin Oncol* 2001;19:343.
- 716- **Klijn J Gand others** : Anti- tumor and endocrine effects of chronic LHRH agonist treatment (buserelin) with or without tamoxifen in premenopausal metastatic breast cancer, *Breast Cancer Res Treat* 1984;4:204.
- 717- **Klijn JGM and others** : Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study, *Natl Cancer Inst* 2000;92:903.
- 718- **Koenig KL, and others** : Hair dye use and breast cancer : a case-control study among screening participants, *Am J Epidemiol* 1991; 135:985-995.
- 719- **Koenig, C., Tavassoli, F.A.,** : Mucinous cystadenocarcinoma of the breast, *Am J Surg. Pathol.* 1998;22:698.
- 720- **Kolb TM, Lichty J, Newhouse JH:** Occult cancer in women with dense breasts: detection with screening US-diagnostic yield and tumor characteristics, *Radiology* 1998;207:191-199.
- 721- **Kollmorgen, D.R., and others** : Paget's disease of the breast : a 33-year experience, *J Am Coll surg* 1998; 187:171.
- 722- **Kopans DB** : Analyzing the mammogram. In: Kopans DB., editor : *Breast imaging*, ed 2, Philadelphia, 1998, Lippincott-raven, PP 247-350.
- 723- **Kopans DB.,** : Discriminating analysis uncovers breast lesions, *Diagn Image* 1991; 9:94-101.
- 724- **Kopans DB.,** : Mammographic positioning. In: Kopans DB., editor: *Breast imaging*, ed2, Philadelphia, 1998, Lippincott-Raven, PP 171-209.
- 725- **Kopans DB., Meyer JE., Homer MJ, Grabbe J** : Dermal deposits mistaken for breast calcifications, *Radiology* 1983;149:592-594.
- 726- **Kopans DB:** Screening for breast cancer. In: Kopans DB, editor: *Breast imaging*, ed 2, Philadelphia, 1998, Lippincott-Raven, pp 55-100.
- 727- **Kramer S, Schulz-Wendtland R, Hagedorn K, Bautz W, Lang N,** : Magnetic resonance imaging in the diagnosis of local recurrences in breast cancer. *Anticancer Res* 1998; 18 (3c): 2159.
- 728- **Krieger N and others** : Breast cancer and serum organochlorines: a prospective study among white, black and Asian women, *J Nat cancer Inst* 1994; 86:589-599.

- 729- **Krieger N., Hiatt RA.,** : Risk of breast cancer after benign breast diseases: Variation by histologic type, degree of atypia, age at biopsy, and length of follow-up, *Am J Epidemiol* 1992; 135:619-631.
- 730- **Kristensen VN., and others** : A rare Cyp 19 (aromatase) variant increase the risk of breast cancer, *Pharmacogenetics* 1998; 43-48.
- 731- **Kroll SS and others** : Local recurrence risk after skin-sparing and conventional mastectomy : a 6 year follow-up, *Plast Reconstr Surg* 1999; 104(2): 421-425.
- 732- **Kroll Ss, Schusterman MA, Larson DL, Fender A.,** : Long-term survival after chest-wall reconstruction with musculocutaneous flaps. *Plast Reconstr Surg* 1990; 86:697.
- 733- **Krueger EA and others** : Complications and patient satisfaction following expander implant breast reconstruction with and without radiotherapy, *Int Radiat Oncol Biol Phys* 2001; 49:713-721.
- 734- **Kuller LH.,** : Epidemiology of breast cancer. In Vogel VG, editor: Management of patients at high risk for breast cancer, Malden, MA, 2001, *Blackwell Science, PP 1-18.*
- 735- **Kundson AG** : Mutation and cancer: statistical study of retinoblastoma, *Proc Natl Acad Sci USA* 1971; 68:820-823.
- 736- **Kurita H, Ostertag CB, Baumer B, Kopitzki K, Warnke P C.,** : Early effects of PRS-irradiation for 9L gliosarcoma: Characterization of interphase cell death. *Minim Invasive Neurosurg* 2000; 43:197-200.
- 737- **Kurtz J** : Radiotherapy for early breast cancer: was a comprehensive overview of trials needed? *Lancet* 2000; 355:1739-1740
- 738- **Kurtz JM and others** : Breast-conserving therapy for macroscopically multiple cancers, *Ann Surg* 1990; 212:35-44.
- 739- **Kurtz JM and others** : Local recurrence after breast-conserving surgery and radiotherapy: frequency, time course, and prognosis, *Cancer* 1989; 63: 1912-1917.
- 740- **Kurtz JM and others** : Results of salvage surgery mammary recurrence following breast conserving therapy, *Ann Surg* 1988; 207: 347-351.
- 741- **Kurtz JM and others** : Results of wide excision of mammary recurrence after breast-conserving therapy, *Cancer* 1988; 61:1969-1972.
- 742- **Kurtz JM and others** : Why are local recurrences after breast-conserving therapy more frequent in younger patients? *J Clin Oncol* 1990; 591-698.
- 743- **Kuskasjarvi T, Kononeu J, I4elin K, et al.** : Loss of estrogen receptor in recurrent breast cancer is assualid with poor response to and otherapy. *J. din oncol* 1996; 14:2584.
- 744- **Kutz JM, Spitalier JM., Amalric R., et al.** : The prognostic significance of late local recurrence after breast conserving therapy. *Int J Radiat Oncol Phys* 1990; 18: 87-93.
- 745- **Labrie F., Labrie C., Belanger A., et al.** : EM-652 (ScH57068), a third generation SERM acting as a pure antiestrogen in the mammary gland and endometrium. *J Steroid Biochem Mol Biol* 1999;69:51-84.
- 746- **Lagios M, Richards V, Rose m, Yee E** : Segmental mastectomy without radiotherapy: short- term follow up. *Cancer* 1983;52:2173
- 747- **Lagios M.,** : Duct carcinoma in situ : Pathology and treatment, *Surg Clin North Am* 1990;70:853-871.

- 748- **Lagios M:** Controversies in diagnosis, biology, and treatment, *Breast J* 1995; 1:68-78.
- 749- **Lagios MD, Westdahl PR, Margolin ER, et al. :** Duct carcinoma in situ: relationship of extent of noninvasive disease to the Frequency of occult invasion, multicentricity, lymph node metastases and short-term treatment failure. *Cancer* 1982; 50:1309-1314.
- 750- **Lagios MD, Westdahl R, Rose MR :** The concept and implications of multicentricity in breast carcinoma. In Sommers SC, Rosen PP, editors: Pathology annual 1981, part 2, New York, 1981, *Appleton-Century Crafts*.
- 751- **Lagios MD., and others :** A guide to the frequency of nipple involvement in breast cancer: a study of 149 consecutive mastectomies using a serial subgross and correlated radiographic technique, *Am J Surg* 1979;138:35
- 752- **Lagios MD:** Microinvasion in ductal carcinoma n situ . In: Silverstein MJ, ed. Carcinoma in situ of the breast. Baltimor; Williams & Wilkins, 1997:241.
- 753- **Lagios, M.D., :** Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. *Cancer*, 1995; 90:97.
- 754- **Lakhani SR :** The transition from hyperplasia to invasive carcinoma of the breast, *J Pathol* 1999; 187:272-278.
- 755- **Lakhani Sr, Jacquemier J, Sloane JP, et al.:** Pathology of familial breast cancer (II): Multifractional analysis of morphological differences between breast cancer due to BRCA 1, BRCA 2 and controls. *J Natl cancer Instit* 1998, 90:1138.
- 756- **Lam RY, Chlebowski RT :** Tamoxifen for treatment of premenopausal women with breast cancer, *Cancer Invest* 2000;18:681.
- 757- **Lambe M., and others :** Transient increase in the risk of breast cancer after giving birth, *N Engl J Med* 1994; 331:5.
- 758- **Land CE., :** Studies of cancer and radiation dose among atomic bomb survivors: the example of breast cancer, *JAMA* 1995; 274(5): 402-407.
- 759- **Landis S., Taylor M., & Bolden S:** Cancer statistic. *Cancer J. Clin.* 1999; 49:8-31.
- 760- **Lane N., Goskel H. , Salerno A. and Haagenson C.D. :** Clinicopathologic analysis of the surgical curability of breast cancers . A minimal ten - year study of personal cases , *Ann. Surg.* 1981 ; 183: 483-498.
- 761- **Lange M.:** The Breast. In : Decker GA, du Plessis DJ, Lee Mc Gregor's synopsis of surgical Anatomy, 12<sup>th</sup> ed. Wight Bristol, 161-170.1986.
- 762- **Langton BC, Hancock MC, Chan T ;et al. :** A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis- diamine-dichloro-platinum against human breast and ovarian tumor cell lines. *Cancer Res* 1991; 51:4575.
- 763- **Lantsberg L., and others :** Mammoscintigraphy with Tc-99 sestamibi in the evaluation of benign and malignant breast disease, *Breast* 1999; 8: 40-43.
- 764- **Lapidus RG, Ferguson AT, Ottaviano YL, et al.:** Methylation of estrogen and progesterone receptor gene 51 CPG island correlates with lack of estrogen and progesterone receptor gene expression in breast

- tumors. *Clinical Cancer Research* 1996; 2:805.
- 765- **Lapidus RG, Nass SJ, Butash KA, et al.** : Mapping of the LR gene CPG Island methylation by Methylation Specific PCR. *Cancer Res* 1998; 58:25 15.
- 766- **Lapidus RG., Nass SJ., Davidson NE.,** : The loss of estrogen and progesterone receptor gene expression in human breast cancer, *J Mommary Gland Biol Neoplasia* 1998; 3:85-94.
- 767- **Lash TL., Aschengrau A.** : Active and passive cigarette smoking and the occurrence of breast cancer, *Am J Epidemiol* 1999; 149:5-12.
- 768- **Layde PM., and others** : The independent associations of parity age at first full term pregnancy and duration of breast feeding with the risk of breast cancer: Cancer and Steroid Hormone Study Group, *J clin Epidemiol* 1989; 42 (10) : 963-973.
- 769- **Lazovich D and others** : Breast-conservation therapy in the United States following the 1990 National Institutes of Health consensus development conference on the treatment of patients with early stage invasive breast carcinoma, *Cancer* 1999; 86: 628-637.
- 770- **Lazovich D, Solomon CC, Thomas DB, et al.** : Breast conservation therapy in the United States following the 1990 National Institute of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. *Cancer* 1999; 628-637.
- 771- **Le MG and others** : C-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-protein over-expression and a lower risk of metastasis and death in operable patients, *Int J Cancer* 1999; 84:562-567.
- 772- **Leach, S.D., Feig, B.W., Berger D.H.** : Invasive breast cancer, In : *The M.D., Anderson Surgical Oncology Hand book*, 1<sup>st</sup> edition, Chapter 2, ed By Berger, D.H, Feig, B.W., and Fuhrman, G.M., Little Brown and Company, 1995; 2:12-37
- 773- **Lee AK., Rosen PP., Delellis RA.,** : Tumor marker expression in breast carcinomas and relations to prognosis: an immunohistochemical study *A.J.C.*1998, P. 84(6): 687.
- 774- **Lee CH., Philpotts LE., Horvath LJ., et al.** : Follow-up of breasts diagnosed as benign with stereotactic core-needle biopsy: frequency of mammographic change and false negative rate . *Radiology* 1999; 212:159-194.
- 775- **Lee R.J., Albanese, C. Watanabe, G.,** : The cyclin D1 gene is required for transformation and is transcriptionally activated by the c-erb B2 [Abstract 20] 21<sup>st</sup> San Antonio Breast Cancer Symposium, San Antonio TX, 1998.
- 776- **Lee, A.A., and others** : Pathological assessment of sentinel lymph-nod biopsies in patients with breast cancer, *Virchows Arch* 2000;436:97.
- 777- **Lehr, H.A., and others** : Cytokeratin 8 immunostaining pattern and E-Cadherin expression distinguish lobular from ductal breast carcinoma, *Am J Clin Pathol* 2000; 117:190.
- 778- **Leis H.P. Jr., Cammarata A.; La Ruja R.D.** : The management of clinically non palpable breast cancer. In: *BREAST CANCER DIAGN-OSIS AND TREATMENT*, ed by: Ariel I.M. and Cleary J.B. New York, London, McGraw Hill, 1987 ; pp 205
- 779- **Leis HP Jr, Cammarata A, La Raja RD** : Nipple discharge: Significance and treatment, *Breast*

1985;11:6.

- 780- **Leitch AM:** Breast cancer screening: success amid conflict, *Surg Oncol Clin North Am* 1999; 8:657-672.
- 781- **Leitch AM:** Screening for breast cancer, In: *Cancer of the Breast 5<sup>th</sup> edn.* Ed. By Donegan, W.L and Spratt, J.S. Saunders, Philadelphia, London, New York, ST. Louis, Sydney, Toronto, 2002;15:269-286.
- 782- **Leitzel K and others :** Elevated serum c-erb B-2 antigen levels and decreased response to hormone therapy of breast cancer, *J Clin Oncol* 1995; 13:1129-1135.
- 783- **Lenington W., and others :** Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions, *Cancer* 1994; 73:118-124.
- 784- **Lenzi R., Kim EE., Raber MN., Abbruzzese JL., :** Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111 In- Pentetreotide scan, *Ann Oncol* 1998; 9(2): 213.
- 785- **Leslie KO, Howard P :** Oncogenes and antioncogenes in human breast carcinoma, *Patbol Annu* 1992;27:32t-34t.
- 786- **Levine MN, Branwell VH, Pritchard KI, et al. :** Randomized trial of intensive cyclophosphamide, floururacil in premenopausal women with node- positive breast cancer: National cancer Institute of Canada clinical trials group. *J Clin Oncol* 1998; 16:2651-2658.
- 787- **Levy-Lahad E. and others :** Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer and in breast-ovarian cancer families, *Am J Hum Genet* 1997; 60: 1059-1067.
- 788- **Lewin JM and others:** Comparison of full-field digital mammogr-aphy with screen-film mammography for cancer detection: results of 4945 paired examinations, *Radiology* 2001; 218:873-880.
- 789- **Li CI., and others :** Age when maximum height is reached as a risk factor for breast cancer among young U.S. women, *Epidemiology* 1997; 8:559-556.
- 790- **Li FP and others :** A cancer family syndrome in twentyfour kinders, *Cancer Res* 1988; 48:5358-5362.
- 791- **Liaw D. and others :** Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome, *Nat Genet* 1997; 16:64-67.
- 792- **Liberman L, Van Zee K, Dershaw D, et al.:** Mammographic features of local recurrence in women who have undergone breast-conserving therapy for ductal carcinoma in-situ. *AJR Am J Roentgenol* 1997;168:489-493.
- 793- **Liberman L., :** Percutaneous imaging guided core biopsy: state of art at the millennjum, *Am. J. Roent*, 2000; 174:1191-1199.
- 794- **Liberman L., and others :** Lobular carcinoma in situ at percutaneous breast biopsy, *Am J Roentgenol* 1999; 173:291-299.
- 795- **Liberman L., and others :** US-guided core breast biopsy : use and cost-effectiveness, *Radiology* 1998; 208:717-723.
- 796- **Liberman L., Bracero N., Vuolo MA., et al. :** Percutaneous large-core biopsy of papillary breast

- lesions. *Am J Roentgenol* 1999; 172:331-337.
- 797- **Lichtenstein P., and others** : Environmental and heritable factors in the causation of cancer-analysis of cohorts of Twins from Sweden, Denmark, and Finland, *N Engl J Med* 2000; 343:78-85.
- 798- **Lilienfeld AN, Coombs J., Bross IDJ, Chamberlain A.,**: Marital and reproductive experience in community wide epidemiological study of breast cancer. *John Hopkins Med. J.* 1975;136: 157.
- 799- **Liljegren G and others** : 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial, *J Clin Oncol* 1999; 17: 2326-2333.
- 800- **Lingos TI, Recht A, Vicini F, et al.** : Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy, *Int Radiat Oncol Biol Phys* 1991; 21:355-360.
- 801- **Linver MN, Paster SB**: Mammography outcomes in a practice setting by age: prognostic factors, sensitivity, and positive biopsy rate, *Monogr Natl Cancer Inst* 1997;22:113-118.
- 802- **Liotta LA, Steeg PS, Stetler-Stevenson WG**: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. *Cell* 1991;64:327.
- 803- **Lloyd, H.M., Meares, J.D. Jacobi, J.**: Effects of estrogen and bromocryptine on vivo secretion and mitosis in prolactin cells. *Nature*, 1975;255-497.
- 804- **Lippman M.E.**: Endocrine-Responsive Cancer. In Williams textbook of ENDOCRINOLOGY ,9<sup>th</sup> Edition. 1998;(35)1675 – ed. By W.B. SAUNDERS COMPANY.
- 805- **Lippman ME and others** : Autocrine and paracrine growth regulation of human breast cancer, *Breast Cancer Res Treat* 1986;7:59.
- 806- **Lippman ME**: Endocrine responsive cancers o man. In Wilson JD, Foster DW, editors: Williams text-book of endocrinology, ed 7, Philadelphia, 1985, WB Saunders, PP 1304-1326.
- 807- **Lipsztein R, Dalton JF, Bloomer WD** : Sequelae of breast irradiation, *JAMA* 1985; 263:3582-3585.
- 808- **Lipton A and others** : Aromatase activity in primary and metastatic human breast cancer, *Cancer* 1987;54:774.
- 809- **Lipton A and others** : Elevated serum, Her-2/neu levels predicts decreased response to hormone therapy in metastatic breast cancer, *J Clin Oncol* 2002, 20(6)0:1467-1472.
- 810- **Lipworth L., and others** : Maternal pregnancy hormone levels in an area with a high incidence (Boston, USA) and in an area with a low incidence (Shanghai, China) of breast cancer, *Br J Cancer* 1999; 79(1) :7-12.
- 811- **Lipworth L., Bailey LR., Trichopoulos,** : History of breast-feeding in relation to breast cancer risk a review of the epidemiologic literature, *J Natl Cancer Inst* 2000; 92:302-312.
- 812- **Liu Y., Wang JL., Chang H., et al.** : Breast cancer diagnosis with nipple fluid bFGF: *lancet* 2000; 356 (9229): 567.
- 813- **London SJ., and others** : Prospective study of relative weight, height, and risk of breast cancer, *JAMA* 1989; 262:2853-2858.
- 814- **Longnecker MP.,** : Alcoholic beverage consumption in relation n to risk of breast cancer: meta-

- analysis and review, *Cancer Causes Control* 1994; 5:73-82.
- 815- **Longnecker MP., and others:** Risk of breast cancer in relation to lifetime alcohol consumption, *J Natl Cancer Inst.* 1995; 87:923-929.
- 816- **Lonning BE, Bajetta E, Murray R, et al. :** Activity of exemestane in metastatic breast cancer after failure of non steroidal aromatase in- hibitors: a phase II trial. *J Clin Oncol* 2000;18:2234-2244
- 817- **Love RR and others :** Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer, *J Cline Oncol* 2002; 20: 2554.
- 818- **Love RR( 1989):** Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects, *Clin Oncol* 1989;7:803.
- 819- **Love RR., Mazess, RB., Torney DC., et al. :** Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. *Breast cancer Res Treat* 1998; 2:297-302.
- 820- **Love SM., Hunt KK., :** Diagnostic approaches to breast masses, In: *Mastery of Surgery*, 3<sup>rd</sup> ed. Ed. by: Nyhus LM., Baker RJ., Fischer JE., Little, Brown and company, Boston, New York, Toronto, London. Volume 1, 1997, 44:563-569.
- 821- **Lovrics P and others :** A prospective study of PET scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer (abstract P-13), presented at the meeting of the Society of Surgical Oncology, Washington, DC, March 15-18, 2001.
- 822- **Lu H-M, Cash E, Nixon A, et al. :** The impact of CT-simulation on the planning of tangential fields for left breast treatment. *Int J Radiat Oncol Biol phys* 1999; 45:159 (abst).
- 823- **Lu Q, Nakmura J, Savinor A et al. :** Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancer. *Endocrinology* 1996; 137:3061-3068.
- 824- **Lubet RA., Steele VE., Casebolt TL., et al. :** Chemopreventive effects of the aromatase inhibitors varozole (R-83842) and 4-hydroxy androstenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. *Carcinogenesis* 1994; 15:2775-2780.
- 825- **Lucas F.V., Perez-Mesa, G.M., :** Inflammatory carcinoma of the breast, *cancer* 1978; 41:1595.
- 826- **Lucas FL., and others :** Bone mineral density and risk of breast cancer: differences by family history of breast cancer. Study of osteoporotic Fractures Research Group, *Am J Epidemiol* 1998; 148: 22-29.
- 827- **Lumachi F and others :** Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation ith different prognostic factors, *Anticancer Res* 2000; 20:4751-4755.
- 828- **Luo S., Sourla A., Labrie C., et al. :** Effect of twenty-four weeks treatment with antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. *Endocrinology* 1998; 139:2645-2656.
- 829- **Lynch ED and others :** Inherited mutations in PTEN that are associated with breast cancer, Cowden disease, and Juvenile polyposis, *Am J Hum Genet* 1997; 61:1254-1260.
- 830- **Mac Mahon B and others :** Age at first birth and breast cancer risk, *Bull WHO* 1970; 43:209-221.
- 831- **MacDonald P.C., Edman C.D., Hemsell D.L., Porter, J.C., Siiteri P.K.,:** Effect of obesity on conversion of plasma androstenedione to estrone in postmenopa-usal women with

- and without endometrial cancer. *Am. J. Obstet. Gynecol.* 1978;130: 446-55.
- 832- **MacDonald P.C., Rombaut, R.P., Siiteri, P.K.,**: Plasma precursors of estrogen. I Extent of conversion of plasma 4-androstenedion to estrone in normal males and non pregnant normal castrated and adrenalectomized females. *J. Clin. Endocrinal Metab.* 1967;27: 1103-11.
- 833- **Mackarem G, Roche CA, Silverman ML, Hughs KS,** : The development of new, primary non-invasive carcinoma of the breast. 29 years after bilateral radical mastectomy. *Breast J* 1998; 4:51.
- 834- **Macmura M, Dickson RB:** Are cellular adhesion molecules involved in the metastasis of breast cancer? *Breast Cancer Res Treat* 1994;32:239.
- 835- **Mahoney, M.C.,** : Breast Imaging: Mammography, Sonography, and Emerging Technology, In: *Cancer of the Breast*, 5<sup>th</sup> ed. Ed. by Donegan W., Spratt J.S., Saunders 2002; 16:287-310.
- 836- **Majeski J, Austin RM, Fitzgerald RH** : Cutaneous angiosarcoma in an irradiated breast after breast conservation therapy for cancer: association with chronic breast lymphedema, *J Surg Oncol* 2000; 74: 208-213.
- 837- **Malkin D. and others** : Germline P53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms, *Science* 1990; 250:1233-1238.
- 838- **Malone KE.,** : Diethylstilbestrol (DES) and breast cancer, *Epide-miol Rev* 1993; 15:108-109.
- 839- **Maluf, H.M., Kaerner, F.C.,** : Solid papillary carcinoma of the breast, *Am J Surg Pathol* 1995; 19:1237.
- 840- **Maluf, H.M., Koerner, F.C.,** : CARCINOMA of the breast with endocrine differentiation: a review, *Virchows Arch* 1994;425-449-457.
- 841- **Mamounas EP, fisher B, Bryant J, et al.** : Does delaying breast irradiation in order to administer adjuvant chemotherapy increase the rate of ipsilateral breast tumor recurrence (IBTR)? Results from two NSABP adjuvant studies in node-positive breast cancer (B-15 and B-16). *Breast Cancer Res Treat* 1996; 41:219(abst).
- 842- **Mamounas EP., Bryant J., Fisher B., Wickerham DL., Wolmark N.,** : Primary Breast Cancer (PBC) as a risk factor for subsequent Contralateral Breast Cancer (CBC): NSABP experience from nine randomized adjuvant trials. *Breast Cancer Res Treat* 1998; 50:230.
- 843- **Mang TS, Allison R, Hew son G, Snider W, Moskowitz R.,** : A phase II/III clinical study of Tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer, *Cancer J Sci Am* 1998; 4:378.
- 844- **Mann CC, and Russel RCG** : Surgery of the breast. In : *Bailey and Loves Short Practice of Surgery.* 22<sup>nd</sup> edn. Chapman and Hall medical, London, Glasgow, New York 1995; pp543-562.
- 845- **Mann GB., Borgen PI.,** : Breast cancer genes and the surgeon. *J Surg Oncol* 1998; 67:267-274.
- 846- **Manni A.,**: Hormone receptors and breast cancer. *N. Engl. J. Med.* 1983;309: 1383-5.
- 847- **Mansfield CM, Komarnicky LT, Prescott RJ** : Ten-year results in 1070 patients with stage I and II breast cancer treated by conservative surgery and radiantion therapy. *Cancer* 1995;75:2328.
- 848- **Mansour EG, Ravdin PM, Dressier L** : Prognostic factors in early breast carcinoma, *Cancer* 1994;

74:381-400.

- 849- **Marcus JN, Watson P, Page DL, et al.** : hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage, *Cancer* 1996;77:647.
- 850- **Margolese R and others** : The technique of segmental mastectomy (Lumpectomy) and axillary dissection: a syllabus from the National Surgical Adjuvant Breast Project workshops, *Surgery* 1987; 102(5): 828-834.
- 851- **Margolese RG, Foster RS Jr** : Tamoxifen as an alternative to surgical resection for selected geriatric patients with primary breast cancer, *Arch Surg* 1989; 124(5): 548-550.
- 852- **Margolese RG**: Diagnosis and management of local recurrence after breast-conservation surgery, *Can J Surg* 1992; 35(4): 378-381.
- 853- **Mari E, Borrelle G, Sacco M, et al.** : Sitam-01: an Italian clinical trial comparing 2 versus 5 years of adjuvant tamoxifen in breast cancer patients aged. 50 years: preliminary results. *Proc Am Soc Clin Oncol* 2000;14:331a
- 854- **Marks JR and others** : Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer, *Ann Surg* 1994;219:332-341.
- 855- **Marshall, E.** Search for a killer: Focus shifts from fats to hormones. *Science*,1993; 259-618.
- 856- **Marshall, L.M** : Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. *Cancer Epidemiol Biomarkers* 1997; 6:297-301.
- 857- **Martin A M, Weber BL** : Genetic and hormonal risk factors in breast cancer, *Natl Cancer Inst* 2000; 92:1126-1135.
- 858- **Martin-Hernandez A., Francis D. J. and Silverberg S.G.**: Elastosis and other stromal reaction in benign and malignant breast tissue. *Cancer*. 1992; 80 : 700 - 705
- 859- **Marttunen M., Hietanen P., Tiitinen A., et al.** : Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. *J Clin Endocrinol Metab* 1998;83:1158-1162.
- 860- **Mateos JJ., and others** : Scintigraphic evolution of a breast cancer with Tc-99, MIBI Scintimammography, *Clin Nucl Med* 2000, 25(9): 701-703.
- 861- **Mattson A and others**: Radiation induced breast cancer: long term follow-up of radiation for benign breast disease, *J Natl Cancer Inst* 1993; 85: 1679-1685.
- 862- **Maycock IA, Dillon P, Dixon JM** : Morbidity related to intercostobrachial nerve damage following axillary surgery for breast cancer, *Breast* 1998; 7:209-212.
- 863- **Mc Culloch PG, MacIntyre** : Effects of surgery on the generation of lymphokine-activated killer cells in patients with breast cancer. *Br J Surg* 1993; 80: 1005-1007.
- 864- **Mc Devitti R.W.,** : Breast carcinoma, *Human pathol*, 1978;9:3.
- 865- **Mc Divitti R, Boyce W, Gersell D**: Tubular carcinoma of the breast: Clinical and pathological observations concerning 135 cases. *Am J Surg Pathol* 1982; 6:401.
- 866- **Mc Guickin MA, Cummings MC, Walsh MD, et al.** : Occult axillary node metastases in breast cancer: their detection and prognostic significance. *Br J Cancer* 1998;73:88.

- 867- **Mc Master, K.M., and others** : Sentinel lymph-node biopsy for breast cancer. Not yet the standard of care, *N Engl J Med* 1998; 339:990.
- 868- **Mc Masters KM and others** : Dermal injection for breast cancer sentinel lymph node biopsy: results of a multi-institutional study, *Ann Surg* 2001;233:676-687.
- 869- **MC Masters KM and others** : Defining the optimal surgeon experience for breast cancer sentinel lymph node (SLN) biopsy: a model for implementation of new surgical techniques. *Ann Surg* 2001;234:242-300.
- 870- **Mc Masters KM and others** : Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used, *J Clin Oncol* 2000;18:2560-2566.
- 871- **Mc Masters KM, Giuliano AE, Ross MI, et al.** : Sentinel lymph node biopsy for breast cancer -not yet standard of care, *N Engel J Med* 1998;334:440-445.
- 872- **MC Masters KM, Hunt kk** : Neoadjuvant chemotherapy, locally advanced breast cancer, and quality of life ,*J Clin Oncol* 1999;17(2):441-444
- 873- **McCatty KS Jr** : Proliferative stimuli in the normal breast: estrogens or progestins? *Hum Pathol* 1989;20(12): 1137-1138.
- 874- **McCready DR and others** : The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer, *Arch Surg* 1989; 124:21-25.
- 875- **Mc-Divitti RW.,** : The breast, In: Anderson's Pathology, 9<sup>th</sup> ed. By kissane JM., The C .v Mosby Co. 1990;35:1734-1749.
- 876- **McGinnis LS and others:** National Cancer Data Base survey of breast cancer management for patients from low income zip codes, *Cancer* 2000; 88:933-945.
- 877- **McGrath P.C., Holley D.T., Freeman J.W., Hamby L.S., Jennings C.D., and Mattingly C.A.,** : Significance of nucleolar proliferation antigen p120 in breast cancer: Correlation to conjunction with society of head and Neck Surger, March 18-21, Los Angeles 1993; 5:113.
- 878- **McGuire WL** : Prognostic factors in primary breast cancer, *Cancer Surv* 1986;5:527-536.
- 879- **McLaughlin R, McGrath J, Grimes H, Given HF** : The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer, *Int Biomarkers* 2000; 15-340-342.
- 880- **Mc-Pherson K., steel CM., and Dixon JM.,** : Breast cancer epidemiology, risk factors and genetics clinical review. *Br. M.J* 2000; 321:624-628.
- 881- **Meiser B., Butow P., Friedlander M., et al.** : Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. *J clin Oncol* 2000; 18:2250-2257.
- 882- **Meites, J.:** Neural control of lactation. In the neuroendocrinology of human reproduction, edited by Mack, H.C., and Sherman, A.I. Sprin, Field, Charles, C., Thomas, Publisher. 1971
- 883- **Melbye M., and others** : Induced abortion and the risk of breast cancer, *N Engl J Med* 1997; 336:81-85.
- 884- **Meltzer A** : Dormancy and breast cancer, *J Surg Oncol* 1990; 43:181-188.
- 885- **Menard S. and others:** Role of HER2 gene overexpression in breast carcinoma, *J Cell Physiol* 2000;

18(92):150-162.

- 886- **Mendonca GA, and others** : Organochlorines and breast cancer: a case-control study in Brazil, *Cancer* 1999; 83:596-600.
- 887- **Merson M., and other** : Breast carcinoma presenting as axillary metastases without evidence of a primary tumor, *Cancer* 1992; 70:504-508.
- 888- **Mettlin C**: Global breast cancer mortality statistics, *CA Cancer J Clin* 1999; 49:138-144.
- 889- **Meurisse,-M; Defechereux,- T; Meurisse,-N; Bataille,-y; Hamoir,-E**: New challenges in the treatment of early breast cancer or surgery for early breast cancer can less be more?. *Acta-Chir-Belg.* 2002 Apr; 102 (2) :97 - 109.
- 890- **Meyer JE., Smith DN., Lester Sc.,** : Large core needle biopsy of non palpable breast lesions, *JAMA* 1999; 281:1628-1641.
- 891- **Meyer JS** : Cell kinetics of breast and breast tumors. In Donegan WL, Spratt JS, editors: *Cancer of the breast*, Philadelphia, 1995, WB Saunders, PP 279-280.
- 892- **Meyer JS, Province MA** : S-phase fraction and nuclear size in long term prognosis of patients with breast cancer, *Cancer* 1994;74:2287-229.
- 893- **Meyer, J.** : In cellular kinetics of breast cancer from: *Cancer of the breast*, 5<sup>th</sup> ed. By : Donegan, W. and Spratt, J.N., 2002; 19:377-416
- 894- **Michna H, Nishino Y, Neef G et al.** : Progesterone antagonists: tumor inhibiting potential and mechanism of action. *J. Steroid Biochem Mol. Biol* 1992; 41:339.
- 895- **Middleton, L.P., and others** : Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis, *Am J Surg Pathol* 2000; 24:1650.
- 896- **Miki, Y. Swensen J, Shattuck-Eidens D, et al.** : A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 1994; 266:66-71.
- 897- **Miller AB and others**: Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis, *N Engl J Med* 1989; 321:1285-1289.
- 898- **Miller AB, Baines CJ, To T, et al.**: Canadian national breast screening study I. breast cancer detection and death rates among women aged 40 to 49 years. *Can Med Assoc J* 1992;147:1459-1476.
- 899- **Miller AB, Baines CJ, To T, et al.**: Canadian national breast screening study II. Breast cancer detection and death rates among women aged 50 to 59 years. *Can Med Assoc J* 1992; 147:1477-1488.
- 900- **Miller AB, to T, Baines CJ, well C**: Canadian national breast screening study-2:13-year results of a randomized trial in women aged 50 – 59 years. *J Natl Cancer Inst* 2000; 42:1490-1499.
- 901- **Miller DM, Bates PJ, Nabell L** : Molecular biology of breast cancer. In: Donegan WL, Spratt Js, *Cancer of the Breast* 5<sup>th</sup> ed: Saunders, Philadelphia, London. New York. St Louis. Sydney. Toronto. 2002; 11:181-198.
- 902- **Miller KD, Sledge GWJr** : Chemotherapy for early and advanced breast cancer In: Donegan WL, Spratt Js, *cancer of the Breast* 5<sup>th</sup> ed Saunders, Philadelphia, London. New York. St Louis. Sydney. Toronto. 2002;30:654-642

- 903- **Miller WH. Jr.,** : The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. *Cancer* 1998; 83:1471-1482.
- 904- **Miller WR, Ellis IO, Sainsbury JRC** : Prognostic factors. In: Dixon JM. (ed) ABC of Breast Diseases, 2<sup>nd</sup> edn. London: *BMJ Book*, 2000; 72-77.
- 905- **Millikan R., and others** : The need for epidemiologic studies of m-situ carcinoma of the breast, *Breast Cancer Res Treat* 1995; 35:65-77.
- 906- **Millikan RC., and others:** Cigarette smoking, N-acyl- Transferase 1 and 2, and breast cancer risk, *Cancer Epidemiol Biomarkers Prev.* 1998; 7:371-378.
- 907- **Mills JM and others** : Preservation of cosmesis with low complication risk after conservative surgery and radiotherapy for ductal carcinoma in situ of the breast, *Int Radiat Oncol Biol Phys* 1997; 39:637-641.
- 908- **Mincey BA, Bammer T, Atkinson FJ, Perez EA** : Role of axillary node dissection in patients with T10 and T1b breast cancer, *Arch Surg* 2001; 136:779-782.
- 909- **Mittra I, Baum M, Thornton H, et al.:** Is clinical breast examination an acceptable alternative to mammographic screening? *BMJ* 2000;321:1071-1073.
- 910- **Mittra I, Hayward J.L., McNeilly A.,:** Hypothalamic-pituitary thyroid axis. In : breast cancer. *Lancet* 1974;1: 885.
- 911- **Moinfar, F., and others** : Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("Clinging ductal carcinoma in-situ"): a simulator of normal mammary epithelium, *Cancer* 2000;88:2072.
- 912- **Mokhtar N.,** : Cancer pathology Registry 1985-1989. National cancer Institute, Cairo university, published by the department of pathology NCI 1991; 19-25.
- 913- **Mol JA, Henzen - Longmans SC, Hagemen P et al.:** Expression of the gene encoding growth hormone in the human mammary gland. *J. Clin Endocrinol Metab* 1995; 80:3094.
- 914- **Moller P., Evans G., Haites N., et al.** : Guidelines for follow-up of women at high risk of inherited breast cancer: Consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast cancer, *Dis. Markers* 1999; 15:207-211.
- 915- **Monsees BS, Destovet JM:** A screening mammography program: Staying alive and making it work. *Radial clin North Am* 1992;30:211-219.
- 916- **Monsees BS.,** : Evaluation of breast calcifications, *Radial clin North Am* 1995; 33(6) :1109-1121.
- 917- **Moore MM:** Treatment of ductal carcinoma in situ of the breast. *Semin Surg Oncol* 1991;7:267-70.
- 918- **Moore MP, Kinne DW** : Axillary lymphadenectomy: a diagnostic and therapeutic procedure, *J Surg Oncol* 1997; 66-2-6
- 919- **Mora EM, Buzdar AU, Johnston DA.,** : Aggressive therapy for loco-regional recurrence after mastectomy in stage II and III breast cancer patients. *Ann Surg Oncol* 1996; 3:162.
- 920- **Morabia A., and others** : Relation of breast cancer with passive and active exposure to tobacco smoke, *Am J Epidemiol* 1996; 143:918-928.
- 921- **Moradi T., and others** : Breast cancer risk and lifetime leisure-time and occupational physical activity (Sweden), *Cancer Causes Control* 2000; 11:523-531.

- 922- **Morimoto T and others** : Cancerous residue breast conserving surgery, *J Surg Oncol* 1993; 52:71-76.
- 923- **Morris MM, Powell SN** , : Irradiation in the setting of collagen vascular disease acute and late complications. *J Clin Oncol* 1997; 15:2728.
- 924- **Morrow M** : Axillary dissection: When and How radical? *Semin Surg Oncol* 1996; 12:321-327.
- 925- **Morrow M** : Role of axillary dissection in breast cancer management, *Ann Surg Oncol* 1996; 3(3): 233-234.
- 926- **Morrow M, Foster RS Jr** : Staging of breast cancer: a new rationale for internal mammary node biopsy, *Arch Surg* 1981; 116:748.
- 927- **Morrow M, Rademaker AW, Bethke KP, et al.** : Learning sentinel node biopsy :results of a prospective randomized trail of tow techniques. *Surgery* 1999 ;126:714-722.
- 928- **Morrow M, Schmidt RA, Cucci C** : Breast conservation for mammographically occult carcinoma, *Ann Surg* 1998; 227(4): 502-506.
- 929- **Morrow M, Wong S, Vental** , : The evaluation of breast masses in women younger than forty years of age. *Surgery* 1998; 124:634-641.
- 930- **Morrow M.** , : Insurance policies for prophylactic surgery: to cover or not to cover? [Editorial] . *Am Surg Oncol* 2000; 7:321-322.
- 931- **Morrow M.** , : When can stereotactic core biopsy replace excisional biopsy? A clinical perspective, *Breast Cancer Restreat* 1995; 36:1.
- 932- **Morrow M., Bucci G., Rademaker A.**, : Medical contraindications are not the major factor in the underutilization of breast conserving therapy. *J Am Coll Surg* 1998; 186:269.
- 933- **Morrow M., Venta L., Stinson T., et al.** : Is core biopsy the diagnostic procedure of choice for all mammographic abnormalities? *Proc. Am Soc. Clin Oncol* 1999; 18:79a.
- 934- **Morrow M:** The woman at increased risk for breast cancer; evaluation and management strategies cancer. *Eur J. Cancer Prev*, 1995; 4:7.
- 935- **Moss SM, Coleman DA, Chamberlain TJ, et al.** : 16-year mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. *Lancet* 1999;353:909-1914.
- 936- **Mullen EE, Deutsch M, Bloomer WD.**, : Salvage radiotherapy for local failures of lumpectomy and breast irradiation. *Radiother Oncol* 1997; 42:25.
- 937- **Mumtaz H, Davidson T, Hall-Craggs MA, et al.** : Comparison of magnetic resonance imaging and conventional triple assessment in locally recurrent breast cancer. *Br J Surg* 1997; 84: 1147.
- 938- **Mumtaz H., and others** : Staging of symptomatic primary breast cancer with MR imaging, *AJR Am J Roentgenol* 1997; 169 :417-424.
- 939- **Mund DF and others** : Mammographically detected recurrent nonpalpable carcinoma developing in a transverse rectus abdominis myocutaneous flap, *Cancer* 1994; 74: 2804-2807.
- 940- **Munster PN, Hudis CA** : Role of Taxanes in adjuvant therapy. *Cancer Invest* 2000;18:32-38
- 941- **Murad TM, Contesso G, Mouriessse H** , : Nipple discharge from the breast, *Ann Surg* 1982; 195:259-264.

- 942- **Murray P.A., Barrett-Lee P., Travers M., and Lugmani Y.,** : The prognostic significance of transforming growth factors in human breast cancer, *Br. J. Cancer*,1993; 67(6):1408.
- 943- **Muss HB and others** : C-erbB -2 expression and response to adjuvant therapy in women with node-positive early breast cancer, *N Engl J Med* 1994; 330:1260-1266.
- 944- **Muss HB and others** : High-versus standard - dose megestrol acetate in women with advanced breast cancer: a phase III Trial of the Piedmont Oncology Association , *J Clin Oncol* 1990; 8:1797.
- 945- **Mustafa IA and others** : The impact of histopathology on nodal metastases in minimal breast cancer, *Arch Surg* 1997; 132:384-391.
- 946- **Nabholtz J M and others** : prospective randomized Trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy: 304 study Group, *J Clin Oncol* 1999,17:1413-1424
- 947- **Narod SA., Risch H., et al.** : Oral contraceptives and the risk of hereditary ovarian cancer. *Hereditary ovarian cancer clinical Study Group.* 1998; 339 (7): 424 – 428.
- 948- **Nasca PC., and others** : An epidemiologic case control study of breast cancer and exposure to hair dyes, *Ann Epidemiol* 1992; 2:577-586.
- 949- **Nass SJ Davidson NE:** The biology of breast cancer. in *Hematol/Oncol Clinics of North America*, 1999, Voll3 No2 Apr.
- 950- **National Cancer Institute-sponsored conference, Bethesda, Maryland, September 9-10, 1996, with representatives of the American Society of Cytopathology Papanicolaou Society of Cytopathology, American College of Radiology, American College of Obstetricians & Gynecologists, American Academy of Family physicians Society of Surgical Oncology, College of American Pathologists, National Consortium of Breast Cancer Society, International Academy of Cytology, American Society of Clinical Pathologists, American Cancer Society, American College of Surgeons, and the American Society for Cytotechnology.** The uniform approach to breast fine needle aspiration biopsy: a synopsis, *Breast Journal* 1996; 2:357-363.
- 951- **National Comprehensive Cancer Network (NCCN) Update** : NCCN practice guidelines for the treatment of breast cancer. *Oncology (Huntingt)* 1999; 13:41-66.
- 952- **National Institute of Health Consensus Conference (NIHCC)** : Treatment of early-stage breast cancer, *JAMA* 1991; 265(3): 391-395.
- 953- **National Institute of Health Consensus Development Conference Statement (NIHCDCS):** Adjuvant therapy for breast cancer, November 1-3, 2000, *J Natl Cancer Inst* 2001; 93:979-989.
- 954- **National Institute of Health Consensus Development Panel (NSHCDP)** : treatment of primary breast cancer, *N Engl J Med* 1979;301-340.
- 955- **National Institute of Health Consensus Development Conference Statement (NIHCDCS)** : Adjuvant therapy for breast cancer, November 1-3, 2000, *J Natl Cancer Inst* 2001; 1;93(13): 979-989.
- 956- **National Institutes of Health Consensus Development Panel (NIHCDCP):** breast cancer screening for women 40-49, January 21-23, 1997. *J Natl Cancer Inst* 1997; 39:1015-1026.

- 957- **National Institutes of Health Consensus Statement (NIHCS):** Adjuvant therapy for breast cancer 2000; 17(4) November 1-3:13.
- 958- **Nattinger AB, Hoffmann RG, kneusel R, Schapira MM :** Relation between appropriateness of primary therapy for early-stage breast carcinoma and increased use of breast . conserving surgery, *Lancet* 2000, 356:1148-1153
- 959- **NCCN :** Breast cancer Risk-Reduction Guidelines *Oncolog* 1999;13:241.
- 960- **NCCN :** Breast cancer treatment guidelines for patients : *version II, In touch* 1999; October/ November: 67-97
- 961- **Negrini M ., Sabbioni S., Possati, L. :** Suppression tumorigenicity of breast cancer cells by micro-cell-mediated chromosome transfer: Studies on chromosomes 6 and 11. *Cancer Res.* 1994;54:1331.
- 962- **Nemoto T and others :** Factors affecting recurrence in lumpectomy with irradiation for breast cancer, *Cancer* 1991; 678:2079-2082.
- 963- **Nendenhall,-N-P:**Hematol.Oncol-clinn-North-Amr.2001 pr.;15(2): 219-42
- 964- **Neugut AI, Robinson E, Lee WC, :** Lung cancer after radiation therapy for breast cancer, *Cancer* 1993; 71:3054-3057.
- 965- **Newcomb PA., and others :** Fracture history and risk of breast and endometrial cancer, *Am J Epidemiol* 2001; 153:1071-1078.
- 966- **Newman LA and other :** Local Recurrence and survival among black woman with early -stage breast cancer treated with breast -conservation therapy or mastectomy , *Ann Surg Oncol* 1999;6(3):241-248
- 967- **Newman LA, Kuerer HM, Hunt KK, et al. :** Presentation, Treatment, and outcome of local recurrence after skin-sparing mastectomy and immediate breast reconstruction, *Ann Surg Oncol* 1998; 5:620.
- 968- **Nielsen C, Lang RS:** Principles of screening *Med Clin North Am* 1999; 83:1323-1337.
- 969- **Nielsen M, Thomas JL, Primdahl S, et al.:** Breast cancer and atypia among young and middle aged women: a study of 110 medicolegal autopsies: *Br J cancer* 1987;56:814-819.
- 970- **Nieweg OE and others :** positron emission tomography with fluorine- 18- deoxyglucose in the detection and of breast cancer, *Cancer* 1993;71:3920-3925.
- 971- **NIH Consensus Development Conference :** Treatment of early stage breast cancer. *JAMA* 1991; 265: (3)391-395.
- 972- **Noguchi L. Slamon D., Leyland B., Jones B., et al. :** Overall survival, advantages to simultaneous chemotherapy plus humanized anti-HER2 monoclonal antibody Herceptin in HER2 overexpressing metastatic breast cancer, *Am Soceity. Clin. Oncol*, 1999;18:483.
- 973- **Noguchi M and others :** Clinical and biological prediction of axillary and internal mammary lymph node metastases in breast cancer, *Surge Oncol* 1993;2:51-58.
- 974- **Noguchi M and others :** Internal mammary nodal status is a more reliable prognostic factor than DNA ploidy and c-erbB2 expression in patients with breast cancer, *Arch Surg* 1993;128:242-246.
- 975- **Noguchi S, and others :** Down-regulation of transforming growth factor-  $\alpha$  by tamoxifen in human breast cancer, *Cancer* 1993; 72:131.

- 976- **Norton L, Salmon- D, Leyland-Jones B, et al.** : overall survival<sup>(os)</sup> advantage to simultaneous chemotherapy plus the humanized anti- HER-2 monoclonal antibody Herceptin in HER- 2- over expressing metastatic breast cancer. *Proc. Am Soc Clin Oncol* 1999; 18:483A
- 977- **Norum J, Andreassen T** : Screening for metastatic disease in newly diagnosed breast cancer patients: What is cost-effective? *Anticancer Res* 2000; 20:2193-2196.
- 978- **O' Dwyer PJ and others** : CEA and CA 15-3 in primary and recurrent breast cancer, *World J Surg* 1990; 14:562-566
- 979- **O'Connell P, Pekkel V, Fuqua S, Osborne CK, Alired DC.** : Molecular genetic studies of early breast cancer evolution. *Breast Cancer Res Treat* 1994;32:5-12.
- 980- **Offit, K.** : Clinical cancer genetics: risk counseling and management, New York, NY, 1998, Wiley-Liss, Inc.
- 981- **O'Higgins N.J.,** : Breast and Breast reconstruction. In: surgical management., O'Higgins N.J., Chisholm G.D., Williamson R.C.N. (eds): Butterworth Heinemann, 2<sup>nd</sup> ed; 1991; 900.
- 982- **Ohtake T and others** : computer- assisted complete three- dimensional reconstruction of the mammary ductal lobular systems, *Cancer* 2001;91:2263-2272
- 983- **Okazaki A., Hirata K., Okazaki M., et al.** : Nipple discharge disorders: current diagnostic management and the role of fiber-ductoscopy. *Eur Radiol* 1999; 9:583-590.
- 984- **Olsen O, Gotzsche PC:** *Cochrane* review on screening for breast cancer with mammography, *Lancet* 2001;358:1340-1342.
- 985- **Olsson H., Hagglund G** : Reduced cancer morbidity and mortality in a prospective cohort of women with distal forearm fractures, *Am J Epidemiol* 1992; 136:422-427.
- 986- **Omar S., Contesso G., Khaled H.,** : Surgery of Breast Cancer, In : Breast Cancer, 4<sup>th</sup> ed. Ed. By : Omar S., Contesso G., Khaled H., 2001, (8): 87 – 104.
- 987- **Omar S., Contesso G., Khalid H.,** : Breast imaging, In: Breast Cancer, 4<sup>th</sup> ed. Ed. by Omar S., Contesso G., Khalid H, 2001;6:57-72.
- 988- **Omar SH., Contesso G, Khaled H.** : Prognostic factors, in Breast Cancer,4<sup>th</sup> ed. Edt. By Omar SH., Contesso G, Khaled H.,2001;14:191-213
- 989- **Omar SH., contesso G., and Khaled H.,** : Epidemiology of breast cancer, In : Omar SH., contesso G., and Khaled H., :*Breast cancer, 4<sup>th</sup> ed. 2001; 1: 1-8.*
- 990- **Omar Sh., Contesso G., and Khaled H.,** : Surgery of breast cancer, In: Breast cancer, 4<sup>th</sup> edn. 2001; 7: 87-104.
- 991- **Omer S, Contesso G, khaled H** : pathology of breast carcinoma, In: Breast cancer, 4<sup>th</sup> edn. Ed. By Omer S, Contesso G, khaled H, 2001;6:73-87.
- 992- **Omoto Y and others** : Clinical value of the wild-type estrogen receptor beta expression in breast cancer. *Cancer Lett* 2001;163:207-212.
- 993- **O'Neill JS, Elton RA, Miller WR.,** : Aromatase activity in adipose tissue from breast quadrants : a link with tumor site, *BMJ* 1988; 296:741-743.
- 994- **Orel S., and others** : MR imaging in ductal carcinoma in situ, *Radiology* 1997; 202 :413 – 420.

- 995- **Orel SG, Schnall MD:** MR imaging of the breast for the detection, diagnosis and staging of breast cancer, *Radiology* 2001;220:13-30.
- 996- **Orel SG., :** MR imaging of the breast, *Radiol Clin North Am* 2000; 38 (4): 899.
- 997- **Orel SG., and others :** Breast carcinoma : MR imaging before re-excisional biopsy, *Radiolog* 1997; 205:429-436.
- 998- **Ormandy CJ, Hall RE, Manning DI, et al.:** Co expression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. *J Clin Endocrinol Metab* 1997; 82:3692.
- 999- **Osborne CK, Boldt OH, Clark GM et al.:** Effects of tamoxifen on human breast cells cycle Kinetics. *Cancer Res* 1983;43:3583.
- 1000- **Osborne Ck, Yochmowitz MG, Knight WAD, et al. :** The value of estrogen and progesterone receptors in the treatment of breast cancer. *Cancer* 1980;46:2884-2888.
- 1001- **Osborne M, Borgen P, Wong G, et al. :** Salvage mastectomy for local control and regional recurrence after breast-conserving operation and radiation therapy. *Surg Gynecol obstet* 1992; 174: 189-194.
- 1002- **O'shaughnessy JA., and others :** Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients, *Clin Cancer Res* 1999; 5(11): 3438-3444.
- 1003- **Ottelman LA, Long HJ:** Hypercalcaemic flare with megestrol acetate, *Cancer Treat Rep* 1984;68:1420
- 1004- **Ottman R., Pike MC., and king MC, :** Practical guide for estimating risk for familial breast cancer, *Lancet* 1983; 2:556.
- 1005- **Ozbun MA, Bute JS :** Tumor suppressor P53 mutations and breast cancer: a critical analysis, *Adv cancer Res* 1995;66:71-141.
- 1006- **Paci E, Alexander FE:** Study design of randomized controlled clinical trials of breast cancer screening *Monogr Natl Cancer Inst* 1997; 22:21-25.
- 1007- **Paeck K., and others :** Differential ligand activation of estrogen receptors ERalpha and ER beta at AP1 sites, *Science* 1997; 277:1508-1510.
- 1008- **Page D., and others :** Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy, *Cancer* 1995; 76:1197-1200.
- 1009- **Page D., Anderson T.,:** Diagnostic histopathology of the breast, New York, 1987, *Churchill Livingstone, PP157-174.*
- 1010- **Page D., Eillis I. And Elston C., :** Histological grading of breast cancer, *British J. Surg.*, 1995;69:697.
- 1011- **Page DL, Dupont WD, Rogers LW, et al.:** Intraductal carcinoma of the breast: follow-up after biopsy only. *Cancer* 1982;49:751-758.
- 1012- **Page DL, Steel CM, Dixon JM., :** Carcinoma in situ and patients at high risk of breast cancer. In : *Dixon IM(ed) ABC of Breast Diseases, 2<sup>nd</sup> edn. London: BMJ Books, 2000; 90-96.*
- 1013- **Page DL., Simpson JF :** Ductal carcinoma in situ the focus for prevention, screening, and breast conservation in breast cancer, *N Engl J Med* 1999; 340:1499-1500.

- 1014- **Page PI and Donegan WI.** : Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated by biopsy only . *Cancer*. 1995 ; 76 :1197
- 1015- **Palmer JR., and others** : Breast cancer and cigarette smoking: a hypothesis, *Am J Epidemiol* 1991; 134:1-13.
- 1016- **Palmer JR., Rosenberg L.,** : Cigarette smoking and the risk of breast cancer, *Epidemiol Rev* 1993; 15:145-156.
- 1017- **Papotti, M., and others** : Neuroendocrine differentiation in carcinoma of the breast : a study of 51 cases. *Semin Diagn Pathol* 1989;6:174-188.
- 1018- **Papotti, M., and others** : Primary oat cell (neuroendocrine) carcinoma of the breast, *Virchows Arch A Pathol Anat* 1992;420:103.
- 1019- **Park CC, Mitsumori M, Nixon A, et al:** Outcome at 8 years after breast conserving surgery and Radiation Therapy for invasive breast cancer, influence of margin status and systemic therapy on local recurrence. *J Clin Oncol* 2000;18(80):1668.
- 1020- **Park SK., and others** : Alcohol consumption, glutathione S-Transferase M1 and T1 genetic polymorphisms and breast cancer risk, *Pharmacogenetics* 2000; 10:301-309.
- 1021- **Parker SH., and others** : Percutaneous large core breast biopsy: a multi-institutional study, *Radiology* 1994;193:359-364.
- 1022- **Parker SH., and others** : US-guided automated large-core breast biopsy, *Radiology* 1993; 187:507-511.
- 1023- **Parker SH., Klaus AJ.,** :Performing a breast biopsy with a directional vacuum-assisted biopsy instrument, *radiographics* 1997; 17:1233-1252.
- 1024- **Parkin DM., and others** : Cancer incidence in five continents, *JARC Sci Publ* 1997; 7:1-1240.
- 1025- **Parmigiani G., Berry D., Aguilar O.,:** Determining carrier probabilities for breast cancer-susceptibility genes *BCA1* and *BRCA2*. *Am J Hum Genet* 1998; 62: 145-158.
- 1026- **Patchefsky AS, Schwartz GF, Finkelstein SD, et al.** : Heterogeneity of intraductal carcinoma of the breast. *Cancer* 1989; 6:731-741.
- 1027- **Pauletti G and others** : Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a immunohisto-chemistry, *Clin Oncol* 2000; 18:3651-3664.
- 1028- **Pearson OH and others** : Endocrine versus endocrine plus five drug chemotherapy in postmenopausal women with stage II estrogen receptor- positive breast cancer, *Cancer* 1989; 64:1819.
- 1029- **Pearson OH, Manni A, Chambers M, Brodkey J, Marshall JS,:** Role of pituitary hormones in the growth of human breast cancer, *cancer*; 1978,12:85.
- 1030- **Peeters PHM, Verbeek ALM, Straatman H, et al.:** Evaluation of overdiagnosis of breast cancer in screening with mammography: results of the Nijmegen programme *Int J Epidemiol* 1989;18:295-299.
- 1031- **Pegg AE.,** : Recent advances in the biochemistry of polyamines in eukaryotes, *Biochem J* 1986; 234:249-262.
- 1032- **Pegg AE., McCann PP.,** : Polyamine metabolism and function, *Am J Physiol* 1982; 243(5):C212-c221.

- 1033- **Pegram M, Paulatti G, Salmon D** : HER-2/neu as a predictive marker of response to breast cancer therapy. *Breast cancer Res Treat* 1998;52:65-77.
- 1034- **Penault-Liorca F, Le Bouedec G, Pomel C, et al.** : Microinvasive carcinoma of the breast: is axillary lymph node dissection indicated? *Lab Invest* 1998; 78:25A (abst).
- 1035- **Pendas S and others** : Sentinel node biopsy in ductal carcinoma in situ patients, *Am Surg Oncol* 2000;7:15-20.
- 1036- **Perera FP and others** : Carcinogen-DNA adducts in human breast tissue, *Cancer Epidemiol Biomarkers Prev* 1995; 4:233-238.
- 1037- **Persson I, and others** : Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden), *Cancer Causes Control* 1994; 5:523-528.
- 1038- **Peters MV**: Carcinoma of the breast : stage II- radiation range. Wedge resection and irradiation : an effective treatment in early breast cancer , *JAMA*; 2002;20 :134-135
- 1039- **Peterson ME, Schultz DJ, Reynolds C, et al.** : Outcomes in breast cancer patients relative to margin status after treatment with breast conserving surgery and radiation therapy: the university of Pennsylvania experience. *Int J Radiat Oncol Biol Phys* 2000 (in press).
- 1040- **Peto J. and others**, : Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer, *J. Natl Cancer Inst.* 1999; 91:943-949.
- 1041- **Peto J., Mack TM.**, : High constant incidence in Twins and other relatives of women with breast cancer, *Nat Genet* 2000; 26(4):411-414.
- 1042- **Peto R**: Five year of Tamoxifen - or more ? *J Natl Cancer Inst* 1996;88:1741-1743.
- 1043- **Petrek JA, Heelan MC** : Incidence of breast carcinoma-related lymphedema, *Cancer* 1998; 83: 2776-2781.
- 1044- **Phillips KA, Glendon G, Knight JA** : Putting the risk of breast cancer in perspective, *N Engl Med* 1999; 340(2): 141-144.
- 1045- **Philpotts LE., Shaheen NA., Carter D., et al.** : Comparison of rebiopsy rates after stereotactic core needle biopsy of the breast with 11-G vacuum suction probe vs. 14-G automatic gun. *Am J Roentgenol* 1999;172:683-687.
- 1046- **Pickle LW., and others** : Atlas of U.S cancer mortality among whites, 1950-1980, Washington , DC, 1987; US Govt Printing office.
- 1047- **Pierce L Strawderman M, Narods, et al.** : No deleterious effects of radiotherapy in woman who are heterozygote for a BRCA-1 or BRCA-2 mutation following breast - conserving therapy, *proc Am Soc Clin Oncol* 1999;18:86A(abest).
- 1048- **Pierce LJ Oberman HA, Strawderman MH, Lichter AS**: Microscopic extracapsular extension in axilla: is this an indication for axillary radiotherapy? *Int Radiat Oncol Biol Phys.* 1995;33(2) :253-254.
- 1049- **Pierce LJ, Strawderman M, Narod SA, et al.** : Effect of radiotherapy following breast-conserving treatment in women with breast cancer and germline BRCA 1/2 mutations. *J Clin Oncol* 2000; 18:3360-3364.

- 1050- **Pierce SM, Recht A, loingos TI, et al.** : Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. *Int J Radiat Oncol Biol Phys* 1992; 23:915-923.
- 1051- **Pike MC., and others** : Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk, *Epidemiol Rev* 1993; 15:17-35.
- 1052- **Poelman SM and others** : Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression, *Clin Cancer Res* 2000; 6:4048-4048.
- 1053- **Poetilainen T and others** : Expression of p53 protein has no independent prognostic value in breast cancer, *J Pathol* 1995;177:225-232.
- 1054- **Polgar C, Sulyok Z, Foder J et al.** : Sole brachytherapy of the tumor bed after conservative surgery for T1 breast cancer: Fine-year results of a phase I-II study and initial findings of a randomized phase III trial. *J Surg Oncol* 2002; 80: 121-128.
- 1055- **Pollak MN** : Endocrine effects of IGF-I on normal and transformed breast epithelial cells: Potential relevance to strategies for breast cancer treatment and prevention. *Breast Cancer Res Treat* 1998; 47:209.
- 1056- **Poller, D.N., others** : Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erb B-2 protein expression, *Mod Pathol* 1994; 7:257.
- 1057- **Potischman N., Troisi R.,:** In utero and early life exposure in relation to risk of breast cancer, *Cancer Causes Control* 1999; 10:561-573.
- 1058- **Potter JD., and others** : Progesterone and estrogen receptors and mammary reoplasia in the Iowa Women's Health study: how many kinds of breast cancer are there? *Cancer Epidemiol Biomarkers Prev* 1995; 4:319-326.
- 1059- **Pottern LM., and others** : Occupational cancer among women: a conference overview, *J occup Med* 1994;36:809-813.
- 1060- **Powe JE., :** Positron emission Tomography (PET) scanning in breast cancer, *Br J Radiol* 1997; 70:668-770.
- 1061- **Powles T** : Breast cancer chemoprevention- quo vadis? *Breast* 2001; 10(suppl.3):58
- 1062- **Powles T., and others** : Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemop-revention trial, *Lancet* 1998; 352(4122): 98-101.
- 1063- **Powles TJ, Paterson AHG, Nevantaus A et al.** : Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer [Abstract 468]. *Proc Am Soc Clin Oncol* 1998; 17:1234.
- 1064- **Prasad ML, Giri G, Hoda S.:** Clinicopathologic features of microinvasive (<1mm) Carcinoma of the breast. *Lab Invest* 1998; 78:25A (abst).
- 1065- **Prasad, M.L., and others** : Double immunolabeling with cytokeratin and smooth-muscle actin in confirming early invasive carcinoma of breast, *Am J Surg Pathol* 1999; 23:176.
- 1066- **Preece, P.E., :** The breast, In: *Essential surgical Practice*, ed, by Cuschieri, A., Giles, G.R., and

- Mossa, A.R., 3<sup>rd</sup> ed. chapter 66, Vol. 3, Butter-worth- Heinemann Ltd. 1995;3:979-995.
- 1067- **Price P and others** : Patterns of breast relapse after local excision ± radiotherapy for early stage breast cancer, *Radiother Oncol* 1988; 13:53-60.
- 1068- **Prior P, Waterhouse JAH** : Incidence of bilateral tumors in a population-based series of breast cancer patients. I: Two approaches To an epidemiological analysis, *Br J Cancer* 1978; 37(4): 620-634.
- 1069- **Pritchard KI and others** : CMF added to tamoxifen as adjuvant therapy in postmenopausal women with node positive (+VE) estrogen (ER) and 1 or progesterone receptor (PgR)+VE breast cancer negative results from a randomized clinical Trial (abstract), *Proc Am Soc Clin Oncol* 1994;14:65.
- 1070- **Pritchard KI** : Current and future directions in medical therapy for breast carcinoma. *Cancer* 2000; 88:3065-3672.
- 1071- **Pritchard KI** : Should Tamoxifen be used to treat premenopausal women with breast cancer? *Cancer Invest* 2000;18:685.
- 1072- **Pritchard KI and others** : Randomized trial of cyclophosphamide, methotrxate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node positive estrogen and 1 or progesterone receptor- positive breast cancer a report of the national cancer Institute o Canada Clinical Trials Group, *J Clin Oncol* 1997;15:2302.
- 1073- **Pronzato P and others** : Megestrol acetate: phase II study of a single daily administration in advanced breast cancer *Breast Cancer Res Treat* 1990;17:51.
- 1074- **Quinn M, Allen E** : Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. United kindom Association of Cancer Registries. *BMJ* 1995;311:1341-1345.
- 1075- **Rache M. Simmons**: Breast surgery : past, present and Future. *Amr.-J. Surg.* 2000, 180: 246 - 248.
- 1076- **Radford DM, Zehnbaauer BA**: Inherited breast cancer. *Surg clin North Am* 1996; 76:205-20.
- 1077- **Radmacher MD., Simon R.,** : Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors. *J Natl Cancer Inst* 2000; 92:48.
- 1078- **Radvin PM** : A practical view of prognostic factors for staging, adjuvant treatment planning, and as baseline studies for possible future therapy, *Hematol Oncol Clin North Am* 1994; 8: 197-211.
- 1079- **Radvin PM** : Can patient and tumor characteristics allow prediction of axillary lymph node status? *Semin Breast Dis* 1998; 14:141.
- 1080- **Railo M.J., Von Smitten K. and Pekonen F.,** : The prognostic value of Insulin-like growth factor-1 in breast cancer patients, Results of a follow-up study on 128 patients *Eur. J. Cancer.* 1994;30A(3) :307.
- 1081- **Ramzi S., Come S.E., Handerson J., C., et al.** : Female Breast, In: Robbins pathologic basis of diseases 6<sup>th</sup> edn. Ed. By: W.B Saunders Company. Philadelphia, London, Toronto 1999; 1095-1115.
- 1082- **Read L.D, Sruder CE, Miller JS et al.** : Legand- modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. *Mol Endocrino* 1988; 2:265.
- 1083- **Rebeck TR** : Inheretid genetic predisposition in breast cancer : a population-based perspective, *cancer* 1999;86:2501.

- 1084- **Rebbeck TR., and others** : Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations, *N Engl J Med* 2002; 346:1616-1622.
- 1085- **Rebbeck TR., Levin AM., Eisen A., et al.** : Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. *J Natl cancer Inst* 1999; 91: (17) 1475-1479.
- 1086- **Rebner M., Chesbrough R., Gregory N.,** : Initial experience with the advanced breast biopsy instrumentation device, *AJR Am J Roentgenol* 1999; 173:221-226.
- 1087- **Recht A and others** : Loco-regional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group (ECOG), *J Clin Oncol* 1999; 17:1689-1700.
- 1088- **Recht A, Come S, Gelman R, et al.** : Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage node-positive breast cancer: sequencing, timing, and outcome. *J Clin Oncol* 1991; 9:1662.
- 1089- **Recht A, Come SE, Hayman J** : The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. *N Engl J med* 1996; 334:1356-1361
- 1090- **Recht A**: Selection of patients with early stage invasive breast cancer for treatment with conservative surgery and radiation therapy, *Semin Oncol* 1996; 23(suppl2): 19-30
- 1091- **Reed, W., Oppedal, B.R., Eeg-Larsen, T.** : Immunohistology is valuable in distinguishing between Paget's disease, Bowen's disease and superficial spreading malignant melanoma, *Histopathology* 1990;16:583.
- 1092- **Reidy J, Hoskins D**: Controversy over mammography screening. *BMJ* 1988; 297:932-933.
- 1093- **Reintgen D and others** : Final results-of the DOD multicenter breast lymphatic mapping (abstract), presented at the meeting of the Society of surgical oncology Washington, DC, March, 15-18, 2001.
- 1094- **Resch A, Mock U, Fellner C, et al.** : Breast conserving surgery and PDR-brachytherapy for recurrent breast cancer after primary breast conserving treatment including EBT and HDR-brachytherapy-preliminary results. *Eur J Cancer* 1997; 33: 5159 (Abst).
- 1095- **Rescigno J, McCormick B, Brown A, Myskowski PL** : Breast cellulites after conservative surgery and radiotherapy. *Int J Radiat Oncol Biol Phys* 1994; 29:163.
- 1096- **Retch A**: Side effects of radiotherapy. In Silverstein M, editor: *Ductal carcinoma in situ of the breast*, Baltimore, 1997, Williams & Wilkins, PP 347-352.
- 1097- **Reyniak, J.V.** : Physiology of the breast. In *the breast*, edited by Gallager, H.S., Leis, H.P., Synderman, R.K. and Urban, J.A. The C.V. Mosby Company Saint Louis.1978.
- 1098- **Rhei E, Kang L, Bogomolny F, Federici MG, Borgen PI, Boyd J.**: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. *Cancer Res*1997;57:3657-9.
- 1099- **Ribeiro GG, Magee B, Swindell R, Harris M, Bameryjee SS** : The Christie Hospital breast conservation trial: an update at 8 year from inception. *Clin Oncol (R. Coll Radiol)* 1993; 5:278-283.
- 1100- **Rich-Edward J, Goldman M., Willett W., et al.** : Adolescent body mass index and ovulatory infertility, *Am Obst Gynaecol* 1994; 171:171-176.

- 1101- **Richter, G.O., Dockerty, M.B., Clagett, O.T.** : Diffuse infiltrating Scirrhus carcinoma of the breast. Special consideration of the single-filing phenomenon. *Cancer* 2000; 20:363.
- 1102- **Ries LAG., Kosary CI., Hankey BF., et al. eds.** : SEER cancer statistics Review, 1973-1996, Bethesda, MD; *National Cancer Institute* 2000.
- 1103- **Ritchie AC.,** : The breast, In : *Boyd's textbook of pathology*, 9<sup>th</sup> ed. Lea & febiger, Philadelphia, London, 1990; 43:1404-1433.
- 1104- **Rivkin SE and others** : Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node- positive, and estrogen receptor- positive breast cancer patients: Southwest Oncology Group study. *J Clin Oncol* 1994;12:2078
- 1105- **Robbins, S.L., Cotran, R., and Kumar, V.,** : *Pathologic basis of diseases*, 1995;20:428.
- 1106- **Robert B, Dickson, Marce, E., and Lippman** : Hormonal therapy for breast cancer in : *Cancer: Principles and practice of onchology* 5<sup>th</sup> ed, Lippincott-Roven Publishers, Philadelphia 1997; P: 1541-1552.
- 1107- **Robert NJ** : Biologic indicators of prognosis in breast cancer, *Hosp Pract* 1990; 25:93-98.
- 1108- **Robertson JM and others** : Breast conservation therapy: severe breast fibrosis after radiation Therapy in patients with collagen vascular disease, *Cancer* 1991;68:502-508
- 1109- **Robinson, E.K., and Hunt, K.,** : Non-invasive breast cancer, In: T HE M.D. ANDERSON SURGICAL ONCOLOGY HAND BOOK. 2<sup>nd</sup> ed., Ed by: Barry W. feig, David,, H.B., and George, M., Lippincott Williams & Wilkins. Philadelphia, New York, London. 1999; pp1-12.
- 1110- **Robson M and others:** Breast conservation Therapy for invasive breast cancer in Ashkenazi woman with BRCA gene founder mutations , *J Natl Cancer Inst* 1999;91:2112-2117
- 1111- **Rockhill B., and others** : A prospective study of recreational physical activity and breast cancer risk, *Arch Intern Med* 1999; 159:2290-2269.
- 1112- **Rockhill B., and others** : Physical activity and breast cancer risk in a cohort of young women, *J Natl Cancer Inst* 1998; 90(15):1155-1160.
- 1113- **Rockhill B., and others** : Validation of the Gial et al. model of breast cancer risk prediction and implications for chemoprevention, *J Natl Cancer Inst* 2001; 93(5): 358-366.
- 1114- **Rodenhuis S, Bontembal M, Beex L, et al.** : Randomized phase III study of high dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. *Proc Am Soc Clin Oncol* 2000;14:286A
- 1115- **Roderick NM., Macsueen and Kinne D.,** : Proinvasive carcinoma of breast cancer 1992; 74(2) :702-6.
- 1116- **Roe SM., Mathews JA., Burns RP., et al.** : Stereotactic and ultrasound core needle breast biopsy performed by surgeons. *Am J Surg* 1998; 174:699-704.
- 1117- **Rohan TE., and others** : Dietary fiber, vitamins A. C, and E, and risk of breast cancer: a cohort study, *Cancer Causes Control* 1993;4:29-37.
- 1118- **Rohan TE., and others** : Dietary Folate consumption and breast cancer risk, *J Natl cancer Inst* 2000; 92(3): 366-262.

- 1119- **Rosai J.**, : Breast In : Ackerman's SURGICAL PATHOLOGY, 8<sup>th</sup> ed. Ed. by Rosai J., Mosby-year Book, Inc., 1996; 20:1665-1660.
- 1120- **Rosati RL., Da Silva Jardine P., et al.** : Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydrona-phthalene. *J Med Chem.* 1998;41:2928-2931.
- 1121- **Rosen PP and others** : Discontinuous or "skip" metastases in breast carcinoma: analysis of 1228 axillary dissections, *Ann Surg* 1983;197:276.
- 1122- **Rosen PR, Braun Dw Jr, Kinne DE:** The clinical significance of pre-invasive breast carcinoma, *Cancer* 1980;46:919-925.
- 1123- **Rosen, P.P., Obermaan, H.A.,** : Tumors of the mammary gland, Washington, D.C, 1993, Armed Forces Institute of Pathology.
- 1124- **Roses CF and others:** Complications of level I and II axillary dissection in the treatment of carcinoma of the breast, *Ann Surg* ,230(2):144-201(not mentioned)
- 1125- **Rosfjord E, Dickson RB:** Cell adhesion and metastasis. In : Bowcock A, ed. Contemporary approaches to breast cancer. Totowa, NJ: Humana Press, 1999;285.
- 1126- **Rosner B., Colditz G., Willet W.,** : Reproductive risk factors in a prospective study of breast cancer: The Nurses Health study : *Am J Epidemiol* 1994; 139:819.
- 1127- **Ross RK., and others** : Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin, *J Natl Cancer Inst* 2000; 92(4): 328-332.
- 1128- **Roth H., Pippin, J., and Drebin, J. A:** Her-2/nen- Specific antisense oligodeoxynucleotides induce apoptosis in human breast cancer cells that overexpress HER-2/nen [Abstract 373], 21<sup>st</sup> San Antonio Breast Cancer Symposium, San Antonio TX. 1998.
- 1129- **Rubin E** : Breast ultrasound: beyond cyst vs. Solid, *Mammo-Matters* 1999; 6:45-52.
- 1130- **Rubio I., Mirza N., Sahin A., et al.** : Role of specimen radiography in patients treated with skin-sparing mastectomy for ductal carcinoma in situ of the breast. *Ann Surg Oncol* 2000; 7: 544-548.
- 1131- **Rudland PS and others** : Prognostic significance of the metastatic-inducing protein S100A4 (p9Ka) in human breast cancer, *Cancer Res* 2000;60:1595-1603.
- 1132- **Russo IH., Russo J.,** : Hormone prevention of mammary carcinogenesis: a new approach in anticancer research, *Anticancer Res* 1988; 8(6): 1247-1264.
- 1133- **Russo J., Russo IH.,** : Toward a physiological approach to breast cancer prevention, *Cancer Epidemiol Biomarkers Prev.* 1994; 3:353-364.
- 1134- **Ryu J and others** : Radiation therapy after breast augmentation or reconstruction in early or recurrent breast cancer, *Cancer* 1990;66:844-847.
- 1135- **Sabiston DC.,** : Pulmonary embolism In: Sabiston DC Jr, editor: Davis Christopher Textbook of Surgery, ed 12, Philadelphia, 1981, WB saunders. P 1839.
- 1136- **Sacks NP M, Baum M** : Primary management of carcinoma of the breast. *Lancet* 1993; 342:1402-1408.
- 1137- **Sainsbury J. R., Needham G. K., and Farndon J.R.,:** Epidermal Growth Factor Receptor status as a

- predictor of early recurrence and death from breast cancer, *Lancet* 1987; 1:1398.
- 1138- **Sakorafas GH, Tsiotou AG** : The molecular basis of cancer, *Hellenic Oncology* 1995; 31:17-24.
- 1139- **Sakorafas GH, and Tsiotou A. G.** : Genetic predisposition to breast cancer: a surgical perspective. *Br. J. Surg.* 2000; 87:149-162.
- 1140- **Sakorafas GH, Tsiotou AG.** : Occult breast cancer : a challenge from a surgical perspective, *Surg Oncol* 1999; 8(1) :27-33.
- 1141- **Salmon R., Ansquer Y., Asselain B., et al.** : Clinical and biological characteristics of breast cancer in post-menopausal women receiving hormone replacement therapy for menopause. *Oncol Rep* 1999; 6:699.
- 1142- **Saloman D.S., Kidwel W.R., Kim N, et al.**: Modulation by estrogen and growth factors of transforming growth factor alpha and epidermal growth factor receptor expression in normal and malignant mammary epithelial cells. *Recent Results Cancer Res.* 1989;113:57-69.
- 1143- **Salvadori B and others**: Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery, *Br J Surg* 1999;86:84-87
- 1144- **Salvadori B, Rovini D, Squicciarini P, et al.** : Surgery for local recurrences following deficient radical mastectomy for breast cancer: a selected series of 39 Cases. *Eur J Surg Oncol* 1992; 18:438.
- 1145- **San Antonio Breast Cancer Symposium** : Arimidex reduces relapse compared to tamoxifen, large study reports, *Clin Cancer Lett* 2001;24(21):1.
- 1146- **Sanderson M., and others** : Perinatal factors and risk of breast cancer, *Epidemiology* 1996; 7:34-37.
- 1147- **Santen R.J., Santner, S.J, Davis B., Veldhuis J. Samojlik B., Ruby B.,**: Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. *J. Clin. Endocrinol. Metab.* 1978;47: 1257-65.
- 1148- **Santen RJ** : Introduction to the conference, aromatase: new perspectives for breast cancer, *Cancer Res* 1982;42(suppl):32685.
- 1149- **Santen RJ, Henderson IC,**: A comprehensive guide to the therapeutic use of aminoglutethimide Berlin: Kroger. 1982
- 1150- **Santen R.J., You W., Naftolin F.,** : The potential of aromatase inhibitors in breast cancer prevention. *Endocrine-Related cancer* 1999; 6:235-243.
- 1151- **Santner S.J., Leszczynski D., Wright C., Manni A., Feil P.D., Santen R.J.,**: Estrone sulfate A potential source of estradiol in human breast cancer tissues. *Breast Cancer Res. Treat.* 1986;7: 89-94.
- 1152- **Santner S.J., Feil P.D., Santen R.J.,** : In situ estrogen production via the estrone sulfatase pathway in breast tumors: Relative importance versus the aromatase pathway. *J. Clin. Endocrinol. Metab.* 1984
- 1153- **Saphner T and others** : Phase II study of Goserelin for patients with postmenopausal metastatic breast cancer, *J Clin Oncol* 1993; 11:1524.
- 1154- **Sapino, A., and others** : Mammographically detected in-situ lobular carcinoma of the breast, *Virchows Arch* 2000;436:421.

- 1155- **Sardi A and others** : The significance of mammographic finding after-conserving therapy for carcinoma of the breast, *Surg Gynecol Obstet* 1991; 173:309-312.
- 1156- **Schairer C., Lubin J., Troisi R., et al.** : Meopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. *JAMA* 2000; 283:485-491.
- 1157- **Scheidjauer IC., and other** : Qualitative [18F] FDG positron emission tomography in primary breast cancer: clinical relevance and practicability, *Eur J Necl Med* 1996 ; 23:618-623.
- 1158- **Schieweck K., Bhatnagar AS., Batzl C., et al.** : Anti-Tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. *J steroid Biochem Mol Biol* 1993; 633-636.
- 1159- **Schillaci O., and others** : Scintrmammography with 99m Tc- tetrafosmin suspected breast cancer, *Anticancer Res* 1997; 17:1623.
- 1160- **Schrag D, Kuntz KM, Garber JE, Weeks JC** : Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. *JAMA* 2000; 283:617.
- 1161- **Schrenk P, Hatzl-Griesenhofer M, Shamiyeh A, Waynad W** : Follow-up sentinel node negative breast cancer patients without axillary lymph node dissection, *J Surg Oncol* 2001, 77: 165-170.
- 1162- **Schrenk P, Rieger R, Shamiyeh A, Wayand W** : Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma, *Cancer* 2000; 88:608-614.
- 1163- **Schwaibold F, Fowble BL, Solin LJ, Schaltz DJ, Goodman RL,** : The results of radiation therapy for isolated local regional recurrence after mastectomy. *Int J Radiat Oncol Biol Phys* 1991; 21:299-310.
- 1164- **Schwartz G and others** : Subclinical ductal carcinoma in situ of the breast: Treatment by local excision and surveillance alone, *Cancer* 1992; 70:2468-2474.
- 1165- **Schwartz G, Schwartz R, Cornfield D, et al.** : Subclinical duct carcinoma in-situ of the breast (DCIS): Treatment by local excision and surveillance alone. *Proc Am Soc Clin Oncol* 1996; 15:101.
- 1166- **Schwartz GF, Giuliano AE, Veronesi U and the can sensus conference committel** : Proceeding of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-21, 2001, Philadelphia, PA, USA. *The Breast* 2002: In Press.
- 1167- **Schwartz LM, Woloshin S, Sox HC, et al.:** U.S women's attitudes to false positive mammography results and detection of ductal carcinoma in situ: Cross sectional survey. *BMJ* 2000; 320:1635-1640.
- 1168- **Schwartz MK and others** : Monitoring therapy by serum HER-2/neu; *Int J Biol Markers* 2000; 15(4):324-329.
- 1169- **Schwartz, G.F., and others** : Subcincinal ductal carcinoma in-situ of the breast treatment by local excision and surveillance alone, *Cancer* 1992; 70:2468.
- 1170- **Scopinaro F and others:** A three center study on the diagnostic accuracy of 99m Tc-MIBI scinti-mammography, *Anticancer Res* 1997;17:1631-1634.
- 1171- **Scopinaro F., and others** : A three center study on the diagnostic accuracy of 99m TC-MIBI scintimammograohy, *Anticancer Res* 1997; 17: 1631-1634.
- 1172- **Scott LJ., Wiseman LR.,** : Exemestane. *Drugs* 1999; 58:675-680.

- 1173- **Scott-Canner CE.,** : Management of women at increased risk for breast cancer. In: Manual of Breast Diseases. Ed. by Ismail Jatoi. Lippincott Williams & Wilkins. Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo, 2002, 23:505-518.
- 1174- **Scully R, Chen J, Plug A, et al.** : Association of BRCA 1 with Rad 51 in mitotic and meiotic cells, *Cell* 1997;88:265.
- 1175- **Scully R. and others** : Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage, *cell* 1997; 88:265-275.
- 1176- **Secreto G, Toniolo P., Pisani P. et al.** : Androgens and breast cancer in premenopausal women. *Cancer Res.* 1989;49: 471-476.
- 1177- **Sedlacek SM:** An overview of megestrol acetate for the treatment of advanced breast cancer, *Semin Oncol* 1988;15 (suppl. 1)3.
- 1178- **Sedlmayer F, Rahim HB, Kogelnik HD et al.** : Quality assurance in breast cancer brachytherapy: geographic miss in the interstitial boost treatment of the tumor bed. *Int J Radiat Oncol Biol Phys* 1996; 34:1133-1139.
- 1179- **Semiglazov VF, Moiseyenko VM, Bavli JL, et al.:** The role of breast-self examination in early breast cancer detection (results of the 5-years USSR/WHO randomized study in Leningrad). *Eur J Epidemiol* 1992;8: 498-502.
- 1180- **Semiglazov VF, Moiseyenko VM, Manikhas AG, et al.:** Interim results of a prospective randomized study of self-examination for early detection of breast cancer (in Russian). *Vopr onkol* 1999; 45:265-271.
- 1181- **Senie RT., and others** : Obesity at diagnosis of breast carcinoma influences duration of disease-free survival, *Ann Intern Med* 1992; 116(1):26-32.
- 1182- **Shaff SM., and others** : Early-life physical activity and postmenopausal breast cancer: effect of body size and weight change, *Cancer Epidemiol Biomarkers Prev* 2000; 9:591-595.
- 1183- **Shank B** : Breast irradiation for recurrence in a patient with Silicone implant, *Oncol* 1988; 2:58.
- 1184- **Shao ZM., Nguyen M.,** : Nipple Aspiration in Diagnosis of Breast Cancer, *Semin Surg oncol*, 2001; 20:175-180.
- 1185- **Shapiro S., and others** : Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen progestogen contraceptives, *Am J Epidemiol* 2000; 151:396-403.
- 1186- **Sharan SK, Morimatsu M, Albrecht U, et al.** : Embryonic lethality and radiation hypersensitivity mediated by Rad 51 in mice lacking BRCA, *Nature* 1997;386:804
- 1187- **Sharkey, F.E., Allred, D.C., and Valente, P.T.** : Breast In: Anderson's pathology, 10<sup>th</sup> ed. Edited by Damjanoy. I. And Linder, J., Mosby. 1996;70:2354-2385.
- 1188- **Shen KW., Wu J., Lu Js., et al.** : Fiberoptic ductoscopy in breast cancer patients with nipple discharge, *Surg Endosc*, 2000; 89: 1512-1519.
- 1189- **Sherman B.M., Korenman S.G.,:** Inadequate corpus luteum: A patho-physiological interpretation of human breast cancer epidemiology. *Cancer.* 1974;33: 1306.
- 1190- **Shibata A., Minn Ay.,** : Perinatal sex hormones and risk of breast and prostate cancers in adulthood, *Epidemiol Rev.* 2000; 22(2): 239-248.

- 1191- **Shin, S.J., and other** : Small carcinoma of the breast. A clinico-pathologic and immunohistochemical study of nine patients. *Am J Surg Pathol* 2000; 24:1231.
- 1192- **Shons A, Joseph E, Cox CE, et al.** : Predictors of sentinel lymph node metastases in the lymphatic mapping of breast cancer patients, *Breast Cancer Res Treat* 1997;46:24(abst).
- 1193- **Sickles EA.,** : Non palpable circumscribed, noncalcified solid breast masses : likelihood of malignancy based on lesion size and age of patient, *Radiology* 1994; 192:439-442.
- 1194- **Sickles EA.,** : Breast masses : mammographic evaluation, *Radiology* 1989; 173:297-303.
- 1195-**Siiteri P.K., Williams J.E., Takaki N.K.,:** Steroid abnormalities in endometrial and breast carcinoma. A Unifying Hypothesis. *J. Steroid Biochem.,* 1976;4: 897
- 1196- **Siiteri PK** : Review on studies of estrogen biosynthesis in the human, *Cancer Res* 1982;12(suppl): 32695.
- 1197- **Silvennoinen O, Schindler C, Schlessinger J, Levy DE** : Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. *Science* 1995 ;26 1:1736.
- 1198- **Silver SA, Tavassoli FA** : Mammary ductal carcinoma in situ with microinvasion, *Cancer* 1998; 82:2382.
- 1199- **Silverberg, S.G., and Masood, S.,** : The breast. In: Principles and practice of surgical pathology and cytopatology. 3<sup>rd</sup> ed., edited by Silverberg S.G, Delellis, R.A., and Froble, W.J., Churchill Livingstone. 1997;19:575-673.
- 1200- **Silverstein M and others** : The influence of margin width on local control in patients with ductal carcinoma in situ (DCIS) of the breast, *N Engl J Med* 1999; 340:1455-1461.
- 1201- **Silverstein M. and others** : Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast, *Eur J cancer* 1995; 31 A : 1425-1427.
- 1202- **Silverstein M., and others** : Outcome after local recurrence in patients with ductal carcinoma in situ of the breast, *J clin Oncol* 1998; 16:1367-1373.
- 1203- **Silverstein M., Lagios MD., Groshen S., et al.** : The influence of margin width on local control of ductal carcinoma in situ of the breast. *N Engl J Med* 1999; 340:1455-1461.
- 1204- **Silverstein M.,and others** : Can intraductal breast carcinoma be excised completely by local excision? Clinical and pathologic predictors, *Cancer* 1994; 73:2985-2989.
- 1205- **Silverstein M.,and others** : Duct carcinoma in situ : 227cases without microinvasion, *Eur J Cancer* 1992; 28:630-634.
- 1206- **Silverstein M.,and others** : Radiation therapy for intraductal carcinoma : is it an equal alternative? *Arch Surg* 1991;126:424-428.
- 1207- **Silverstein MJ,** : Not everyone with ductal carcinoma in situ of the breast treated with breast preservation needs post-excisional radiation therapy. *Breast* 2000; 9: 189-193.
- 1208- **Silverstein MJ, Lagios MD, Groshen S et al.** : The influence of margin width on local control of ductal carcinoma in situ of the breast. *N Engl J Med* 1999; 340:1455-1461.
- 1209- **Silverstein MJ. Ed.** : Ductal carcinoma in situ of the breast. Baltimore: Williams & Wilkins, 1997:580.

- 1210- **Silverstein MJ.**, : Not every one with ductal carcinoma in situ of the breast treated with breast preservation needs post-excision radiation therapy. *The Breast* 2000; 9:189-193.
- 1211- **Silverstein MJ.**, : Prognostic factors and local recurrence in patients with ductal carcinoma in situ of the breast, *Breast J* 1998; 4:344-362.
- 1212- **Silverstein MJ.**, : Van Nuys experience by treatment. In: Silverstein MJ., ed. Ductal carcinoma in situ of the breast. Baltimor: Williams & Wilkins, 1997 :443
- 1213- **Silverstein MJ., and Baril NB.**, : In situ carcinoma of the Breast. In: Cancer of the Breast, 5<sup>th</sup> ed. Ed. By Donegan W., Spratt JS., Saunders 2002; 23 : 507 – 534.
- 1214- **Silverstein MJ., and others** : A prognostic index for ductal carcinoma in situ of the breast, *cancer* 1996; 77:2267-2274.
- 1215- **Silverstein MJ., Poller DN., Waisman JR., et al.** : Prognostic classification of breast ductal carcinoma in situ. *Lancet* 1995 ; 345:1154 -1157.
- 1216- **Silverstein, M.J., and others** : Prognostic classification of breast ductal carcinoma in-situ, *Lancet* 1995;345:1154.
- 1217- **Silvestrini R and others** : p53 as an independent prognostic marker in lymph node-negative breast cancer patients, *J Natl Cancer Inst* 1993; 85:965-970.
- 1218- **Simard J., Labrie C., Belanger A., et al.** : Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen- induced proliferation of T-47D, ZR-75-1 and McF-7 human breast cancer cells in uitro, *Int J Cancer* 1997; 73:104-112.
- 1219- **Simmons RM** : Review of sentinel lymph node credentialing: how many cases are enough? *Am coll Surg* 2001; 193(2): 206-209.
- 1220- **Simmons RM and others** : Local and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies, *Ann Surg oncol* 1999; 6(7): 676-681.
- 1221- **Simpson J. F, and Page dl.** : Prognostic value of histopathology in the cancer breast. *Semin oncol.* 1992; 19: 245.
- 1222- **Singletary SE, Taylor SH, Guinee VF, et al.** : Occurrence and prognosis of contralateral breast cancer. *J Am Coll Surg* 1994; 178:390-396.
- 1223- **Skelley A., Besch M.,:** Steroid activity of normal and neoplastic breast tissue. *Clin. Obst. Gyne.* 1975;18(2).
- 1224- **Sklar MD, prochnick EV:** Modulation of cis-platinum resistance in friend erythroleukemia cells by C-myc. *Cancer Res* 1991;51:2118.
- 1225- **Skolnick MH.,Cannon-Albright, LA., Goldgar D., et al.** : In heritage of proliferative breast disease in breast cancer Kindreds, *Science* 1990; 250:1715.
- 1226- **Slanetz PJ and others:** Occult contralateral breast cancer detected by breast MR [abstract], *Radiology* 1998;209:467.
- 1227- **Sloan B** : Cathepsin B and cyctatines: evidence for a role in cancer progression. *Semin Cancer Biol* 1990; 1:37.
- 1228- **Smart CR, Hendrick RE, Rutledge JH III, et al.** : Benefit of mammography screening in women

- ages 40 to 49 years. Current evidence from randomized controlled trials. *Cancer* 1995; 75:1619-1626.
- 1229- **Smathers RL,** : Advanced breast biopsy instrumentation device: Percentage of lesion and surrounding tissue removed, *AJR Am J Roentgenol* 2000; 175(3): 801-803.
- 1230- **Smith IE, de Boer RH** : Role of systemic treatment for primary operable breast cancer. In: Dixon JM (ed) *ABC of Breast diseases*, 2<sup>nd</sup> ed London: BMJ Books, 2000;55-60
- 1231- **Smith IE, Gregory K**: The sequencing of systemic and local therapies in primary breast cancer. *Semin Breast Dis* 1999; 2:110.
- 1232- **Smith LF, Cross MJ, Klimberg vs** : subareolar injection is a better technique for sentinel lymph node biopsy. *Am J Surg* 2000;180:434-437.
- 1233- **Smith RA**: Principles of successful cancer screening, *Surg Oncol Clin North Am* 1999; 8:587-609.
- 1234- **Smith TE, Harrold EV, Matloff BC, et al.** : BRCA 1,2 status, family history and ipsilateral breast tumor relapse following conservative surgery and radiation therapy. *Proc Am Soc Clin Oncol* 1999; 18:62-1a (abst)
- 1235- **Smith-Warner SA., and others** : Alcohol and breast cancer in women: a pooled analysis of cohort studies, *JAMA* 1998; 279(7): 535-540.
- 1236- Smitt MC, Nowels KW, Zdeblick MJ, Jeffrey S, Carlson RW, Stockdale FE and Goffinet DR** : The importance of the lumpectomy surgical margin status in long term results of breast conservation. *Cancer* 1995;76:254-267.
- 1237- **Solin L, Fourquent A, Mc Cormack B, et al.** : Salvage Treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast. *In Radiat oncol Biol phys* 1994; 30:3-9.
- 1238- Solin L., and others** : Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma of the breast, *Cancer* 1991; 68:2337-2344.
- 1239- **Solin L., and others**: Fifteen-year results of breast-conserving surgery and definitive breast irradiation for treatment of ductal carcinoma in situ of the breast, *J Clin Oncol* 1996; 14:754-763.
- 1240- **Solin LJ and others** : The detection of local recurrence after definitive irradiation for early stage carcinoma of the breast, *Cancer* 1990; 65:2497-2502.
- 1241- **Soline L and other** : Mammographically detected, clinically occult ductal carcinoma in situ (intraductal carcinoma) Treated with breast conserving surgery and definitive breast irradiation, *Cancer J Sci Am* 1996; 2:158-165.
- 1242- **Sondik EJ,** : Breast cancer trends. Incidence, mortality, and survival, *Cancer* 1994; 74:995-999.
- 1243- **Soo Ms.,** : Imaging-guided core biopsies in the breast, *South Med J* 1998; 91:994-1000.
- 1244- **Sosa IA and others** : Association between extended of axillary lymph node dissection and survival in patients with stage I breast cancer, *Ann Surg Oncol* 1998; 5:140-149.
- 1245- **Spandidos DA and others** : Eexpression of ras, Rb1, and p53 proteins in human breast cancer, *Anticancer Res* 1992; 12:81-89.
- 1246- **Speroff L., Glass, R.H., Kase N.G.,**: Clinical gynaecologic endocrinology and infertility. The Williams and Wilkins Co. Baltimore. 1973

- 1247- **Spillane, AJ; Sacks, NP:** Role of axillary surgery in early breast cancer: review of the current evidence. *Aust-N-Z-J-Surg.* 2000 Jul; 70(7): 515-24.
- 1248- **Spratt JS and Donegan WL:** Surgical techniques. In: *Donegan WL. Spratt JS. Cancer of the Breast. 5<sup>th</sup> ed. Saunders. Philadelphia, London. New York. ST Louis. Sydney. Toronto 2002,28:601-637.*
- 1249- **Spratt Js:** Epidemiology of screening for cancer. In Hickey RC, editor: *Current problems in cancer,* Chicago, 1982, Year Book Medical.
- 1250- **Spyratos F., Maudelonde T., and Rochefort H., :** Cathepsin D: an independent prognostic factory for breast cancer, *Lancet* 1989; 8672:1115.
- 1251- **Stacker SA., Sacks NP., and Thompson CH., :** A serum test for the diagnosis and monitoring of the progress of breast cancer. In: *immunological approaches to the diagnosis and therapy of breast cancer* Cariani R.L. (ed.) Plenum press, New York 1987; P. 217.
- 1252- **Stadtmauer E,O'Neill A, Goldstein L, et al. :** phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5- fluorouracil for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the Philadelphia Inter-group Study (PBT-1). *Proc Am Soc Clin Oncol* 1999;18:1A
- 1253- **Staren ED., :** Ultrasound-guided biopsy of nonpalpable breast masses by surgeons, *Ann Surg Oncol* 1996; 3(5): 476-482.
- 1254- **Staren Ed., Fine RE., :** Breast ultrasound for surgeons. *Am Surg* 1996; 62:108-112.
- 1255- **Starbite:** Change in breast cancer incidence by stage, *J Natl Cancer Inst* 1998; 90:1429.
- 1256- **Stearns V, Yamauchi H, Hayes OF :** Circulating tumor markers in breast cancer:accepted utilities and novel prospects, *Br Cancer Res Treat* 1998;52:239-259.
- 1257- **Steeg PS, Cohn Kh, Leone A. :** Tumor metastasis and nm23: current concepts. *Cancer Cells* 1991 ;3 :257.
- 1258- **Steeg PS, De Ia Rosa A, Flatow U, MacDonald NJ, Benedict M and Leone A :** Nm23 and breast cancer metastasis. *Breast Cancer Res Treat* 1993;25:175.
- 1259- **Steeg Ps., :** Pathology of malignant diseases of the breast, In: *Strom-beck JO., and Rosato FE., (eds), Surgery of the breast,* 1993; P:66-92.
- 1260- **Stefanek M, Hartman L, Nelson W.,:**Risk reduction mastectomy: clinical issues and research needs, *J Natl Cancer Inst* 2001;93:1297-1306.
- 1261- **Stevens RG., :** Electric power use and breast cancer: a hypothesis, *Am J Epidemiol* 1987; 125:556-561.
- 1262- **Stewart HJ, Forrest AP, Everington D, et al. :** Randomized comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. *Br J Cancer* 1996;74:297-244
- 1263- **Stewart JF and others :** Steroid receptors and prognosis in operable (stage I and II) breast cancer, *Eur J Cancer Clin Oncol* 1983; 19:1381-1387.
- 1264- **Stockdale A and others :** Radiotherapy for Paget's disease of the nipple : a conservative alternative, *Lancet* 1989; II (8664): 3:25-42.

- 1265- **Storm HH, Andersson M, Boice JD** : Adjuvant radiotherapy and risk of contralateral breast cancer, *J Natl Cancer Inst* 1992; 84:1245-1250.
- 1266- **Stotter AT and others** : Predicting the rate and extent of loco-regional failure after breast conservation therapy for early breast cancer, *Cancer* 1989; 64:2217-2225.
- 1267- **Stotter AT and others** : Survival following locoregional recurrence after breast conservation therapy for cancer, *Ann Surg* 1990;212:166-172
- 1268- **Stratton MR,** : Recent advances in understanding of genetic susceptibility to breast cancer. *Hum Mol Genet* 1996; 5: 1515-19.
- 1269- **Streckfus C and others** : The presence of soluble c-erbB-2 in saliva and serum of women with breast carcinoma: a preliminary study, *Clin Cancer Res* 2000; 6(6):2363-2370.
- 1270- **Studzinski G, Harrison L,** : Genetic Basis for the Emergence and Progression of Breast Cancer, In: *Cancer of the breast*, 5<sup>th</sup> ed. Ed. By Donegan W., Spratt JS, Saunders 2002;10:169-180.
- 1271- **Su Y., Swift M.,** : Mortality rates among carriers of ataxia-telangiectasia mutant alleles, *Ann Intern Med* 2000; 133(10): 770-778.
- 1272- **Sugg SL, Ferguson DJ, Posner MC, Heimann R** : Should internal mammary nodes be sampled in the sentinel lymph node era? *Ann Surg Oncol* 2000; 7:188-192.
- 1273- **Sugg, S.L., Donegan, W.L** : Staging and prognosis. In: *Cancer of the Breast* 6<sup>th</sup> edn. Ed. By Donegan, W.L and Spratt, J.S. Saunders, Philadelphia, London, New York, ST. Louis, Sydney, Toronto, 2002;22:477-506.
- 1274- Suteri P.K., MacDonald P.C.:** Role of extraglandular estrogen in human endocrinology. *Handbook of physiology*. 1973; 2 (7):612. Washington D.C., American Physiological Society.
- 1275- **Swanson CA., and others** : Alcohol consumption and breast cancer risk among women under 45 years, *Epidemiology* 1997; 8:231-237.
- 1276- **Swanson CA., and others** : Body size and breast cancer risk among women under 45 years, *Am J Epidemiol* 1996; 143:698-706.
- 1277- **Swanson CA., and others** : Breast cancer risk assessed by anthropometry in the NHA NESI epidemiological follow-up study, *Cancer Res* 1988; 48:5363-5367.
- 1278- **Swanson GM:** May we agree to disagree, or how do we develop guidelines for breast cancer screening in women. *J Nat Cancer Inst* 1994; 86:903-905.
- 1279- **Sweeney K JE, Musgove EA, Watts Ckul et al.** : Cyclins and breast cancer. In Dickson RB, Lippman ME (eds): *Mammary tumour cell cycle , differentiation and metastasis* - Boston Kluwer academic publishers, 1996, p 141
- 1280- **Swift M, Morell D, Massey RB, et al.:** Incidence of cancer in 161 families affected by ataxia-telangiectasia. *N Engl J Med* 1991;325:1831-1836.
- 1281- **Tabar L and others: Beyond randomized controlled trials:** Organized mammographic screening substantially reduces breast carcinoma mortality, *Cancer* 2001; 91:1724-1731.
- 1282- **Tabar L and others:** Efficacy of breast screening by age, *Cancer* 1995; 75:2507-2517.

- 1283- **Tabar L, Chen HH, Duffy SW, et al.** : A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14mm invasive breast cancers: a prospective study. *Lancet* 2000; 355:429-433.
- 1284- **Tabar L, Fagerbeg CJ, Gad A, et al.** : Reduction in mortality from breast cancer after mass screening with mammography: randomized trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. *Lancet* 1985; 1:829-832.
- 1285- **Tafra L and others** : Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye, *Ann Surg* 2001; 233:51-59
- 1286- **Tafra L, Guenther M, Giuliano AF:** Planned segmentectomy: a necessity for breast carcinoma, *Arch Surg* 1993; 128:1014-1020.
- 1287- **Taghian AG, Assad S, Kuter I et al.** : Increased risk of radiation pneumonitis in breast cancer patients treated by concomitant taxol and radiation therapy. *In Radiat Oncol Biol Phys* 1999; 45:316(abst).
- 1288- **Takeuchi, T., Komatsuzaki, M., Minesaki, Y.,** : Paget's disease arising near a male areola without an underlying carcinoma. *J Dermatol* 1999;26:248.
- 1289- **Tardivan A., Masselat J., and Vanel D.,** : Breast imaging In: breast cancer, 3<sup>rd</sup> edition. Ed. by Omar, S., and Contesso G., Association medicale France-Egyptienne, 1997; 5:45-61.
- 1290- **Tari A., King MD., George M., Fuhrman MD.,** : Image-Guided Breast Biopsy, *Semin Surg oncol* 2001; 20:197-205.
- 1291- **Tavassoli F.,** : Intraductal Carcinoma. In Tavassoli FA, editor: Pathology of the breast, Norwalk, conn, 1992, Appleton & Lange, PP 229-261.
- 1292- **Tavassoli FA:** Pathology of the breast, ed2, Stanford, CT, 1999, Appleton & Lange, P 440.
- 1293- **Tavassoli, F.A.,** : Ductal carcinoma in-situ: introduction of the concept of ductal intraepithelial neoplasia. *Mod Pathol* 1998;11:140.
- 1294- **Tavassoli, F.A., Pestaner, J.P.,** : Pseudoinvasion in intraductal carcinoma, *Mod Pathol* 1995;8:380.
- 1295- **Tavassoli, F.A., Purcell, C.A., Man, Y.G.,** : Down regulation of bcl2, ER, PR associated AR expression is triggered by apocrine differentiation in mammary epithelium, *Mod Pathol* 1996; 9:25.
- 1296- **Taylor H, Baker R, Fortt RW, Taylor JH:** Sector mastectomy in selected cases of breast cancer, *Br J Surg* 1971; 58(3): 161-163.
- 1297- **Taylor I, Renaut AJ.,** : What's new in general surgery-a review of the Journals (Breast). In, Taylor I, Johnson CD. Recent Advances in Surgery. Churchill Livingstone, Edinburgh, London, New York, Philadelphia, Sydney, Toronto, 1999; 15:187-217.
- 1298- **Taylor ME and others** : Factors influencing cosmetic results after conservation therapy for breast cancer, *Int Radiat Oncol Biol Phys* 1995; 31:753-764.
- 1299- **The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialist Group** : Anastrozole alone or in combination for adjuvant treatment of postmenopausal women with early breast cancer: the first results of the ATAC randomized trial. *Lancet* 2002;354:2131-2134.
- 1300- **The W, Wilson ARM:** The role of ultrasound in breast cancer screening: a consensus statement by the

European Group for Breast Cancer Screening, *Eur J Cancer* 1998;34:449-450.

- 1301- **Thijssen JJ.H., Blankenstein M.A.,:** Endogenous estrogens in normal and malignant endometrial and mammary tissues. *Eur. J. Cancer. Clin. Oncol.* 1989;125: 1953-1959.
- 1302- **Thomas DB, Gao DL, Self SG, et al.:** Randomized trial of breast-self examination in Shanghai: methodology and preliminary results. *J Natl cancer Inst* 1997; 89:355-365.
- 1303- **Thomas HV., and others :** A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women the island of Guernsey, *Br J cancer* 1997; 76: 401-405.
- 1304- **Thompson AM, and Dewar JA:** Disorders of the breast, In: *Essential Surgical Practice, Higher Surgical Training in General Surgery.* Edt. By Sir Cuschieri A, Steele RJ. C and Mossa AR, 2002;3:61-94.
- 1305- **Thompson HJ., and others :** Effects of D, L- $\alpha$  difluoromethylornithine on murine mammary carcinogenesis, *Carcinogenesis* 1984; 5:1649-1651.
- 1306- **Thompson PA., Ambrosone C., :** Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer, *J Natl Cancer Inst Monogr* 2000; 27:125-134.
- 1307- **Thomson E.B., Lippman M.E., eds.:** Steroid receptors and the management of cancer. Florida: *CRC Press.* 1979
- 1308- **Thor AD and others :** Accumulation of p53 tumor suppressor gene protein : an independent marker of prognosis in breast cancer, *J Natl Cancer Inst* 1992;84:845-855.
- 1309- **Thor AD, Berry DA, Budman DR, et al. :** C-erbB-2, p53, and efficacy of adjuvant therapy in lymph node positive breast cancer. *J Natel Cancer Inst* 1998;90:1346-1360
- 1310- **Thorlacius sand others:** Population- based study of risk of breast cancer in carriers of BRCA2 mutation, *Lancet*; 1998;352:1337-1339.
- 1311- **Tilson-Mallett N., Santner S.J., Fell P.D, Santen R.J.,:** Biological significance of aromatase activity in human breast tumors. *J. Clin. Endocrinal Metab.* 1983;57: 1125-8.
- 1312- **Titus- Ernstoff L., and others :** Exposure to breast milk in infancy and adult breast cancer risk, *J Natl cancer Inst* 1998; 90:921-924.
- 1313- **Titus-Ernstoff L., and others :** Menstrual factors in relation to breast cancer risk, *Cancer Epidemiol Biomarkers Prev* 1998; 7:783-789.
- 1314- **Todd J. H., Dowle C. and Williams M., :** Confirmation of prognostic index in primary breast cancer, *Br. J Cancer*,1987; 56:489.
- 1315- **Tokunage M and others:** Incidence of femal breast cancer among atomic bomb survivors, 1950-1985, *Radiat Res* 1994; 138:209-223.
- 1316- **ToT, T. :** The cytokeratin profile of medullary carcinoma of the breast, *Histopathology* 2000;37:175.
- 1317- **ToT, T., :** Patterns of distribution of cytokeratins 20 and 7 in special types of invasive breast carcinoma: a study of 123 cases, *Ann Diagn Pathol* 1999; 3: 350.
- 1318- **Tran NV and others :** Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy; *Plast Reconstr Surg* 2001; 108:78-82.

- 1319- **Tran NV and others** : Post-operative adjuvant irradiation: effects on transverse rectus abdominis muscle flap breast reconstruction, *Plast Reconstr, Surg* 2000; 106 (2): 313-317.
- 1320- **Tremblay A., Tremblay GB., Labrie C., et al.** : EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors A and B. *Endocrinology* 1998 ; 139:111-118.
- 1321- **Trentham-Dietz A., and others** : Body size and risk of breast cancer, *Am J Epidemiol* 1997; 145:1011-1019.
- 1322- **Trentham-Dietz A., and others** : Weight change and risk of postmenopausal breast cancer (United States), *Cancer Causes Control* 2000; 11:533-542.
- 1323- **Trentham-Dietz A., Love RR., Newcomb PA.,** : Population-based prevention strategies. In Vogel VG., editor: Management of patients at high risk for breast cancer, Oxford, UK, 2001, Blackwell Science, PP 277-294.
- 1324- **Trichopoulos D., Lippman RD.,** : Mammary gland mass and breast cancer risk, *Epidemiolog* 1992; 3:523-526.
- 1325- **Trichopoulos D., Mac Mahon B., Cole P.,** : Menopause and breast Cancer risk, *J Natl Cancer Inst* 1972; 48(3): 605-613.
- 1326- **Tulinius H, sigvaldason H, Olafsdottir G.,** : Left and right sided breast cancer. *Pathol Res Pract*, 1990; 186:29-94.
- 1327- **Turner BC, Harrold E, Matloff E et al.** : BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations (See Comments). *J Clin oncol* 1999; 17:3017-3024.
- 1328- **Umekita Y, Ohi Y, Sagara Y, Yoshida H** : Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients, *Int J Cancer* 2000; 89:484-487.
- 1329- **Vaidya JS, Baum M, Tobias JS et al.** : Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. *Ann Oncol* 2001; 12:1075-1080.
- 1330- **Vaidya J, Vays J, & Thokur M.,** : Role of ultrasonography to detect axillary node involvement in operable breast cancer. *Eur. J. Surg. Oncol* 1999; Vol. 22 P:140-143.
- 1331- **Vaidya JS** : Intra-operative radiotherapy for breast cancer. In : Recent Advances in Surgery 26. Ed. By Taylor I, Johnson C. The Royal Society of Medicine Press Limited 2003; 13:165-181.
- 1332- **Vaidya JS,** : A Novel Approach for Local Treatment of Early Breast Cancer. *PhD Thesis, University of London* 2002; 1-242.
- 1333- **Vaidya JS, Baum M, Tobias JS, Morgans, DSouza D.,** : The novel technique of delivering targeted intranoperative radiotherapy (Targit) for early breast cancer. *Eur J Surg Oncol* 2002; 28: 447-454.
- 1334- **Vaidya JS, Baum M:** Benefits and risks of screening mammography in women with BRCA1 and BRCA2 mutations. *JAMA* 1997; 278:290.
- 1335- **Vaidya JS, Baum NI** : Paradoxes and provocations in breast cancer. In Recent Advances in Surgery.

Churchill Livingstone, 21 Ed, 1998.

- 1336- **Vaidya JS, Joseph D, Hilaris BS et al.** : Targeted intraoperative radiotherapy for breast cancer an international trial. *Abstract Book of ESTRO. 21, Prague 2003; 21:135.*
- 1337- **Vaidya JS, Vyas JJ, Chinoy RF, Merchant N, Sharma op, Mitra I** : Multicentricity of breast cancer: Whole organ analysis and clinical implications. *Br J Cancer 1996; 74: 820-824.*
- 1338- **Valastos G and others** : Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases, *Ann Surg Oncol 2001; 8(5): 425-431.*
- 1339- **Valstos G and others** : The feasibility of minimally invasive surgery for stage II A, II B and III A carcinoma patients after tumor down-staging with induction chemotherapy, *Cancer 2000; 88:1417-1424.*
- 1340- **Van Agthoven T. Timmermans M. Foekens JA. Dorssers CJ. Henzen-Logmans SC.** : Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. *Am J Pathol 1994;144:1238-1246.*
- 1341- **Van der Ent FWC and others** : Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer, *Ann Surg 2001; 234(1): 79-84.*
- 1342- **Van Tienhoven G, Voogd AC, Peterse JL, et al.** : Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomized trials (EORTC 10801 and DBCG-82 TM). *Eur J Cancer 1999; 35:32.*
- 1343- **Van Wauwe J., Coene MC., Cools W., et al.** : Liarazole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid. *Biochem Pharmacol 1994;47:737-741.*
- 1344- **Van Wauwe J., Van Nyen G., Coene Mc., et al.** : Liarazole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. *J Pharmacol ther 1992;261:773-779.*
- 1345- **Van Zee KJ, Liberman L, Samli B, et al.** : Long-term follow-up of women with ductal carcinoma in situ treated with breast conserving surgery: The effect of age. *Cancer 1999; 86:1757-1767.*
- 1346- **Van-der-Hage,-J-A;Van-der-Velde,-C-J;Julien,-J-P;Floiras,J-L; Delozi-er,-T; Van-der-velden,-C;Duchatacau,-L.**: Improved survival after one course of perioperative chemotherapy in early breast cancer Patients. Long-term results from the European Organization for Research and Treatment of Cancer (EORTC) trial 10854. *Eur.J-Cancer; 2001 Nov; 37 (17):2184-93*
- 1347- **Vanderweyer E, Deraemaeker R.,** : Radiation therapy after immediate breast reconstruction with implants, *Plast Reconstr Surg 2000; 106:56-60.*
- 1348- **Vasen HF., Haites NE., Evans DG., et al.** : Current policies for surveillance and management in women at risk of breast and ovarian cancer : a survey among 16 European family cancer clinics. *Eur J Cancer 1998; 34:1922-1926.*
- 1349- **Vatten LJ., Kvinnsland S.,** : Body height and risk of breast cancer: a prospective study of 23,831 Norwegian women, *Br J Cancer 1990; 61:881-885.*
- 1350- **Vecchione A** : New and old in prognosis determination, *In Vivo 1993;7:623-626.*
- 1351- **Velanovich V, Szymanski W** : Quality of life of breast cancer patients with lymphedema, *Am J Surg 1999; 177: 187-188.*

- 1352- **Venable, J.G., Schwartz, A.M., Silverberg, S.G.** : Infiltrating cribriform carcinoma of the breast: a distinctive clinicopathologic entity, *Hum Pathol* 1990; 21:333-338.
- 1353- **Venne VL., Buys SS.,** : Genetic Testing for breast cancer predisposition. In: *Manual of Breast Diseases*. Ed. by Ismail Jatoi. Lippincott Williams & Wilkins. Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo, 2002 ; 21:459-480.
- 1354- **Venta LH.,** : Image-guided biopsy of non-palpable breast lesions. In: Harris JR., Lippman MF., Morrow M., Osborne CK,eds. *Diseases of the breast*. Philadelphia; Lippincott Williams & Wilkins. 2000.
- 1355- **Verhoeven DT., and others** : Vitamins C and E, retinol, beta-carotene and dietary fiber in relation to breast cancer risk : a prospective cohort study, *Br J cancer* 1997; 75:149-155.
- 1356- **Verkooijen HM., Peeters PHM., Pijnappel RM., Koot VCM., Schipper MEI., and Borel Rinkes IHM.,** : Diagnostic accuracy of needle-localized open breast biopsy for impalpable breast disease, *Br J Surg* 2000; 87:344-347.
- 1357- **Verloop J., and others** : Physical activity and breast cancer risk in women aged 20-54 years, *J Natl cancer Inst* 2000; 92:128-135.
- 1358- **Verma AK.,** : Ornithine decarboxylase: a possible target for human cancer prevention, In Steele VE., and others, editors: *Cellular and molecular targets for chemoprevention*, Boca Raton, Fla 1992, *CRC Press*, PP 207-224.
- 1359- **Vermuelen A., Destypre J.P., Paridaens R., et al.:** Aromatase, 17-B-hydroxysteroid hydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. *Eur. J. Cancer. Clin. Oncol.* 1986;22: 515-525.
- 1360- **Veronesi U and others** : Breast conservation is a safe method patients with small cancer of the breast: long-term results of three randomized trials on 1.973 patients, *Eur J Cancer* 1995; 31A (10): 1574-1579.
- 1361- **Veronesi U and others** : Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes, *Ann Surg* 1985; 202:702-707.
- 1362- **Veronesi U and others** : Quadrantectomy versus lumpectomy for small size breast cancer, *Eur J Cancer* 1990; 26:671-673.
- 1363- **Veronesi U and others** : Radiotherapy after breast preserving surgery in women with localized cancer of the breast, *N Engl J Med* 1993; 328:1587-1591.
- 1364- **Veronesi U and others** : Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer, *J Natl Cancer Inst* 1999; 91: 1847.
- 1365- **Veronesi U and others** : Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series, *J Natl cancer Inst* 1999; 91:368-373.
- 1366- **Veronesi U and others** : The dissection of internal mammary nodes does not improve the survival of breast cancer patients: 30-year results of a randomized trial, *Eur J Cancer* 1999; 35:1320-1325.
- 1367- **Veronesi U, and others** : Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients, *Ann Surg* 1984; 198 :681.

- 1368- **Veronesi U, Bonadona G, Zurrada S, et al.** : Conservation Surgery after primary chemotherapy in large carcinomas of the breast, *Ann Surg* 1995; 222(5): 612-618.
- 1369- **Veronesi U, Luini A, Del Vecchio M et al.** : Radiotherapy after breast-preserving surgery in women with localized cancer of the breast (See comments). *N Engl J Med* 1993; 328:1587-1591.
- 1370- **Veronesi U, Orecchia R, Luini A et al.** : A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancer that are conservatively treated. *Eur J Cancer* 2001; 37:2178-2183.
- 1371- **Veronesi U, Paganelli G, Galimberti V:** sentinel node biopsy to avoid dissection in breast cancer with clinically negative lymph nodes. *Lancet* 1997;344:1864-1867.
- 1372- **Veronesi U, Valagussa P** : Inefficacy of internal mammary node dissection in breast cancer surgery, *Cancer* 1981, 47:170.
- 1373- **Veronesi U., and others** : Prevention of breast cancer with tamoxifen : Preliminary findings from the Italian randomized trial among hystrectomised women, *Lancet* 1998;352:93-97.
- 1374- **Veronesi U., Palo G., Marubini E., et al.** : Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. *J Natl Cancer Inst* 1999; 91:1847-1856.
- 1375- **Veronesi U., Rilke F., and Luini R.** : Distribution of axillary node metastasis by level of invasion. An analysis of 539 cases. *Cancer* 1987;59:682-687.
- 1376- **Veronesi,-U; Cascinelli,-N; Mariani,-L; Gerco,-M; Saccozzi,- R; Luini,-A; Aguilar,-M; Marubini,- E:** Twenty-years follow up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. *N-Eng-J-Med.* 2002 Oct. 17; 347 (16): 1227-32
- 1377- Veronesi-U, De Palo- G, Marubini-E, et al.:** Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. *J Natl Cancer Inst.* 1999;91:1847-1856.
- 1378- **Vicini FA and others** : Recurrence in the breast following conservative surgery and radiation therapy for early stage breast cancer, *Monogr Natl Cancer Inst* 1992; 11:33-39.
- 1379- **Victor, S.J, Howitz, E.M., Kini, V.R.** : Impact of clinical, pathologic and treatment-related factors on outcome of patients with locally advanced breast cancer treated with multimodality therapy, *Am J clin oncol* 1999; 22:199.
- 1380- **Vilcog JR, Calle R, Stacey P, Ghossein NA** : The outcome of treatment by tumorectomy and radiotherapy of patients with operable breast cancer, *Radiat Oncol Biol Phys* 1981; 7:1327-1332.
- 1381- **Villanueva- Meyer J., and others** : Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer, *J Nucl Med* 1996; 37:926.
- 1382- **Vincini FA, Kestin LL, Goldstein NS, et al.** : Impact of young age on outcome in patients with ductal carcinoma in-situ treated with breast conserving therapy. *J Clin Oncol* 2000;18:296-306.
- 1383- **Vinod SK, Pendlebury SC** : Review of internal mammary chain irradiation in breast cancer, *Breast* 1999; 8:245-250.
- 1384- **Von smitten K** : Surgical management of breast cancer in the future. *ACTa Oncol* 2000; 34(3):437-439.
- 1385- **Voogd AC** : Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients, *Cancer* 1999; 85:437-446.

- 1386- **Vorherr, H.:** The breast morphology, physiology and lactation. New York, Academic Press. 1974
- 1387- **Vorherr, H.:** The breast morphology, physiology and lactation. New York, Academic Press.1974.
- 1388- **Vos CB, Cleton-Jansen, AM, Berx G, et al. :** E-cadherin inactivation in lobular carcinoma in-situ of the breast; an early event in tumorigenesis. *Br. J Cancer* 1997;76:1131.
- 1389- **Vrieling C, Collette L, Fourquet A, et al. :** the higher local recurrence rate after breast conserving therapy in young patients explained by larger tumor size and incomplete excision at first attempt? *Int J Radiat Oncol Boil Phys* 1998, 42:125(abst).
- 1390- **Wagner TM., Moslinge R., Langbauer G., et al. :** Attitude towards prophylactic surgery and effects of genetic counseling in familiar with BRCA mutation S. *Br. J Cancer* 2000; 82 :1244-1253.
- 1391- **Wahl RL., :** Nuclear medicine techniques in breast imaging, *Semin Ultrasound CTMR* 1996; 17:494-505.
- 1392- **Walker AP., :** Diagnosis and Management of occult primary breast cancer. In: *Cancer of the Breast*, 5<sup>th</sup> ed. Ed. by: Donegan W., spratt JS., Saunders. Philadelphia, London, New York, St. Louis Sydney, Toronto, 2002; 45: 445-949.
- 1393- **Walker, R. :** The breast. In: *General and systemic pathology*, ed. By Underwood, J.C..E., Churchill Livingstone 1994; 16:457-484.
- 1394- **Walsh BW., Kuller LH., Wild RA., et al. :** Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. *JAMA* 1998; 279:1445-1485.
- 1395- **Wanebo H.J., Huves A.G. and Urban J.A., :** Treatment of minimal breast cancer, *Cancer*, 1985;33:349.
- 1396- **Wanebo Hj, and others:** Bilateral breast cancer: risk radution by contralateral biopsy , *Ann surg* 1986; 201(6):667-677.
- 1397- **Wang Dy., and others :** Relationship of blood prolactin levels and the risk of subsequent breast cancer, *Int J Epidemiol* 1992; 21:214-221.
- 1398- **Wang H, Rubin M, Fenig E et al. :** Basic Fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. *Cancer Res* 1997;57:1750.
- 1399- **Warnberg F., yen J. Holmberg L., :** Risk of subsequent invasive breast cancer after breast carcinoma in situ (letter), *Lancet* 2000; 355: 724-725.
- 1400- **Warner E. and others :** Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer, *J. Natl Cancer Inst* 1999; 91:1241-1247.
- 1401- **Warri AM and others :** Apoptosis in toremifene induced growth inhibition of human breast cancer cells in vivo and in vitro, *J Natl Cancer Inst* 1993; 85: 1412.
- 1402- **Watanabe J., and others :** Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer, *Pharmacogen-etics* 2000; 10:25-33.
- 1403- **Watson PH, pon RT, Shiu RP :** Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. *Cancer Res* 1991 ;5 1:3996.

- 1404- **Wazer DE and others** : Factors influencing cosmetic and radiotherapy for early-stage breast carcinoma, *J Clin Oncol* 1992; 10:356-363.
- 1405- **Wazer DE and others** : Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-Stage breast carcinoma, *J Clin Oncol* 1992; 10:356-363.
- 1406- **Weber S, Storm FK, Stitt J, Mahvi DM** : The role of frozen section analysis of margins during breast conservation surgery, *Cancer J Sci Am* 1997; 3:273-277.
- 1407- **Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S and Gasparini G** : Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. *J Natl Cancer Inst* 1992; 84:1875.
- 1408- **Weidner N, Semple JP, Wech WR, Folkman J** : Tumour angiogenesis and metastasis-correlation in invasive breast carcinoma. *New Engl J Med* 1991 ;324: 1.
- 1409- **Weidner, N., Semple, J.P.,** : Pelomorphic variant of invasive lobular carcinoma of the breast, *Hum Pathol* 1992; 23:1167.
- 1410- **Weinberg D.s.** : proliferation indices in solid tumors. *Adv. Pathol. Lab. Med* 1992; 5:163-6.
- 1411- **Weiss HA., and others** : Epidemiology of in situ and invasive breast cancer in women aged under 45, *Br J Cancer* 1996; 73:1298-1305.
- 1412- **Weiss RB, Rifkin RM, Stewart FM, et al.** : high dose chemotherapy for high - risk primary breast cancer : an on- site review of the Bezwoda study. *Lancet* 2000;355: 444-1003
- 1413- **Wellings, S.R., Jensen, H.M., Marcum, R.C.,** : An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. *J Natl Cancer Inst*, 1975,55:231-237
- 1414- **Werneke U:** Ataxiatelangiectasia and risks of breast cancer. *Lancet* 1997; 250:739-740.
- 1415- **Whelan TJ, Julian J, Wright J, et al.** : Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. *J Clin Oncol* 2000; 18:1220-1229.
- 1416- **White JR, Wilson JF.,** : Radiation therapy for breast cancer. In : Donegan WL. Spratt JS. *Cancer of the Breast*. 5<sup>th</sup> ed. Saunders. Philadelphia, London. New York. ST Louis. Sydney. Toronto 2002; 29:639-658.
- 1417- **Whitworth P and others** : State-of-the-art lymph node staging for breast cancer in the year 2000, *Am J Surg* 2000; 180: 262-267.
- 1418- **Wild CP., Pisan P.,** : Carcinogen-DNA and carcinogen protein adducts in molecular epidemiology. In Toniolo P and others, editors: *Application of biomarkers in cancer epidemiology*, Lyon 1997; International Agency for Research on cancer.
- 1419- **Willet WC.,** : Recent finding regarding life style risk factors in the epidemiology of breast and colon cancer. Accomplishment in cancer research. In Fortner JE., (eds.), Philadelphia, J.B LippincottCo.1993; P. 164-177.
- 1420- **Willet WC., and others** : Epidemiology and nongenetic causes of breast cancer. In Harris JR and others, editors: *Diseases of the breast*, ed2, Philadelphia, 2000, Lippincott Williams & Wilkins, PP 175-220.

- 1421- **Williams JK and others** : The effects of radiation Treatment after TRAM flap breast reconstruction, *Plast Reconstr Surg* 1997; 100:1153-1160.
- 1422- **Williams MB., and others** : Future directions in imaging of breast diseases, *Radiology* 1998; 206:297-300.
- 1423- **Williams MD, Murr OC** : Paget's disease of the breast: is breast conservation therapy appropriate? *Surg Rounds* 1993; July : 521-527.
- 1424- **Willner J, Kiricuta IC, Kolbl O** : Loco-regional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. *Int J Radiat Oncol Biol Phys* 1997; 37:853.
- 1425- **Willner J, Kiricuta IC, Kolbl O, Flentje M.,** : Long-term survival following post-mastectomy loco-regional recurrence of breast cancer, *Breast* 1999; 8:200-204.
- 1426- **Wilson AJ** : Response in breast cancer to a second hormonal therapy. *Rev Endocrine-Related Cancer* 1983; 14:5.
- 1427- **Wilson LD and others** : Conservative surgery and irradiation in the treatment of synchronous ipsilateral breast cancers, *Cancer* 1993; 72:137-142.
- 1428- **Wilson RE and others** : The 1982 National Survey of Carcinoma of the Breast in the United States by the American College of Surgeons, *Surg Gynecol Obstet* 1984, 159:309.
- 1429- **Winchester DJ and others** : Sentinel lymphadenectomy for breast cancer: experience with 180 consecutive patients: efficacy of filtered technetium 99m sulphur colloid with overnight migration time, *J Am Coll Surg* 1999; 188:597-603.
- 1430- **Winchester DJ, Menck HR** : National treatment trends ductal carcinoma in situ of the breast, *Arch Surg* 1997; 132:660-665.
- 1431- **Winchester DJ., Sener SF., Winchester DP., et al.** : Sentinel lymphadenctomy for breast cancer: experience with 180 consecutive patients: efficacy of filtered technetium 99m sulphur colloid with overnight migration time. *J Am Coll Surg* 1999; 188:597-603.
- 1432- **Winchester DP, Menck HR, Osteen RT, et al.:** Treatment trends for ductal carcinoma in situ of the breast. *Ann Surg Oncol* 1995; 2:207-213.
- 1433- **Winer EP, Morrow M, Osborne CK, Harris JR,** : Malignant tumors of the breast. In : Devita VT Jr, Hellman S, Rosenberg S, *Cancer principles & Practice of oncology*, 6<sup>th</sup>. Lippincott Williams & Wilkins, Philadelphia, Baltimore, New York London. Buenos Aires. Hong Kong. Sydney. Tokyo 2001 (vo14); 37(2): 1651-1717.
- 1434- **Witherspoon LE., and Burns RP.,** : Special Diagnostic Techniques for Breast Cancer, In : *MANUAL OF BREAST DISEASES*, ed. by Ismail Jatoi, Lippincott Williams Rwilkins. Pheladelphia, New York, London, Sedney, Tokyo, 2002;10:231-248.
- 1435- **Witzig TE, Ingle JN, Schaid DJ, Wold LE, Barlow JF, Gonchoroff NJ, Gerstner JB, Krook JE, Grant CS, and Katzrnann JA** : DNA ploidy and percent S Phase as prognostic factors in node-positive breast cancer results from patients enrolled in two prospective randomized trials. *J Clin Oncol* 1993;11, 351.

- 1436- **Wohlfahrt J., and others** : Reproductive risk factors for breast cancer by receptor status, histology, laterality and location, *Int J Cancer* 1999; 81:49-55.
- 1437- **Wolfe JN., Saftas AF., Salane M.,** : Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study, *Am J Roentgenol* 1987;148:1087-1092.
- 1438- **Wolff AC, Davidson NE,** : Primary systemic therapy in operable breast cancer. *J Clin Oncol* 2000;18:1558.
- 1439- **Wolff MS., and others** : Blood levels of organochlorine residues and risk of breast cancer, *J Natl Cancer Inst* 1993; 85:648-652.
- 1440- **Wolmark N and others** : The role of radiotherapy and tamoxifen in the management of node negative invasive breast cancer-1.0 cm treated with lumpectomy: preliminary results of NSABP protocol B-21, *J Clin Oncol* 2000; 19: 271.
- 1441- **Wolmark N, Dignam J, Margolese R, et al.** : The role of radiotherapy and tamoxifen in the management of node negative invasive breast cancer < 1 cm treated with lumpectomy: preliminary results of NSABP protocol B-21. *Proc Asco* 2000; 19: abst 271.
- 1442- **Wolmark N.,** : Tamoxifen after surgery/RT decreases local recurrence risk in DCIS patients, *Oncology News International*,1999; 12.
- 1443- **Wolmark N., Dignam J., Fisher B.,** : The addition of tamoxifen to lumpectomy and radiotherapy in the treatment of ductal carcinoma in situ (DCIS): preliminary results of NSABP protocol B-24. San Antonio Symposium proceedings. *Breast cancer Res* 1998; 21 :227 (abst)
- 1444- **Wong SL and others** : Predicting the status of non-sentinel axillary nodes: A multicenter study, *Arch Surg* 2001; 136:563-568.
- 1445- **Wong SL and others** : Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false negative rate. Presented at the American College of Surgeons Eighty-sixth Annual Clinical Congress Papers Session, Chicago, IL, October 2000.
- 1446- **Wong SL, Chao C, Edwards MJ, and Mc Masters KM** : Lymphatic Mapping and Sentinel Node Biopsy. In : Donegan WL. Spratt JS. *Cancer of the Breast*. 5<sup>th</sup> ed. Saunders. Philadelphia, London. New York. ST Louis. Sydney. Toronto, 2002;25: 567-578.
- 1447- **Wood WC, Budman DR, Korzun AH** : Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. *N Engl J Med* 1994; 330:1253-1259.
- 1448- **Wooster R, Bignell G, Lancaster J, et al.** : Identification of the breast cancer susceptibility gene BRCA2. *Nature* 1995:378-789.
- 1449- **Wooster R, Ford D, Mangion J, Ponder PA, Peto J, Easton DF. Et al.** : Absence of linkage to the ataxia telangiectasia locus in familial breast cancer. *Hum Genet* 1993; 92:91-4.
- 1450- **Wooster R, Meuhausein sL, Mangion J, et al.** : Localization of a breast cancer susceptibility gene, BRCA2, To chromosome 13q12-13. *Science* 1994; 265:2088-2090.
- 1451- **Wu LC, Wang ZW., Tsan JT., Spillman MA., phung A., Xu XL., et al.** : Identification of a RING protein that interacts in vivo with BRCA1 gene product. *Nat Genet* 1996; 14:430-440.
- 1452- **Wyshak G., Frisch RE.,** : Breast cancer among former college athletes compared to non-athletes : a

- 15 year follow-up, *Br J Cancer* 2000; 82: 726-730.
- 1453- **Xie D., and others** : Population –based, case-control study of HER2 genetic polymorphism and breast cancer risk, *J Natl Cancer Inst* 2000; 92: 412-417.
- 1454- **Yaffe K., and others** : Cognitive function in postmenopausal women treated with raloxifene, *N Engl J Med* 2001; 344(16): 1207-1213.
- 1455- **Yager JD.,** : Endogenous estrogens as carcinogens through metabolic activation, *Jn Natl Cancer Inst* 2000; 27:67-73.
- 1456- **Yager JD., Liehr JG.,** : Molecular mechanism of estrogen carcinogenesis. *Ann Rev Pharmacol Toxicol* 1996; 36: 203-232.
- 1457- **Yamashita K and others** : Breast cancer with bone only metastases: visceral metastases-free rate in relation to anatomic distribution of bone metastases, *Cancer* 1991; 68:634.
- 1458- **Youngson BJ., Cranor M., Rosen PP.,** : Epithelial displacement in surgical breast specimens following needling procedures. *Am J Surg Pathol.* 1994; 18:896-903.
- 1459- **Yu H, Rohan T:** Role of insulin like growth factor family in cancer development and progression, *J Natl Cancer Inst* 2000;92:1472.
- 1460- **Zannis VJ., Aliano KM.,** : The evolving practice pattern of the breast surgeon with disappearance of open biopsy for nonpalpable lesions. *Am J Surg* 1998; 176:525-528.
- 1461- **Zarotsky J, Hansen N, Brennan M, et al.** : Lymph node metastasis from ductal carcinoma in situ with microinvasion. *Cancer* 1999; 85:2439-2443.
- 1462- **Zeleniuch-Jacquotte A., and others** : Relation of serum levels of testosterone and dehydro epiandrosterone sulfate to risk of breast cancer in postmenopausal women, *Am J Epidemiol* 1997; 145: 1030-1038.
- 1463- **Zellars RC and others** : Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients, *J Clin Oncol* 2000,18:1906-1913.
- 1464- **Zhang LI, Tomblin C; Weber B** : BRCA1, BRCA2 and response: Collision or collusion? *Cell* 92:433, 1998.
- 1465- **Zhang S., and others** : Dietary carotenoids and vitamin A, C, and E and risk of breast cancer, *J Natl cancer Inst* 1999; 91:547-556.
- 1466- **Zhang Y., and others** : Bone mass and the risk of breast cancer among postmenopausal women, *N Engl J Med* 1997; 336: 611-617.
- 1467- **Zheng T., and others** : DDE and DDT in breast adipose Tissue and risk of female breast cancer, *Am J Epidemiol* 1999; 150:453-458.
- 1468- **Zhu K., Williams SM.,** : Methyl-deficient diets methylated ER genes and breast cancer: an hypothesized association, *Cancer Causes Control* 1998; 9(6): 615-620.
- 1469- **Ziegler RC., Hover R., Nomura A., et al.** : Relative weight, weight change, height and breast cancer risk in Asian-American women. *J Natl Cancer Inst* 1996; 88:650-655.
- 1470- **Zonderland HM.,** : The role of ultrasound in the diagnosis of breast cancer, *Semin ultrasound CT MRI* 2000; 21(4): 317-324.
- 1471- **Zonderland HM., and others** : Triple diagnostic approach versus ultrasound-guided 18-gauge core

biopsy in suspicious BREAST MASSES, *Breast* 1998;7:168-172.

1472- **Zumoff B., Levin J., Rosenfield R.S., et al.:** Abnormal 24 hr. concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. *Cancer Res.* 1981;41: 3360-63.